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Platinum-based chemotherapeutics such as cisplatin, carboplatin and 
oxaliplatin have been the mainstay of chemotherapy regimens for the 
treatment of many cancers for the last few decades. Nonetheless, clinical 
interest in new platinum agents appears to be waning with only a handful 
entering clinical trials recently. Till date, thousands of novel cytotoxic 
platinum complexes have been synthesized but only a few attain clinical 
relevance. This thesis highlights existing limitations of platinum drug design 
and proposes avenues for further exploration with focuses on molecularly-
targeted platinum chemotherapeutics with novel mechanisms of action and on 
combined immuno-chemotherapeutic platinum agents. 
 
The work described in chapters 2 and 3 are the foundation underpinning the 
subsequent chapters. In chapter 2, we developed a facile conjugation strategy 
via chemoselective imine ligation to tether relevant biomolecules to a 
platinum(IV) prodrug scaffold. This strategy was used repeatedly to synthesize 
the targeted platinum(IV)-peptide conjugates described in chapters 4 and 5. In 
chapter 3, we sought to answer whether our class of asymmetrical platinum(IV) 
aryl scaffolds  were really prodrugs of cisplatin. Validation of the platinum(IV) 
prodrug hypothesis is important because it is the underlying working 
assumption behind the targeted platinum(IV)-peptide strategies described in 
chapters 4 and 5. 
 
The recognition that certain molecular pathways are critical to carcinogenesis 
and continued tumour progression and may therefore represent an Achilles’ 
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heel, has triggered a revolution in cancer drug development. These 
molecularly-targeted chemotherapeutics have made considerable progress in 
the clinical outcomes for many malignancies. In chapter 4, we have developed 
highly potent and selective HER2-targeted platinum(IV)-AHNP prodrugs 
which demonstrate the feasibility of an idea of “targeted necrosis” as a novel 
strategy to circumvent apoptosis-resistance. 
 
Finally, in chapters 5 and 6, we describe our conceptualisation and realization 
of combined platinum-based immuno-chemotherapeutic agents which 
represents a significant paradigm shift from the conventional approach of 
directly targeting cancer. Historically, the role of the immune system towards 
chemotherapy outcomes has been neglected as anti-cancer drugs were 
believed to be immuno- and myelosuppressive. Nonetheless, this has been 
challenged by contemporary evidence which now suggests that many 
chemotherapeutics, including platinum-based agents, do stimulate the innate 
and/or adaptive immune system and that these “secret allies” contribute 
tangibly towards clinical outcomes. While it has been generally accepted that 
platinum agents principally exert direct cytotoxic action against cancer cells 
via the formation of covalent platinum-DNA adducts, the recognition of 
platinum-induced anti-tumor immunomodulation is only beginning to gain 
traction. There have been compelling empirical evidence corroborating the 
immunomodulating capacity of platinum-based therapy with favourable 
chemotherapy outcomes. The work described here may ultimately pave the 
way towards superior immuno-chemotherapeutic agents and a better clinical 
outcome in patients.  
x 
 
List of Publications 
1. D. Y. Q. Wong*, W. W. F. Ong*, W. H. Ang, Induction of immunogenic 
cell death by chemotherapeutic platinum complexes, Angew. Chem. Int. Ed. 
2015. Very Important Paper 
2. D. Y. Q. Wong*, J. H. Lim*, W. H. Ang, Induction of targeted necrosis 
with HER2-targeted platinum(IV) anticancer prodrugs, Chem. Sci. 2015, 6, 
3051-3056 
3. J. X. Ong, S. Q. Yap, D. Y. Q. Wong, C. F. Chin, W. H. Ang, Platinum(IV) 
carboxylate prodrug complexes as versatile platforms for targeted 
chemotherapy, CHIMIA Int. J. Chem. 2015, 69, 100-103 
4. M. J. Chow, C. Licona, D. Y. Q. Wong, G. Pastorin, C. Gaiddon, W. H. 
Ang, Discovery and investigation of anticancer ruthenium-arene schiff-base 
complexes via water-promoted combinatorial three-component assembly, J. 
Med. Chem. 2014, 57, 6043-6059 
5. D. Y. Q. Wong*, C. H. F. Yeo*, and W. H. Ang, Immuno-
chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer 
agents, Angew. Chem. Int. Ed., 2014, 26, 6752-6756 
6. D. Y. Q. Wong, W. H. Ang, Development of platinum(IV) complexes as 
anticancer prodrugs: The story so far, COSMOS, 2012, 8, 121-134 
7. D. Y. Q. Wong, J. Y. Lau, W. H. Ang, Harnessing chemoselective imine 
ligation for tethering bioactive molecules to platinum(IV) prodrugs, Dalton 
Trans., 2012, 41, 6104-6111 
8. C. F. Chin, D. Y. Q. Wong, R. Jothibasu, W. H. Ang, Anticancer platinum 
(IV) prodrugs with novel modes of activity, Curr. Top. Med. Chem. 2011, 11, 
2602-2612      * Equal contribution 
xi 
 
List of Schemes 
Scheme 1.1. Oxidation of platinum(II) to platinum(IV) complexes  18 
 
Scheme 1.2. Schematic diagram for symmetrical dicarboxylation of 
platinum(IV) complexes       19 
 
Scheme 1.3. Schematic diagram for asymmetrical carboxylation of 
platinum(IV) complexes       20 
 
Scheme 2.1. Synthesis of platinum(IV) scaffold 1 and subsequent imine 
ligation with various substrates      56 
 



























List of Tables 
Table 1.1. Standard reduction potentials of various platinum(IV) complexes 
adjusted against Standard Hydrogen Electrode reference   27 
 
Table S2.1. Representative summary of experimental data for curve fitting of 
p-anisidine catalyzed imine ligation      87 
 
Table 3.1. Conversion yields of 1 and 2 to cisplatin as well as satraplatin to 
JM118          98 
 
Table S4.1. Tabulated data of apoptosis as evaluated by AnnexinV/ PI staining 
of drug-treated NCI-N87 or BT-474 cells after 24 h    141 
  





























List of Figures 
Figure 1.1. Platinum-based anticancer drugs which have clinical approval 
internationally         4 
 
Figure 1.2. The uptake and cytotoxic pathway of cisplatin   5 
 
Figure 1.3. Illustration of the kink formed by the major 1,2-d(GpG) intrastrand 
crosslink in double stranded DNA      7 
 
Figure 1.4. The platinum(IV) prodrug hypothesis    15 
 
Figure 1.5. JM335 - An active platinum(IV) complex bearing trans equatorial 
geometry          17 
 
Figure 1.6. Ethacraplatin and mitaplatin     22 
 
Figure 1.7. Estrogen tethered platinum(IV) complexes   23 
 
Figure 1.8. Light activated platinum(IV) diazide complexes   25 
 
Figure 1.9. Formation of Pt-DNA adduct upon irradiation   25 
 
Figure 1.10. Combined immuno-chemotherapy. Direct cytotoxicity against 
cancer cells and macrophage activation     31 
 
Figure 1.11. Repolarization of tumor-supporting M2 macrophages into cancer-
killing M1 macrophages       32 
 
Figure 1.12. Some platinum-based agents can trigger immunogenic cell death 
of tumour cells by triggering ER-stress     35 
 
Figure 2.1. (a) cisplatin, (b) satraplatin, (c) ethacrynic acid-conjugated 
platinum(IV) complex and (d) estrogen-tethered platinum(IV) complexes  54 
 
Figure 2.2. Structures of hydrazide or aminooxy functionalized substrates 58 
 
Figure 2.3. HPLC monitoring of formation Pt-benzhydrazide (A) and Pt-
benzylhydroxylamine (B) over time in 50% DMF/aq. NaOAc   60 
 
Figure 2.4. Comparison between rate of imine ligation between the catalysed 
and uncatalysed reaction mixture      61 
 
Figure 2.5. RP-HPLC (254 nm) reaction monitoring of formation of Pt-
AMVSEF peptide 3 over time in 20% DMF     64 
 




Figure S2.7. Hydrolysis of Pt-Girard’s reagent T 2e    83 
 
Figure S2.8. (A) RP-HPLC reaction monitoring of formation of Pt-AMVSEF 
peptide 3 at 214 nm. (B) 3 after purification by RP-HPLC   84 
 
Figure S2.9. ESI-MS of Pt-AMVSEF peptide 3     85 
 
Figure S2.10. Illustration of imine ligation between Pt-benzaldehyde 1 (A) and 
benzhydrazide to yield the mono-ligated product (B) and the bis-ligated 
product 2a (C)         86 
 
Figure 3.1. Structures of cisplatin, oxaliplatin, satraplatin and newly 
synthesized platinum(IV) scaffolds 1 and 2     89 
 
Figure 3.2. The platinum(IV) prodrug hypothesis: reductive elimination of 
platinum(IV) prodrugs occurs with the release the active platinum(II) core as 
well as both axial carboxylate ligands.     91 
 
Figure 3.3. HILIC and RPLC chromatograms of the reduction of 1 by ascorbic 
acid          95 
 
Figure 3.4. HILIC and RPLC chromatograms of the reduction of satraplatin by 
ascorbic acid         97 
 
Figure 3.5. Rate of reduction of 1, 2 and satraplatin in the presence of 2 mM 
ascorbic acid (left) or 4 mM ascorbic acid (right)    99 
 
Figure S3.1. Semi-preparative trace of the crude 
Pt(II)(NH3)2(Cl)(carboxylbenzaldehyde)     109 
 
Figure S3.2. ESI-MS of the isolated Pt(II)(NH3)2(Cl)(carboxylbenzaldehyde). 
m/z 411.8 [M-H]-        110 
 
Figure S3.3. Aquation of cisplatin to form an unidentified product  110 
 
Figure S3.4. HILIC and RPLC chromatograms of the reduction of 4 by 
ascorbic acid         111 
 
Figure S3.5. Representative calibration curves    111 
 
Figure 4.1. Synthesis of HER2-targeted Pt(IV)-AHNP conjugate consisting of 
an AHNP motif tethered to a cytotoxic Pt pharmacophore   116 
 
Figure 4.2. Pt(IV)-AHNP conjugates exhibits rapid and massive drug uptake 
and selectively kills HER2(+) cells in coculture    120 
 




Figure 4.4. (a) Representative overlaid microscopy images of control and 
treated NCI-N87 (b) 4a-treated NCI-N87 undergoes short-term proliferation 
24 h after drug treatment but display increasing severe nuclear fragmentation 
over 7 d (left to right). (c) Clonogenic assay to assess the long-term 
proliferation ability        127 
 
Figure S4.1. Measurements of cellular ROS on NCI-N87 after drug-treatment 
using 2’,7’–dichlorofluorescein diacetate (DCFDA)    142 
 
Figure S4.2. Intermediate-term potency of the drug conjugates as determined 
by MTT         143 
 
Figure S4.3. Visual fluorescence microscopy monitoring of drug-treated NCI-
N87 over time         144 
 
Figure S4.4. Cell-cycle of drug-treated NCI-N87 cells over time   145 
 
Figure S4.5. Representative photos of clonogenic assay on NCI-N87 to assess 
the long-term proliferation ability of drug-treated cells   146 
 
Figure S4.6 to S4.10. Characterization of compounds    147 – 157 
 
Figure 5.1. Putative multi-modal immuno-chemotherapeutic action  161 
 
Figure 5.2. Synthesis of 1, 2 and subsequent oxime ligation with various FPR-
targeting peptides        163 
 
Figure 5.3. Cytotoxicity IC50 of FPR1/2-targeted platinum(IV)-peptide 
prodrugs against FPR1/2 overexpressing cell-lines    165 
 
Figure 5.4. Summary of drug induced cell-mediated cytotoxicity  169 
 
Figure 5.5. Secretion of the extracellular cytokines, IFN-γ and TNF-, after 
treatment of the complex 4, free WKYMVm peptide and cisplatin   171 
 
Figure S5.1. Platinum uptake studies of platinum(IV)-WKYMVM conjugate 4 
in FPR1/2-expressing U-87MG cells after 4 h    183 
 
Figure S5.2 to S5.21. Characterization of compounds    183 – 195 
 
Figure 6.1. Schematic of drug-induced immunogenic cell death (ICD) 200 
 
Figure 6.2. Structures of platinum agents used in ICD screening study 201 
 
Figure 6.3. Phagocytosis screening      203 
 
Figure 6.4. Pt-NHC elicits biochemical hallmarks of ICD   205 
 
Figure 6.5.  The anti-oxidant, trolox, quenches cellular ROS and this in turn 




Figure 6.6. Cytotoxicity of Pt agents via Annexin V apoptosis assay 208 
 
Figure S6.1. Cells observed under confocal microscopy after drug treatment 


























Cancer has been a leading cause of mortality both globally and locally, with 
increasing incidence rates as a consequence of an aging population, 
environmental factors and lifestyle choices.1 The life-time risk of cancer has 
been estimated to be over 1 in 3 persons.2 Worldwide, there are appx. 6 
million cancer-related deaths annually, a figure which is expected to nearly 
treble to appx. 17 million deaths annually by 2030 according to recent 
estimates by the International Agency of Cancer Research.1 The undisputable 
human cost and economic burden of cancer has been a driving force spurring 
substantial investments into cancer research which has since yielded tangible 
payoffs within the last few decades.3 The five-year survival rate for all cancers 
in the United States is expected to rise from 38 % in the 1960s to 80 % by 
2015.4 The ten-year survival rates of many previously “untreatable” cancers 
such as testicular cancer, malignant melanoma, prostate cancer and many 
forms of leukemia already exceeds > 80 %. Even so, the prognosis for many 
common types of cancer such as lung, pancreatic, colon and stomach cancers 
remains dismal. 
 
Contemporary cancer treatment can be viewed as a four-legged stool perched 
on the legs of surgery, radiation therapy, chemotherapy and immunotherapy.4 
At present, advancements in surgery and radiation techniques have 
tremendously improved treatment outcomes in patients diagnosed with early-
stage cancers. For instance, the surgical resection of stage I/ II breast cancer 
(where the tumor is localized and has not spread) has achieved an impressive 




surgical excision and radiation therapy could ever only achieve curative 
potential in about one-third of incidences when the cancer has not yet 
metastasized.4 Metastasis, which is the cause of 90 % of cancer-related 
deaths,6 has been the biggest, as yet insurmountable challenge in cancer 
treatment which can only be addressed by systemic whole-body modalities 
like chemotherapy. Neither surgery nor radiation therapy can replace this 
niche. Immunotherapy, which harnesses the body’s own immune response 
against cancer, is another form of systematic therapy. It has only very recently 
cemented its position as the fourth leg in the anticancer repertoire.7  
 
Today, platinum-based agents such as cisplatin, carboplatin and oxaliplatin 
(Figure 1.1) are amongst the most widely used and effective cytotoxic agents 
in clinical use as part of a chemotherapy regime,8-10 in combination with a 
broad range of other drugs such as doxorubicin, gemcitabine, vinblastine and 
paclitaxel.11 It has been estimated that between 50 – 70 % of chemotherapy 
cocktails include a platinum-based agent.12 With the exception of breast and 
prostate cancer, platinum-based therapy has been indicated for almost all solid 
malignancies including testicular, ovarian, bladder and non-small cell lung 
cancer.13, 14 Indeed, the dramatic improvement in testicular cancer mortality 
from 90 % to < 5 % could be attributed to the serendipitous discovery of the 
anti-cancer properties of cisplatin in 1965 by Rosenberg and colleagues.15, 16 
 
The key focus of this thesis is on creating a new generation of platinum-based 
agents. Despite its therapeutic value, cisplatin has severe adverse side effects 




limitation is that many common tumours such as colorectal, ovarian and breast 
cancers are either inherently resistant to cisplatin or develop acquired 
resistance after initial treatment.18 Spurred by the clinical success of cisplatin, 
other platinum(II) analogues such as carboplatin (approved in 1989) and 
oxaliplatin (approved in 2002) were developed to address some of the 
aforementioned shortcomings. Nonetheless, despite extensive research and 
evaluation of thousands of platinum (II) complexes, only a handful have 
shown distinguishing pharmacological properties to be singled out for clinical 
use.19 Thus in this context, this thesis attempts to offer a rethink of platinum-
based anticancer drug design via two distinct approaches, molecularly-targeted 
chemotherapeutics and by amalgamated immuno-chemotherapeutic agents 
which combines both chemotherapy and immunotherapy into a synergistic 
two-pronged agent. 
 
Figure 1.1. Platinum-based anticancer drugs which have clinical approval 
internationally.  
 
Cellular uptake and molecular mechanism of action 
The cellular uptake and molecular mechanism of action of cisplatin has been 
extensively studied (Figure 1.2). Following intravenous administration, the 
majority of cisplatin is inactivated due to irreversible binding to plasma 
proteins (e.g. human serum albumin) and is renally excreted.20 Only a fraction 




bloodstream. The uptake of cisplatin across the cell membrane has been linked 
to both passive diffusion across the lipophilic barrier as well as active 
transport via copper transporter (Ctr1).21 Cisplatin binds to the methionine-rich 
motifs of the extracellular domains of Ctr1, a transmembrane-bound 
transporter for monovalent copper which is ubiquitously expressed. 
Downregulation of Ctr1 in yeast and fibroblast cells is tied to decreased 
cisplatin uptake. Accordingly, high Ctr1 expression has been correlated to 
cisplatin efficacy in cancer cells where else mutations in Ctr1 has been 
associated with cisplatin resistance.22 Another set of transporters, ATP7A and 
ATP7B (which are also involved in cisplatin efflux), have been implicated in 
mediating the sub-cellular compartmentalization of cisplatin.22   The organic 
cation transporter (OCT1/2) has been implicated in oxaliplatin uptake, perhaps 














Figure 1.2. The uptake and cytotoxic pathway of cisplatin. Upon entering the 
cell, cisplatin is hydrolyzed forming a reactive aquated species which then 





Within cells, cisplatin is rapidly hydrolyzed due to sharply lowered chloride 
concentrations of between 2 – 30 mM in intracellular regions as compared to 
extracellular concentrations of around 100 mM. This forms a very reactive 
positively charged [Pt(H2O)(Cl)(NH3)2]
+ complex which is highly reactive 
because H2O is a very good leaving group.
24, 25  
 
These positively charged aquated species binds preferentially to the electron 
rich N7 site of guanine residues, and adenosine to a lesser extent, on 
negatively charged DNA to form a mono-adduct.  The other chloride can then 
undergo hydrolysis leading to the formation of a bifunctional adduct. 
Cisplatin-DNA binding can form many types of adducts including 1,2-d(GpG) 
or 1,2-d(ApG) intrastrand cross links, 1,3-intrastrand cross links as well as 
interstrand cross links between DNA molecules or with cellular proteins.9, 11-13 
It is generally accepted that the primary cause of cisplatin cytotoxicity is the 
formation of 1,2-intrastrand cross links which cause DNA to distort 
significantly towards the major groove in double stranded DNA (Figure 
1.3),26-28 although this is still debatable.20  These 1,2-d(GpG) intrastrand cross 
links accounts for 60 - 65 % of bound platinum29 and bend the DNA double 
helix by 30 – 60  towards the major groove with consequent unwinding of the 
helix by up to 23 ,30 thus hindering normal DNA replication and transcription 
processes.13 These distortions are then recognized by various DNA-damage 
recognition proteins and histones, ultimately leading to cell death through 
apoptosis, necrosis or a combination of both.31-33 These proteins include high-
mobility group box protein 1 (HMGB1), TATA box-binding protein and 3-




others. These proteins recognize and process DNA lesion formed by cisplatin 
and oxaliplatin differently as they are structurally different, which may 
account for their differences in cytotoxicity.33 DNA interstrand crosslinks and 
DNA-protein cross-links do play a role in cytotoxicity as well.32  
 
 
Figure 1.3. Illustration of the kink formed by the major 1,2-d(GpG) 
intrastrand crosslink in double stranded DNA.20 
 
Besides DNA binding, cisplatin cytotoxicity has also been linked to non-DNA 
cellular targets. For instance, cisplatin binds to ubiquitin,34 an enzyme 
responsible for the selective degradation of cellular proteins, and to heat shock 
protein (Hsp90),35 a protein responsible for the correct folding of cellular 
proteins including those pivotal in cell cycle regulation. There have also been 
some inquiry into the role of mitochondria as the fundamental target of 
cisplatin cytoxicity.36 Cisplatin also interferes with cellular RNA processing 
through platinum-RNA adducts but the biological significance of this remains 
to be elucidated.37 
 
As mentioned above, the formation of 1,2-intrastrand cross links as the 
primary cause of cisplatin cytoxicity is debatable as only approximately 1 % 




without intricate 3-dimensional pharmacophore features is likely to bind 
promiscuously to a myriad of cellular nucleophiles. It has been shown that the 
cisplatin binds preferentially to macromolecules with molecular masses 
greater than 30 kDa as compared to more abundant smaller molecular weight 
nucleophiles which runs counterintuitive to conventional logic.38 It was 
suggested that the tendency of cisplatin to bind irreversibly to sulfhydryl 
groups, inhibits numerous sulfhydryl-containing enzymes, contributing to 
cisplatin-induced cytotoxicity.39 Furthermore, Price and colleagues elegantly 
demonstrated that cisplatin could initiate apoptosis from the cytoplasm 
independent of the nucleus in kidney cells.40 The participation of CDK2 in 
cisplatin-triggered apoptosis was shown in vivo and in vitro while inhibition of 
CDK2 by p21 conferred protection against cisplatin cytotoxicity. Surprisingly, 
the deletion of the nuclear localization signal of p21 did not affect its 
cytoprotective action against cisplatin toxicity, bringing into question the role 
of the nuclear DNA. 
 
While a short introduction of the biochemical mechanisms of cisplatin activity 
has been given herein, an in-depth review is beyond the scope of this 
introduction as the subject matter is very extensive and studies are still on-
going. In particular, platinum cellular influx mechanisms as well as the precise 
mechanisms by which DNA platination triggers various cellular signaling 
pathways remain to be elucidated.41, 42 Nonetheless, detailed and 
comprehensive reviews on this subject matter have been written by Lippard, 






Side effects.  Historically, cisplatin is notorious for having harsh dose-limiting 
side effects which can be grueling to tolerate and which compromises its 
efficacy in a hospitalization setting where many patients are already frail. This 
is not unexpected, given the indiscriminate killing nature of a non-targeted 
compound like cisplatin. These side effects, which include nephrotoxicity, 
neurotoxicity, ototoxicity and nausea, have been somewhat attenuated but not 
completely resolved by later generations of platinum agents such as 
carboplatin and oxaliplatin.43 For instance, over 85 - 95 % of patients treated 
with oxaliplatin suffered adversely from neurotoxicity, with up to 26 % of 
patients requiring hospitalization as a result and which is often the basis for 
treatment discontinuation.22, 44 The symptoms of oxaliplatin-induced 
neurotoxicity includes numbness in the extremities as well as a loss of fine 
sensory-motor coordination.22 
 
The general toxicity profile differs among different platinum agents. Cisplatin 
triggers acute and/ or chronic kidney injury in about 1/3 of patients, even with 
pre-hydration and prophylactic administration of diuretics,45 and is an 
independent risk factor which dramatically increases mortality by 10 to 15-
fold.46 In contrast, carboplatin is only rarely nephrotoxic while nephrotoxicity 
with oxaliplatin is unheard of.22 Likewise, ototoxicity is clinically significant 
with cisplatin, which occurs in up to 50 % of adults and over 50 % of pediatric 
patients, but not with oxaliplatin.22 In contrast, neurotoxicity occurs at a higher 




Drug resistance phenomena. Drug resistance phenomena against platinum 
agents remains an enduring problem. Many tumours are either inherently 
resistant (eg. colon cancer) to platinum-based antitumour agents or develop 
acquired resistance (eg. ovarian cancer) after several treatment cycles. In many 
cases, the initial favorable response rates of cisplatin treatment are not durable 
due to the onset of resistance which results in high relapse rates and 
consequently low 5-year survival.48 Cellular resistance to cisplatin is multi-
factorial and has been linked to (1) up-regulation of DNA repair and damage 
tolerance pathways,20, 42 (2) decreased intracellular accumulation associated to 
copper efflux transporters ATP7A and ATP7B49, 50 and (3) inactivation by 
thiol containing small molecules such as glutathione.51 Platinum-based drugs 
are also particularly vulnerable to irreversible sequestration by 
macromolecular plasma proteins such as albumin which deactivates the drug 
and has also been associated with some severe side effects of treatment.52  
 
In addition, it is well recognized that the failure of many chemotherapeutics 
(including platinum agents) arises due to an inability, at a cellular level, to 
induce apoptosis.48, 53 Most cancers acquire a bewildering array of pro-survival 
adaptations such as a mutated p53 tumor suppressor gene and upregulation of 
the anti-apoptotic Bcl-2 signal which renders the cancer refractory to cisplatin 
along with many other chemotherapeutics. Although a number of experimental 
strategies to restore apoptosis sensitivity has been explored, these are severely 
challenged by the vast heterogeneity and accumulation of multiple unrelated 
pro-survival mutations simultaneously even within the same tumor mass 




Continued relevance in an age of molecularly-targeted therapy? 
Traditionally, the design of novel platinum(II) complexes entails the 
permutations of both the non-labile non-leaving groups and the labile leaving 
groups.55 As the thermodynamically stable non-leaving groups (NH3 in 
cisplatin and DACH in oxaliplatin) affect the structure of the consequent 
platinum-DNA adducts, they determine the cytotoxicity and spectrum of 
activity against various cancers. It has been hypothesized that oxaliplatin 
overcomes cisplatin resistance by virtue of its bulky hydrophobic DACH 
ligand which thwarts the binding of DNA repair proteins.11 On the other hand, 
the lability of the leaving groups (chloride in cisplatin, 1,1-
cyclobutanedicarboxylate in carboplatin and oxalate in oxaliplatin), has been 
associated with toxicity. Thus carboplatin has fewer side effects than cisplatin 
due to the replacement of the chloride ligands (aquation rate constant of 10-5s-1) 
with 1,1-cyclobutanedicarboxylate (aquation rate constant of 10-8s-1).11 
 
Today, molecularly-targeted therapies have dramatically altered the landscape 
of cancer treatment and have supplanted traditional cytotoxic chemotherapies 
for many malignancies.56, 57  This is paralleled by waning interest in the 
discovery of new cytotoxics with the majority of newly approved anticancer 
agents being now targeted therapies.56, 57 The key idea of molecularly-targeted 
chemotherapy stems from the recognition that certain biomolecular pathways 
are critical to carcinogenesis and continued tumor growth and therefore 
represent an Achilles’ heel which can be exploited. These pathways can be 
inhibited by either small molecule inhibitors or by specific antibodies. 




because it actually reverses the aberrant pathway driving the cancer in the first 
place. Gleevec (Imatinib), which inhibits BCR-Abl responsible for chronic 
myeloid leukemia (CML), is often referred to as a miracle drug which has 
transformed the field of chemotherapeutics. Before Gleevec in 2001, the 5 
year survival rate for patients with CML was only 30 % compared to a 
remarkable > 89 % after Gleevec.58  
 
Critically, the development of molecularly-targeted therapies is directed by a 
hypothesis-driven, rationale drug discovery approach involving biomolecular 
target identification, lead compound generation and subsequent optimization 
with clear well-delineated molecular mechanisms of action.56 In contrast, 
current design strategies of platinum(II) anticancer agents may be described as 
somewhat “trial and error” with only some room for rationale design. In many 
cases, the molecular targets and mechanism of action of novel platinum agents 
are not well-defined, which may discourage commercial pharmaceutical 
interest in the compounds.  
 
In this context, it is important to ask oneself: What is the relevance of 
traditional platinum agents given the rapid scientific advances made in today’s 
treatment strategies? The author feels that current platinum agents, which 
continue to adhere to the age-old strategy of targeting DNA, are unlikely to 
have clinical relevance in today’s drug regulatory climate, simply because 
they can only offer incremental improvements over their older counterparts. 
To date, over 3000 platinum compounds have been synthesized and evaluated, 




based drugs.59 Disappointingly, only fewer than 30 potential candidates have 
entered clinical trials and only oxaliplatin has been approved by the FDA in 
2002 since the approval of carboplatin back in 1989!42 While most of these 
platinum-based compounds have shown much promise in vitro, clinically they 
were more or less like their predecessors and fell short of conferring distinct 
clinical advantages over cisplatin.11 This is unsurprising, since most of these 
complexes tend to be structural congeners of cisplatin and thus inheriting its 
shortcomings.41 In addition, the predominant priority when synthesizing and 
evaluating platinum complexes has primarily been cytotoxicity (eg. screening 
for cytotoxicity against a panel of cancer cell-lines) which may end up 
overlooking other important criteria such as anti-metastatic activity and 
immune-modulation; properties which may differentiate novel platinum 
complexes from their predecessors. It has been suggested that it would be 
difficult to find a promising candidate having clinical properties distinct from 
cisplatin and oxaliplatin, from within this pool of classical platinum(II) 
complexes.43, 60 In summary, the author believes that it is unlikely, short of a 
major paradigm shift that incremental improvements will lead to a viable 
clinical candidate. 
 
In order to stay relevant, post-modern platinum drug design should adopt 
hypothesis-driven design from molecularly-targeted therapy while at the same 
time, occupying niches where targeted therapies fail. For instance, the 
majority of lung cancers, one of the most common cancer subtypes, do not 
have any validated “druggable” targets yet and would still require systemic 




mass with accumulation of multiple unrelated pro-survival mutations 
simultaneously62 has been a frustrating factor which limits the response rate of 
well-defined molecularly-targeted therapies.57, 61 On the other hand, non-
specific alkylating agents like cisplatin and oxaliplatin may have multiple 
modes of action arising from different biological targets including DNA.63, 64 
This broader spectrum of action could be therapeutically favorable because it 
potentially circumvents multi-factorial apoptosis-resistance signaling 
pathways. As a case in point, in chapter 4, we describe the development of 
HER2/neu-targeted platinum(IV) complexes which induces targeted necrosis 
as a novel means of circumventing and outwitting apoptosis-resistant cancers.  
 
The platinum(IV) prodrug strategy 
In recent years, there has been increasing interest in exploiting inert 
platinum(IV) as a prodrug strategy to mitigate the aforementioned limitations 
of platinum(II) anticancer complexes (Figure 1.4).  In principle, the kinetic 
inertness of platinum(IV) complexes (low spin d6 third row transitional-metal 
complexes) would minimize unwanted side reactions in the bloodstream, thus 
reducing toxicity.9 Also, the introduction of two axial ligands in an octahedral 
geometry facilitates fine-tuning of pharmacological properties of the prodrug 
such its specificity, activity and lipophilicity. More excitingly, these axial 
ligands are released concomitantly with the two electron-reduction of the 
platinum(IV) prodrug into its active platinum(II) congener,65 offering the 
possibility of conjugating targeting groups or bioactive co-drugs which may 









Figure 1.4. The platinum(IV) prodrug hypothesis: reductive elimination of 
platinum(IV) prodrugs occurs with the release the active platinum(II) core as 
well as both axial carboxylate ligands. 
 
In general, platinum(IV) anti-cancer prodrugs are based on the octahedral 
[Pt(IV)(A2)(X2)(L2)] motif, where L and X represents the equatorial ammine 
ligands and leaving groups respectively while A represents the axial ligands. 
The metal-ligand bonds of platinum(IV) complexes are kinetically inert, a 
property which have been exploited to chemically modify and design the axial 
ligands.66 While platinum(IV) dihydroxo complexes are substitutionally inert, 
the oxygen atom of dihydroxo groups are strongly nucleophilic and readily 
attacks suitable electrophiles, facilitating the preparation of platinum(IV) 
complexes bearing diverse axial carboxylate ligands.66 The kinetic inertness of 
platinum(IV) complexes was experimentally shown by [1H, 15N] NMR 
spectroscopy of the aquation reactions of a series of platinum(IV) complexes 
bearing the general cis,trans,cis [Pt(II)(X2)(
15NH3)2(Cl2)] (X = Cl, OH and 
acetate).67 Compared to cisplatin which undergoes rapid aquation in water, 






complexes was not observed on a timescale of several weeks although 
significant aquation of cis-[Pt(IV)Cl4(
15NH3)2] did occurred. 
While there are evidences indicating that platinum(IV) complexes can bind 
slowly to DNA in vitro,68, 69, 38, 39 the general consensus is that platinum(IV) 
complexes are prodrugs which must be activated by reduction to its 
platinum(II) congener since platinum(IV) complexes are very unreactive.8 In 
an early study, the antitumoral activity of several platinum(II) derivatives and 
their corresponding platinum(IV) complexes were tested in vivo and only 
platinum(IV) complexes which gives active platinum(II) reduction products 
were found to be active.70 Therefore, platinum(IV) complexes such as mer-
[PtCl3(diethylenediamine)] which is reduced to the inactive platinum(II) 
[PtCl(diethylenediamine)]+  complex are likewise inactive too. More recently, 
an algorithmitic analysis was conducted of 107 platinum(II) and platinum(IV) 
complexes from the National Cancer Institute’s anticancer drug screen against 
its diverse panel of 60 human cancer cell lines (NCI-60). The results revealed 
that the spectrum of activity of these drugs could be correlated to the nature of 
their non-leaving groups and are independent of both the leaving groups and 
oxidation state.71 This is in agreement with the prodrug hypothesis.  
Nonetheless, there are exceptions to this rule as certain inactive trans-
platinum(II) complexes do have corresponding active platinum(IV) 
counterparts. One such example is JM335, trans-
ammine(cyclohexylamine)dichlorodihydroxo-platinum(IV) (Figure 1.5).72 In 
this case, it may be rationalized that oxidation to platinum(IV) can stabilize 







Figure 1.5. JM335 - An active platinum(IV) complex bearing trans equatorial 
geometry 
 
Schemes 1.1, 1.2 and 1.3 comprehensively summarizes the most common 
synthetic routes for preparing axial platinum(IV) carboxylates reported thus 
far. By far the most common and diverse class of platinum(IV) complexes is 
by coordination to axial carboxylate ligards. Oxidation of platinum(II) 
complexes by excess hydrogen peroxide in water yields the corresponding  
symmetrical trans-dihydroxo platinum(IV) species (Scheme 1.1). The 
nucleophilic dihydroxo axial ligands can then be reacted in a general reaction 
scheme with various electrophiles such as anhydrides,73 acid chlorides,74, 75 
pyrocarbonates and isocyanates73 under mild conditions to afford 
dicarboxylate, dicarbonate and dicarbamate platinum(IV) complexes 
respectively. This enormously versatile synthetic route has been used to good 
effect to prepare a wide range of dicarboxylate complexes.76-78 Besides 
oxidation to symmetrical dihydroxo platinum(IV) complexes, synthesis of 
asymmetrical mixed hydroxo-carboxylato complexes can be achieved via 
oxidation in a large excess of carboxylic acid with stoichiometric amount of 
either hydrogen peroxide or tert-butyl hydrogen peroxide.79 This works 
because oxidation of platinum(II) by peroxide occurs via a mechanism 
whereby the axial hydroxido ligand arises from H2O2 while the other axial 
ligand originates from the bulk “solvent”. These complexes can then be further 




synthesis of cis,cis,trans-[Pt(A)2(L)2(OH)(OR)] alkoxyl platinum(IV) 
complexes could be achieved via oxidation with hydrogen peroxide in 
alcohol80, 81 which can then be carboxylated to give cis,cis,trans-
[Pt(A)2(L)2(OCOR
1)(OR)]82 (Scheme 1.1). The precursor trans-dichloro 
platinum(IV) species can be made by oxidizing platinum(II) with chlorine 
gas83 or by hydrolysis of dihydroxo ligands with hydrochloric acid (Scheme 
1.1).84 The mono-carboxylated cis,cis,trans-[Pt(A)2(L)2(OCOR)(Cl)] may be 
then be prepared by reacting trans-dichloro platinum(IV) with silver 
carboxylates.85  
 






Scheme 1.2. Schematic diagram for symmetrical dicarboxylation of 
platinum(IV) complexes. 
 
So far, symmetrical axial dicarboxylates have been the most common and 
most synthetically accessible type of platinum(IV) complexes reported in 
literature. Apart from simple anhydrides and acid chlorides, carboxylation 
with cyclic anhydrides (succinic, glutaric, phthalic and maleic anhydrides)86-90 
yield platinum(IV) carboxylates carrying an uncoordinated pendant carboxyl 
functional group which can be further conjugated via typical  amide or ester 
coupling chemistry (Scheme 1.2).89, 90 Activated carboxylic acids formed by 
typical coupling reagents such as TBTU can also be used as convenient 
alternatives to avoid the need for reactive anhydride or acyl chloride 




widely exploited to tether a considerable array of bioactive or targeting groups 
to platinum(IV) complexes with the aim of potentiating cytotoxicity.9 
 
 
Scheme 1.3. Schematic diagram for asymmetrical carboxylation of 
platinum(IV) complexes. 
 
Recently, there has been a emergent movement towards the preparation of 
asymmetrical platinum(IV) complexes which allows for more customization 
and fine-tuning of the axial ligands.91 One synthetic route is to react trans-
dihydroxo platinum(IV) with limiting acid anhydride under mild and dilute 




dicarboxylate product (Scheme 1.3a).55, 91 The use of limiting pre-activated 
carboxylic acids with N,N'-dicyclohexylcarbodiimide (DCC) also 
preferentially yielded the monocarboxylate species.79 Alternatively, we have 
found that the comparatively less reactive N-hydroxysuccinimide (NHS)-ester 
activated carboxylic acid could be used in great excess and still favor the 
formation of the monocarboxylate product under mild and dilute reaction 
conditions.92, 93 Finally, it was observed that reaction of cis-[Pt(A)2(OH)4] with 
acid anhydrides yielded the tetracarboxylated product but reaction with less 
electrophillic carboxylic acids yielded the cis,fac-[Pt(OCOR)3(OH)] 
tricarboxylated product instead (Scheme 1.3b).94 
 
Bioactive molecules with a free carboxylic acid functional group can be 
conjugated directly to dihydroxo platinum(IV) (Figure 1.6). In an oft-cited 
example, ethacrynic acid was conjugated to cisplatin by acylation of 
cis,cis,trans-[Pt(NH3)2(Cl)2(OH)2] with ethacrynic acyl chloride to form 
ethacraplatin.95 It was postulated that ethacrynic acid, a broad-spectrum 
inhibitor of glutathione-S-transferase (GST), may reverse drug resistance as 
GST has been implicated in cellular defense against xenobiotics. Somewhat 
unexpectedly, ethcraplatin was a potent inhibitor of GST, even more so than 
ethacrynic acid alone. Incubation of a panel of cancer cell lines with 
ethcraplatin also revealed higher cytotoxicity than cisplatin alone within 24 h 
exposure but with similar cytotoxicity after 72 h.  
 
Another research group attached dichloroacetate (DCA), a pyruvate 




is substantial evidence from preclinical trials that DCA induces apoptosis 
selectively in cancer cells by reversing the Warburg effect. The Warburg 
effect is an observation that cancer cells predominately produce energy by 
glycolysis (anaerobic respiration) rather than oxidative phosphorylation 
(aerobic respiration) in mitochondria. This disrupts apoptosis because the 
mitochondria triggers apoptosis by releasing proapoptotic factors such as 
cytochrome c and apoptosis inducing factor. Therefore DCA induces apoptosis 
selectively in cancer cells by inhibiting PDK, shifting cellular metabolism 
from glycolysis to oxidative phosphorylation and reactivating the 
mitochondria. It was postulated that DCA released upon intracellular reduction 
of mitaplatin would sensitize cancer cells towards the cisplatin congener. 
Remarkably, not only did mitaplatin exhibited high cytotoxicity, it was also 
more selective towards cancer cells. In a co-culture of cancer cells with 
normal fibroblasts, cisplatin and the mixture of cisplatin and DCA killed both 
healthy fibroblasts and cancer cells, but mitaplatin only targeted the latter. 
However, these results should be treated with cautious optimism as the 
reduction potential of mitaplatin was measured to be -173 mV, higher than 
satraplatin, indicating that it might be prematurely reduced in blood.97 
 
 
Figure 1.6. Ethacraplatin and mitaplatin are two examples of platinum(IV) 






Figure 1.7. Series of estrogen tethered platinum(IV) complexes. 
 
Besides tethering bioactive ligands directly to the platinum(IV) center, it’s 
also possible to conjugate the bioactive moiety via a linker. For instance, an 
linker-modified estrogen derivative was conjugated via the pendant carboxyl 
group of succinate in the hope of selectively sensitizing estrogen receptor 
positive ER(+) cancer cells compared to ER(-) cancer cells (Figure 1.7).86 It 
was hypothesized that the estrogen-tethered platinum(IV) complex would 
accumulate selectively in estrogen receptor positive ER(+) breast cancer cells 
and the estradiol 3-benzoate ligands released upon reduction and ester 
hydrolysis would induce apoptosis by upregulating HMGB1, a protein which 
shields platinated DNA from nucleotide excision repair. In vitro, it was shown 
that varying the linker length had a tangible effect on cytotoxicity, hinting that 
the kinetics of ester hydrolysis of the linker may affect the drug’s 
pharmacological profile. This same strategy has also been employed to bind 
targeting peptide motifs designed to selectively target extracellular matrix 
proteins which are highly expressed in tumor-induced angiogenesis as a 
“tumour homing device”.98 Against a panel of endothelial and non-endothelial 
cells, platinum(IV) complexes containing either the targeting RGD or NGR 
motif were found to be strong inhibitors of cell growth, at levels that approach 




AGR and Gly peptides were poorly efficacious, supporting the view that the 
strategy could be exploited to develop “tumour homing” drugs. 
 
Besides conjugating bioactive molecules, another interesting class of 
platinum(IV) complexes are the photoactivatable diazido platinum(IV) 
complexes, cis,cis,trans-[Pt(NH3)2(N3)2(OH)2] and its geometrical isomer 
trans,trans,trans-[Pt(NH3)2(N3)2(OH)2] (Figure 1.8).
99-101 The diazido 
complexes were both stable towards blood plasma and glutathione over a 
several weeks. UV irradiation initiates photoconversion of the platinum(IV) 
prodrug to its active cytotoxic platinum(II) form (possibly a reactive diaqua 
species).8 Photoactivatable platinum(IV) prodrugs represent a promising 
strategy which circumvents the dose-limiting side effects of cisplatin by 
locally targeting tumour cells with light, leaving healthy tissue unharmed. 
Moreover, photoactivation of diazido platinum(IV) has an advantage over 
conventional photodynamic therapy in hypoxic tumours because it does not 
rely on the presence of oxygen to generate transient reactive oxygen species. It 
was observed that the diazido complexes only formed platinum-DNA adducts 
and bound to guanosine monophosphate and d(GpG) upon light irradiation and 
that the rate of DNA platination is correlated to light exposure (Figure 1.9). 
Encouragingly, tests against a panel of cell lines have shown the diazido 
complexes to be relatively nontoxic in the dark but significantly more 
cytotoxic upon irradiation. In particular, the trans-azido complex exhibited 
higher cytotoxicity than cisplatin and was not cross resistant with the cisplatin-










Figure 1.9. Formation of Pt-DNA adduct upon irradiation 
 
Issue of premature reduction in blood. One of the key concerns of 
employing platinum(IV) as a prodrug strategy hinges on whether platinum(IV) 
complexes are reduced with the concomitant release of axial ligands 
intracellularly or if the reduction of platinum(IV) occurs prematurely along 
with undesirable  extracellular release of the axial ligands. Some evidence 
endorsing former comes from a series of in vitro studies by Hambley and 
coworkers.102-105 X-ray absorption near edge spectroscopy (XANES), which 
can monitor the oxidation state of platinum complexes, was employed to show 
the uptake of platinum(IV) complexes and subsequent reduction to 
platinum(II) within 24 h of incubation in ovarian (A2780) cancer cells.102 In a 
similar experiment, synchrotron resonance induced X-ray emission (SRIXE) 
imaging  was used to monitor cellular uptake and distribution in ovarian 
(A2780) cancer cells treated with cis,trans,cis-[PtCl2(OC(O)CH2Br)2(NH3)2], 
creatively using bromine as an elemental tag of the axial ligands.104 The 
results showed diffuse distribution of Br throughout the cell, seemingly 
confirming the loss of axial ligands on reduction intracellularly. These results 
should be interpreted with caution however, due to the presence of significant 




Nonetheless despite numerous in vitro substantiation of the intracellular 
reduction of platinum(IV) prodrugs, there are still insufficient evidence to 
substantiate this within actual clinical settings in vivo. The benefits of 
platinum(IV) prodrug will be muted if reduction with concurrent loss of the 
axial ligands occur prematurely in blood. While it has been shown that 
platinum(IV) complexes are inert to most proteins in an in vitro setting,52 in 
reality, the half-life of satraplatin [PtCl2(OAc)2(NH3)(cyclohexylamine)] in 
human blood is only 6.3 minutes compared to 22 hours in a cell culture 
medium97 while tetraplatin (PtCl4(D,L-cyclohexane-1,2-diamine)) has a half-
life of only 3 seconds in blood.106 This may imply that the platinum(IV) 
complexes may not persist long enough in blood to reach its intended 
destination. The rapid reduction has been attributed to the presence of heme 
proteins in hemoglobin. Satraplatin was found to be stable in hemoglobin, 
cytochrome c and glutathione but was rapidly reduced in the presence of 
NADH with either hemoglobin or cytochrome c.107 Conventional viewpoint 
holds that the reductive biotransformation of platinum(IV) prodrugs are 
mediated primarily by highly reducing gluthathione and other thiol-containing 
proteins. However, this is challenged by findings that satraplatin remained 
fairly stable at physiological levels (2 mM) of glutathione.107 In an 
experiment, cell extracts were separated into low and high molecular weight 
fractions in order to assess the role of low molecular mass fractions (such as 
gluthathione) in the reduction of platinum(IV) complexes.38 Surprisingly, the 
rate of reduction by the high molecular weight fraction was very much faster 




extract. These findings suggest that metalloproteins such as hemoglobin and 
cytochrome c are the primary reducing agents in vivo and not gluthathione.  
 
These results may have somber implications on the efficacy of the 
platinum(IV) prodrug strategy and should be investigated further. It was 
observed that analogues of satraplatin exhibited lower activity than cisplatin in 
vivo despite being three orders of magnitude more active on in vitro assays. 
This supports the view that platinum(IV) prodrugs may deceptively exhibit 














+198 mV +38 mV -442 mV 
Table 1.1. Standard reduction potentials of various platinum(IV) complexes 
adjusted against Standard Hydrogen Electrode reference.108 
 
Although there are exceptions, it is generally believed that the rate of 
reduction of platinum(IV) complexes coincides with its reduction potential 
and that the nature of axial ligands exert significant influence on the reduction 




general form, cis,cis,trans-[Pt(A)Cl2(X)2], where A can be ethylenediamine, 
cyclohexylamine, diaminocyclohexane or 1,4-butanediamine, the reduction 
potentials increase in the following order of axial substitution: OH < OAc < Cl 
< OCOCF3 and the ease of reduction correlated to cytotoxicity at least in 
vitro.84, 109, 110  This is consistent with clinical observations that tetraplatin, 
containing axial chloride ligands, was too readily reduced in the bloodstream 
and sequestered by plasma proteins, leading to low clinical anti-cancer activity 
and severe neurotoxicity.9 In contrast, iproplatin (cis,trans,cis-
[PtCl2(OH)2(isopropylamine)2]) was far too inactive due to its unfavorable 
reduction potential and was relatively inert in vivo.43, 108 
 
In essence, the reduction potentials of existing platinum(IV) complexes poses 
a real dilemma.  On one hand, complexes like satraplatin with high reduction 
potential are too susceptible to premature reduction in the bloodstream but on 
the other hand, complexes like iproplatin with low reduction potentials are far 
too inactive. One approach of circumventing premature reductions is by using 
delivery vehicles such as tethering to single-walled carbon nanotubes82 and by 
encapsulation with targeted controlled release polymeric nanoparticles.111  
 
Immuno-modulation by platinum-based agents 
Background. The contribution of the immune system in chemotherapy has 
long been disregarded as cytotoxic drugs were generally believed to be 
immunosuppressive.112-114 Consequently, new chemotherapeutic agents are 
evaluated on immunodeficient mice which neglects any possible immune 




assumption. There is now a growing consensus that a number of 
chemotherapeutics do stimulate the innate and/ or the adaptive immune system 
and that at least part of the observed clinical therapeutic efficacy of these 
agents actually hinges on these off-target immunostimulating mechanisms.112, 
113, 115-117 Thus, certain chemotherapeutics (such as anthracyclines, taxanes and 
gemcitabine) actually relies on off-target immune mechanisms which 
cooperates with direct cytotoxicity for successful tumour eradication in a two 
pronged approach.113, 118  A multi-pronged immuno-chemotherapeutic 
approach would not only shrink tumours but more importantly, reactivate 
dormant immune response against malignancies, eliminating residual cancer 
cells. Accordingly, higher densities of tumour-infiltrating lymphocytes 
following chemotherapy has been correlated with significantly better survival 
outcomes in colorectal and breast cancers.119, 120   
 
Despite being effective anti-cancer agents which form the mainstay of many 
chemotherapy combination regimes,13 the recognition of platinum-induced 
anti-tumor immunomodulation has been barely recognized and is only recently 
beginning to gain gradual traction due to the work described here and by 
others.121 It is concievable that the contribution of the immune system in the 
clinical efficacy of cisplatin has been underestimated. In this dissertation, we 
are interested in the concept of combined immuno-chemotherapy with 
platinum agents and we have explored two orthogonal approaches. The first 
approach is a “macrophage-centric” approach which looks at activating 




approach is a “tumour-centric” approach of triggering immunogenic cell death 
of cancer cells (Figure 1.12). 
 
Although formation of covalent platinum-DNA adducts is generally accepted 
as the principal mode of action,122 classical platinum agents like cisplatin have 
also been known to exert off-target effects on the immune system and are 
potent immunomodulators of both the innate and adaptive immune system.123 
Platinum agents can indirectly promote immune-mediated killing of cancer 
cells through its action on cancer cells by 1) triggering an immunogenic mode 
of tumor cell death via exposure of specific “eat-me” signals,124 2) increasing 
tumour-cell susceptibility for T-cell killing,125, 126 and 3) by down-regulating 
immunosuppressive PD-L2 in a STAT6-dependent manner on tumour cells 
leading to enhanced recognition by T-cells.127 In addition, platinum agents can 
also directly engage immune effector functions by 1) stimulating both 
monocyte and natural killer (NK) cell mediated cytotoxicity,128-132 2) 
promoting antigen-presenting capacity of dendritic cells,133, 134 and 3) by 
reversing immunosuppressive tumour microenvironments by downregulating 
PD-L2 on dendritic cells127 and by selective depletion of inhibitory myeloid-
derived suppressor cells (MDSC) and Treg cells.
135 Interestingly, there has 
been compelling empirical evidence corroborating the immunomodulating 
capacity of platinum-based therapy with favorable chemotherapy outcomes.124, 
135, 136 Nonetheless, the immune-mediating activity of platinum-based agents 
has been neglected in the development of new therapeutics which has focused 
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Figure 1.10. Combined immuno-chemotherapy. Cisplatin can exert both 
direct cytotoxicity against cancer cells as well as activating macrophages 
against cancer cells by upregulating TLR4 receptors on macrophages. 
 
Macrophage activation and repolarization. The first approach we have 
explored is the phenomena of macrophage activation with platinum 
complexes. Although macrophages are one of the primary line of defense 
against cancer by eliminating nascent tumours in many cases, the sustained 
proliferation of cancer despite the afore-mentioned immune-surveillance 
actually represents immune-evasion of cancer.137 It has been established that 
tumour-associated macrophages (TAMs) infiltrating most tumour masses have 
been perversely co-opted into a tumor-supporting M2 phenotype which 
stimulate the proliferation and metastasis through the secretion of growth 
factors and by suppressing the adaptive immune response.138 The presence of 
these tumor associated macrophages (TAMs) has been correlated with poor 
clinical outcomes. Thus, there has been some research interest in “re-
educating” the M2-tumor supporting macrophages back into M1-tumorical 
macrophages as macrophages display a flexible polarization state (Figure 




against human pancreatic cancer via macrophage activation.139 Nonetheless, 
there are not many reported agent till date that can polarize protumour M2-like 
TAMs to tumor-inhibitory M1-like TAMs. While poorly studied,140 there has 
been circumstantial evidence which suggest that platinum-based agents can 
polarize macrophages into a M1-phenotype. Thus, cisplatin-treatment has been 
associated with increased M1 polarization in vivo in several cases.135, 138, 141 
The author hypothesize that cisplatin may activate macrophages via 
upregulation of TLR4 receptors rendering it more sensitive to endogenous 









M1 macrophages  
Figure 1.11. Postulate: We hypothesize that platinum-based therapy is able to 
repolarize tumor-supporting M2 macrophages into cancer-killing M1 
macrophages. 
 
Immuno-modulation: Immunogenic cell death. The second approach 
focuses on the capacity of platinum agents to induce immunogenic cell death 
in tumor cells (Figure 1.12). One of several ways in which chemotherapeutics 
engage a tumor-specific immune response is by triggering immunogenic cell 
death (ICD) whereby the dying cancer cells initiate a robust immune response, 
acting as a de facto anticancer vaccine.117, 142 Thus, immunocompetent (but not 
immunodeficient) mice vaccinated with dying cancer cells pre-treated with 
ICD inducers (eg. anthracyclines, shikonin and hypericin-PDT) are protected 




of multiple cancers suggest that human patients treated with chemotherapy 
together with digoxin, an ICD-promoting agent, had improved overall 
survival, especially when the chemotherapy cocktail does not already contain 
an ICD inducer.144 It was demonstrated that the therapeutic efficacy of 
anthracyclines (ICD-inducer) was negated in mice models when the host 
immune system was compromised.118, 145 This observation suggested that, at 
least in some models of cancer, it was the immune-modulating capacity of 
chemotherapeutics, and not cytotoxicity, which was important.  
 
The ICD-inducing capacity of anticancer drugs has been tied with their 
capacity to elicit endoplasmic reticulum (ER) stress and associated reactive 
oxygen species (ROS) (Figure 1.12).117, 142, 146 It is believed that cancer cells 
dying in response to ROS-mediated ER stress emit a combination of three 
distinct spatiotemporally-defined “danger” signals, which are recognized by 
the immune system and required for ICD.144 These signals, which are now 
established as the biochemical hallmarks of ICD, are: (i) translocation of ER-
resident calreticulin (CRT) to the cell surface during early apoptosis (ii) active 
secretion of ATP and (iii) extracellular secretion of nuclear high-mobility 
group box 1 protein (HMGB1) at late-stage apoptosis. Cell-surface CRT, the 
dominant pro-phagocytotic “eat me” signal,147 promotes the engulfment of 
cancer cells by professional macrophages such as dendritic cells (DCs) for 
tumour antigen presentation.143 Secreted ATP acts as a “find me” signal as 
well as stimulating purinergic P2RX7 receptors on DCs, triggering production 
of IL-1ß, a pro-inflammatory cytokine which is required for IFN-γ production 




like receptor 4 (TLR4) on DCs, triggering a myeloid differentiation primary 
response gene 88 (MYD88)-dependent signalling cascade, which promotes 
antigen processing and presentation to T cells.117, 142, 146  Thus, a dysfunctional 
P2RX7 or TLR4 has been correlated with negative therapeutic outcomes in 
both mice and human studies with ICD-inducing chemotherapeutics such as 
doxorubicin, highlighting the immune component as an essential contribution 
to the efficacy of these agents.117, 142, 146 Dendritic cells which are professional 
antigen-presenting cells (APCs), recognize the DAMPs emitted by the dying 
cancer cells and phagocytize them. After phagocytizing tumour cells, DCs 
degrade the tumour-associated antigens (TAAs) into smaller peptide fragments 
which are used to assemble antigen-major histocompatibility complex (MHC)-
class II complexes. The MHC-class II complexes then prime naïve T cells so 
as to generate CD8+ T lymphocytes (CTLs) which specifically recognize and 
bind to TAAs on cancer cells before destroying them, giving rise to T-cell-
mediated adaptive immunity.  
 
So far, there has only been limited work done to study the ICD inducing 
ability of platinum-based drugs even though platinum-based drugs, in 























3. Kills tumor 
cells specifically
 
Figure 1.12. Some platinum-based agents can trigger immunogenic cell death 
of tumour cells by triggering ER-stress which induces the translocation of 
calreticulin, a potent “eat me” signal. Recognition and phagocytosis of these 
tumour cells by dendritic cells eventually leads to the development of an 
acquired immune response against the tumour cells via a tumour-specific 
cytotoxic T cells response. 
 
Outline of Thesis 
Chapter 2. Harnessing chemoselective imine ligation for tethering 
bioactive molecules to platinum(IV) prodrugs 
In recent years, there has been increasing interest in exploiting platinum(IV) as 
a prodrug strategy to mitigate limitations of conventional platinum(II) 
anticancer complexes. Although this strategy embodies a burgeoning new 
direction to drive the development of platinum(IV) anticancer drugs, existing 
synthetic methodologies of tethering bioactive molecules to the axial sites are 
inadequate to fully exploit its latent potential. These methods suffer from 
limited scope, poor yields and low reliability. This work explores the 
applications of current chemoselective ligation chemistries to platinum(IV) 
anticancer complexes with the aim of addressing the aforementioned 
limitations. Here, we describe the synthesis of a platinum(IV) complex bearing 
an aromatic aldehyde functionality and explored the scope of imine ligation 




Chapter 3. Probing the platinum(IV) prodrug hypothesis. Are 
platinum(IV) complexes really prodrugs of cisplatin? 
The general consensus is that platinum(IV) scaffolds bearing axial carboxylate 
ligands undergo reductive elimination to generate the active square-planar cis 
platinum(II) core together with concomitant elimination and release of the 
axial ligands. However, recent works has thrown doubts to the prodrug 
hypothesis. It was postulated that reduction does not solely progress via 
reductive elimination of the axial acetate ligands but instead occurs via 
dissociation of any combination of the axial acetate and equatorial chloride 
ligands. Validation of the platinum(IV) prodrug hypothesis is important 
because it is the underlying working assumption behind the development of 
platinum(IV)-conjugates. Here, we used a combination of normal and reversed 
phase chromatography to study the reduction of the model platinum(IV) 
complexes by ascorbic acid. Our results clearly demonstrate that our class of 
mono- and bis-functionalised asymmetrical aryl platinum(IV) complexes do 
indeed yield cisplatin upon reduction. 
 
Chapter 4. HER2-targeted platinum(IV) agents induce selectively 
targeted necrosis of HER2/+ tumors following massive cellular influx 
It is well recognized that the failure of many chemotherapeutics arises due to 
an inability to induce apoptosis. Most cancers acquire a myriad of pro-survival 
adaptations. The vast heterogeneity and accumulation of multiple often 
unrelated anti-apoptotic signaling pathways have been a major stumbling 
block towards the development of conventional molecular-targeted therapy 




potent and selective HER2-targeted platinum(IV)-AHNP prodrugs which 
employ an idea of “targeted necrosis” as a novel strategy to circumvent 
apoptosis-resistance and demonstrate the feasibility of this approach. The 
platinum(IV)-AHNP conjugates exhibited a unique biphasic mode of killing. 
The first phase comprise of a rapid killing via necrosis followed by an 
extended and gradual phase of delayed cell death. Our results indicate that the 
platinum(IV)-AHNP conjugates were more potent compared to the free drugs 
in direct cell-killing along with comparable long-term inhibition of 
proliferative capacity and with greater selectivity against HER2-positive 
cancers. 
 
Chapter 5. Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin 
as multimodal anticancer agents 
There is growing consensus that the clinical therapeutic efficacy of some 
chemotherapeutic agents depends on its off-target immune-modulating effects. 
Pt anticancer drugs have earlier been identified to be potent 
immunomodulators of both the innate immune system as well as the adaptive 
immune system. Nevertheless, there has been little development in the rational 
design of Pt-based chemotherapeutic agents to exploit their immune-activating 
capabilities. FPR1/2 receptors are highly expressed in immune cells as well as 
many metastatic cancers. Herein, we report a rationally-designed multimodal 
Pt(IV) prodrug containing a FPR1/2-targeting peptide that combines 
chemotherapy with immunotherapy to achieve therapeutic synergy and 





Chapter 6. Discovery of a potent inducer of immunogenic cell death from 
a screening of platinum complexes 
One way which chemotherapeutics can engage a tumor-specific immune 
response is by triggering an immunogenic mode of tumor cell death (ICD) 
which then acts as a de facto anticancer vaccine. Although a mainstay of 
chemotherapy, there has not been a systematic attempt to screen both existing 
and upcoming Pt agents for their ICD ability. In this work, we have evaluated 
a small library of Pt agents via an in vitro phagocytosis assay and found no 
correlation between cytotoxicity and phagocytosis. We subsequently identified 
a Pt(II) N-heterocyclic carbene complex which displayed the characteristic 
hallmarks of a type II ICD inducer (focused oxidative ER stress, calreticulin 
exposure and both HMGB1 and ATP release). To the best of our knowledge, 
this complex is the first reported instance of a small-molecule type II ICD 
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Harnessing Chemoselective Imine Ligation for Tethering 
Bioactive Molecules to Platinum(IV) Prodrugs 









Platinum(II)-based drugs, namely cisplatin, carboplatin and oxaliplatin, are 
the first line of treatment for many types of malignancies, including testicular, 
ovarian and lung cancer.1, 2 However, their efficacy is severely limited by 
adverse side-effects due to high toxicities and incidences of drug resistance, 
either inherent or acquired.3 Though initially responsive to chemotherapy, 
some patients develop recurrent cancer characterized by acquired drug 
resistance and eventually succumb to the disease.4 In recent years, there has 
been increasing interest in exploiting platinum(IV) as a prodrug strategy to 
mitigate the aforementioned limitations of conventional platinum(II) 
anticancer complexes with satraplatin currently undergoing Phase III clinical 
trials.5 While themselves inactive, platinum(IV) complexes are readily reduced 
intracellularly to its active platinum(II) congener along with concomitant 
release of the axial ligands.6 Platinum(IV) complexes are also coordinatively 
inert and amenable to further conjugation reactions.7 They may therefore 
represent ideal scaffolds upon which to attach bioactive molecules which can 
act as targeting groups to enhance selectivity or as synergistic agents to 
overcome drug resistance.8 Although this strategy embodies a burgeoning new 
direction to drive the development of platinum(IV) anticancer drugs, existing 
synthetic methodologies of tethering bioactive molecules to the axial sites are 
inadequate to fully exploit its latent potential.  
 
When this work was first done, there were only two main techniques of 
functionalizing platinum(IV) complexes. The first is direct axial carboxylation 




versatile route has been used to prepare a wide range of simple aliphatic and 
aromatic dicarboxylate complexes,12-14 there have only several instances 
reported where it has been applied to conjugate bioactive ligands since the 
anhydrides or acid chlorides of these ligands may not be synthetically 
accessible.15-17 The second approach is via carboxylation with cyclic 
anhydrides18-20 to give platinum(IV) carboxylates bearing an uncoordinated 
pendant carboxyl functional group which can be further derivatized via 
classical amide or ester coupling chemistry (Figure 2.1).20-23 Similarly, there 
have only been a handful of examples of conjugation to a genuine potentiating 
ligand e.g. estrogen, targeting peptides and carbon nanotubes.8, 24, 25 The dearth 
of platinum(IV)-conjugates is possibly symptomatic of the limited synthetic 
scope of the aforementioned methods. This is due to poor reaction yields of 
classical amide/ester coupling protocols with platinum complexes as 
substrates. For example, low yields were observed with simple primary amines 
and alcohols,20 and conjugation with stoichiometric excess of several targeting 
tripeptides led to muted yields of the di-functionalized conjugate.24 
 
In order to expand utility of platinum(IV) scaffolds as functionalized prodrugs, 
there is a need to explore and apply current chemoselective ligation 
chemistries to platinum(IV) anticancer prodrugs. This work investigates the 
application of imine ligations for conjugation through hydrazone or oxime 
bond formation. Hydrazone or oxime bond formation are ideal as the 
condensation reaction between an -effect amine with a carbonyl group are 
highly chemoselective and bioorthogonal to most biological functional 




the fastest and mildest bioconjugation reactions available in literature, going to 
completion rapidly in aqueous solution at physiological pH and at low 
stoichiometric concentrations of reactants.28 Hydrazide and aminooxy tags are 
also convenient handles to introduce onto biological macromolecules via 
established chemistries.29 Here, we describe the synthesis of a cis,cis,trans-
diamminedichlorobis(4-formylbenzoate)platinum(IV) scaffold bearing an 
aromatic aldehyde functionality and explored the scope of imine ligation with 
various hydrazide/aminooxy functionalized substrates. As a proof of concept, 
we tethered a six sequence long peptide mimetic (AMVSEF) of the anti-
inflammatory protein, ANXA1. Related N-terminal peptides of ANXA1 have 
demonstrated antiproliferative activity against various cancer cell lines. 30, 31 
The synthetic ease, yields and rate of conjugation reported here clearly 
exceeds all previous instances using conventional amide/ester coupling 
strategies.  
 
Figure 2.1. (a) Cisplatin, (b) satraplatin, (c) ethacrynic acid-conjugated 
platinum(IV) complex, synthesized by direct axial carboxylation with acid 
chloride and, (d) estrogen-tethered platinum(IV) complexes formed by amide 
coupling of an uncoordinated pendant carboxyl functional group with an 





Results & Discussion 
Perhaps a major obstacle in the synthetic development of functionalized 
platinum(IV) bis-carboxylate prodrugs has been the absence of a conjugation 
methodology sufficiently robust to reliably and efficiently combine 
platinum(IV) complexes with relevant bioactive molecules. Being kinetically 
inert and unreactive, platinum(IV) prodrugs are postulated to be chemically 
reduced by endogenous bioreductants such as glutathione to cytotoxic 
platinum(II) species capable of DNA-binding.7 We previously observed 
platinum(IV) bis-carboxylate complex bearing benzoate ligands to be highly 
stable but bind deoxyguanonsine monophosphate (dGMP) to form Pt-dGMP 
adducts upon treatment with bioreductants such as ascorbic acid and 
glutathione. We hypothesized that these kinetically inert platinum(IV) 
complex would be sufficiently stable under the mildly acidic conditions 
typically employed in imine ligation and in the presence of the nucleophilic 
hydrazide and hydroxylamine linkers. We explored the scope of a 
platinum(IV) scaffold bearing symmetric axial benzaldehyde functionality for 
imine conjugation reactions. 
 
Synthesis and characterization. The platinum(IV)-benzaldehyde complex 
(1) was synthesized via a modification of a versatile synthetic method 
previously described by Galanski and Dyson et al for the preparation of trans-
platinum(IV) carboxylates.10, 18 Acylation of the dihydroxylplatinum(IV) 
precursor with the corresponding acid chloride, 4-formylbenzoyl chloride, in 
the presence of pyridine as an organic base gave the expected product 1 in 




Scheme 2.1. Synthesis of trans, cis, cis-bis(4-
formylbenzoate)dichlorodiammine platinum(IV) (1) and subsequent imine 
ligation with various substrates. 
 
Characterization by 1H NMR and ESI-MS were consistent with the expected 
structure (Figures S2.1 and S2.2). The aldehydic proton was the most 
downfield at 10.10 ppm, as expected, and the aromatic protons exhibited an 
AA1BB1 splitting pattern consistent with a para-disubstituted phenyl ring. A 
well-defined spin-spin coupling of the ammine protons to quadrupolar 14N (I = 
1, 1JHN = 52.9 Hz) as well as to 
195Pt (I = 1/2, 2JHPt = 52.3 Hz) could be 
observed in deuterated acetone. Such distinct N-H coupling has also been 
observed with other platinum(IV) diammine complexes with axial aromatic 
ligands.18 The purity of 1 was ascertained by RP-HPLC (> 98% purity, 254 




compound 1 was also effectively stable as monitored by HPLC at 254 nm in a 
solution of 50% DMF/aq. NaOAc (pH 4.8, 2 M) for over 2 weeks and does not 
undergo ligand exchange even in the presence of acetate nucleophiles and 
under weakly acidic conditions required for imine ligation. 
 
In order to evaluate the efficiency and ease of imine ligation, we conjugated 1 
to various hydrazide/aminooxy-functionalized substrates (Scheme 2.1 and 
Figure 2.2). In general, the ligation reaction was carried out by stirring 1 with 
stoichiometric excess of the substrates in an aq. buffer solution containing 
50% v/v DMF at r.t. and effectively gave the desired bis-conjugated products 
2a-f in high yields and purity. Often, only rudimentary washing in water or 
ethanol were necessary to remove the excess unreacted 
hydrazides/hydroxylamines. Conversion of 1 to 2a-f was quantitative as 
monitored by HPLC although the recovered yields for the water-soluble 
conjugates 2c-e were lowered due to aqueous washing during workup. These 
reactions conditions were found to versatile and robust. Though customarily 
catalysed by a slightly acidic medium, imine ligation could also be carried out 
at pH 7 or under catalytic condition in the presence of p-anisidine.32 50% v/v 
DMF/water was a favorable solvent composition to promote the solubility of 1 
although the reaction can also be carried out as a heterogeneous reaction 








Figure 2.2. Structures of hydrazide or aminooxy functionalized substrates. (a) 
benzhydrazide (b) 4-methoxybenzhydrazide (c) l-tyrosine hydrazide (d) 
Girard’s reagent D (e) Girard’s reagent T (f) benzylhydroxylamine and (g) 
hydrazide-functionalised AMVSEF peptide. 
 
Reaction monitoring of imine ligation. Reaction monitoring on the 
formation of 2a with excess benzhydrazide using RP-HPLC showed a clean 
conversion of 1 to the bis-conjugated Pt-benzhydrazide 2a via the mono-
conjugated intermediate (Figure 2.3). The mono-conjugated Pt-benzhydrazide 
product could be observed in an approximately 1:1 ratio with 2a at equilibrium 
when only a stoichiometric equivalent amount of benzhydrazide was used, 
confirmed by ESI-MS analysis of isolated fractions. In general, the 
platinum(IV)-imine conjugates themselves were generally stable under the 
reaction conditions but we did observed noticeable side product formation in 
2b after 4 days in solution presumably due to the slow cleavage of the aryl 
methyl ether at pH 4.8. This was ameliorated when a less acidic 50% DMF/ 
aq. pH 5.5 MES buffer was used as the reaction medium instead. 
 
While hydrazone ligation of 1 to form 2a-e gave a single bis-conjugated 
product at equilibrium, oxime ligation with o-benzylhydroxylamine yielded 
EE and EZ stereoisomeric mixture of 2f with respect to the N=CH-Ph double 




may be chromatographically separated as the energy barrier towards (E)/(Z) 
isomerism is relatively higher. RP-HPLC of 2f indicated the formation of two 
products with closely spaced retention times at 19.0 (87% by integration) and 
18.6 min (10.2%) which were assigned as belonging to the EE and EZ 
stereoisomers respectively. This was corroborated by the presence of two 
oxime protons (N=CH-Ph) at 8.38 and 8.32 ppm corresponding to the (E) and 
(Z) isomer, respectively. The assignment of both the HPLC and NMR peak 
was made on the basis that the (E) isomer should be the predominant product, 
as observed with other aromatic aldooximes, due to steric and thermodynamic 
reasons.33 It has also been previously reported the resonance of the oxime 
proton in the (E)-isomer was shifted downfield relative to that of its (Z)-
isomer.33, 34 The ratio of EE:EZ stereoisomers varied only slightly when 
ligated under different conjugation conditions of pH 4.8, pH 7 and pH 4.8 at 
50 C. In general, imine formation in 2a-f was supported by the disappearance 
of the aldehyde signal at 10.1 ppm and the appearance of a more upfield imine 
signal between 8.11-8.51 ppm in the 1H NMR. The 1H NMR and ESI-MS 
spectra of 2a-f were consistent with their expected structures. 
 
Catalysis by p-anisidine. In order to fully harness the utility of 
chemoselective imine ligation as part of our ongoing efforts to tether 
platinum(IV) prodrugs to therapeutically relevant biomolecules, we explored 
the use of p-anisidine as a catalyst to afford milder conjugation conditions at 
physiological pH instead of under typical acidic conditions which may 
denature sensitive biomolecules. p-ansidine is a potent catalyst of imine 




relatively high pKa, leading to a high concentration of electrophiles for 
subsequent attack by -effect amines like hydrazides and aminooxy groups.32 
Full conversion to the bis-conjugated 2a was achieved within 8 h when 
catalysed by 100 mM p-anisidine at pH 7 (Figure 2.4). In contrast, only about 
<2 and 50% conversion to the bis-conjugated 2a and mono-conjugated 
product respectively was formed within the same period in the uncatalysed 
reaction. The use of p-anisidine as a catalyst was also useful in the synthesis of 
the water-soluble conjugates 2d and 2e with Girard’s reagent D and T since 
they were difficult to separate from an acidic aq. buffer by washing with 
water. p-Anisidine could be easily removed from 2d and 2e by washing in 
ethanol. We observed that catalysis with p-anisidine led cleanly to the 
formation of the bis-product and that 1 and the conjugates formed were stable 
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Figure 2.3. HPLC monitoring of formation Pt-benzhydrazide (top) and Pt-






Figure 2.4. Comparison between rate of imine ligation between the catalysed 
and uncatalysed reaction mixture; the solid and dotted line represents the fitted 
curves for the catalysed and uncatalysed reaction respectively to the 
differential rate equations for a two-step consecutive reversible reaction; 
Uncatalysed reaction: 0.263 mM Pt-benzaldehyde 1, 8.71 mM benzhydrazide; 
Catalysed reaction: 0.263 mM Pt-benzaldehyde 1, 8.71 mM benzhydrazide, 
100 mM p-anisidine. Legend:  -unreacted complex 1,  - mono-Pt-
benzhydrazide, - bis-Pt-benzhydrazide. Filled black symbols and hollow 
gray symbols represent the catalysed and uncatalysed reactions, respectively. 
 
Stability of imine-ligated platinum(IV)-conjugates. We also investigated 
the rate of hydrolysis of hydrazone bonds under physiological conditions as 
the relative lability of hydrazone bonds has often been flagged as a 
shortcoming of imine ligation as compared to other chemoselective ligation 
techniques such as the 1,3-Husigen click reaction.35 Earlier on, the 
platinum(IV) scaffold 1 was intentionally designed with axial benzaldehyde 
handles since imines of benzaldehydes are known to exhibit significantly 
slower rate kinetics of hydrolysis compared to other aldehyde or ketone 
moieties.36 To test this hypothesis, we monitored the hydrolysis of 2e under 




solution at 37 C over 24 h (Figure S2.7). At low concentrations, the 
hydrolysis products should be predominant at equilibrium but the time it takes 
to reach equilibrium is a function of the rate of hydrolysis (k-1 and k-2). There 
was little change in the UV spectra within 10 h, indicating negligible 
hydrolysis during this period. Hydrolysis occurred fairly slowly still 
nonetheless, with about 14% hydrolysis after 24 h as implied by the 
decreasing absorbance at 303 nm.  
 
The rate constants for hydrazone hydrolysis reported in literature are typically 
in the magnitude of 10-5 to 10-7 s-1 which will in principle, take days to 
hydrolyse appreciably.28, 36, 37 Assuming pseudo 1st order irreversible 
hydrolysis in dilute solutions and a hypothetical k-1 of 1 x 10
-6 s-1, it will 
require approximately 29 h and 194 h to reach 10% and 50% hydrolysis 
respectively. In contrast, the half-life for in vivo reduction of platinum(IV) to 
platinum(II) complexes with the concomitant release of axial ligands is 
estimated to range from a few minutes to a few hours depending on cell-line 
and conditions.38-40 Therefore hydrazone ligation of targeting groups and other 
potentiating bioactive molecules to the platinum(IV)-benzaldehyde scaffold 1 
would be sufficiently stable as its dissociation would be very slow relative to 
the rapid reduction of platinum(IV) carboxylates in vivo. Recently, another 
platinum(IV) scaffold bearing a ketone moiety for subsequent hydrazone 
ligation to hydrazide-functionalised polymeric nanoparticles was reported.41 
Although it fulfills the purpose of sustained cisplatin release, the half-life of 
ketone-based hydrazone hydrolysis at pH 7.4 will be much more rapid and in 




ligation such as in 2f may be employed as oximes are inherently more resistant 
towards hydrolysis than hydrazones.42 
 
Till date, there have only been a few examples of platinum(IV)-peptide 
conjugates reported in literature. In one reported instance, several 
angiogenesis-targeting linear tripeptides and cyclic pentapeptides were 
conjugated to a platinum(IV) scaffold via EDC amide coupling with the aim of 
selectively targeting angiogenic tumor endothelial cells over normal tissues.24 
Encouragingly, the targeting peptide-tethered platinum(IV) complexes were 
more cytotoxic towards malignant endothelial cell lines compared to non-
specific platinum(IV)-peptide controls as well as the free targeting peptides, 
demonstrating it is potentially possible to rationally alter the selectivity and 
activity of platinum(IV) prodrugs simply by judicious conjugation with 
therapeutically-relevant peptide moieties. However, the low yields obtained 
from EDC-mediated amide coupling reactions produced mixtures of mono-
functionalised (11-16 %) and di-functionalised (5-8 %) platinum(IV) peptide, 
may be a potential stumbling block towards the development of more diverse 
platinum(IV)-peptide conjugates. 
 
To demonstrate the improvement of imine ligation over amide coupling, we 
tethered 1 to a hydrazide-functionalized AMVSEF peptide, the N-terminus 
mimetic of anti-inflammatory protein ANXA1, as a proof of concept. When 
stirred at r.t., hydrazone ligation in a 20% DMF/H2O solution rapidly attained 
equilibrium within 4.5 h with the complete consumption of 1 to give 




conjugate peptide as the minor product (ca. 7%) as observed by RP-HPLC 
(Figure 2.5). Excluding the unreacted free peptide, the crude reaction mixture 
was relatively clean as indicated by RP-HPLC at 214 and 254 nm which 
consisted of bis-conjugate 3 (82%) and mono-conjugate (7%) products. Their 
identities were confirmed by ESI-MS analysis on isolated RP-HPLC fractions 
of the individual peaks. These results highlighted that the advantage of imine 
ligation over amide conjugation in terms of reaction setup and yield. 
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Figure 2.5. RP-HPLC (254 nm) reaction monitoring of formation of Pt-
AMVSEF peptide 3 over time in 20% DMF. The free hydrazide-
functionalised peptide (Rt = 13.80 min) is not visible at 254 nm. Legend:  - 
bis-conjugated Pt-AMVSEF 3,  - mono-conjugated Pt-AMVSEF and  - 
unreacted complex 1. 
 
Conclusion 
In conclusion, imine ligation to the platinum(IV)-benzaldehyde scaffold 1 was 
found to be robust and high yielding, addressing the synthetic limitations of 
current amide/ester coupling methodologies. The reliability of imine ligation 
may open up the hereinbefore largely untapped potential of platinum(IV) 
conjugates as prodrugs by improving upon the synthetic ease by which these 





Materials and methods. Unless otherwise stated, all reagents were purchased 
from commercial vendors and used without further purification. Potassium 
tetrachloroplatinate(II) was obtained from both Precious Metals Online and 
Strem Chemicals and was purified by filtering its aqueous solution through 
celite to remove trace particulates. cis-diamminedichloroplatinum(II) and 
cis,cis,trans-diamminedichlorodihydroxoplatinum(IV) were synthesized and 
purified as per literature procedures.43, 44 Resin-bound ANXA1 peptide (Ala-
Met-Val-Ser-Glu-Phe) was obtained from GL Biochem (Shanghai). The 
hydrazide linker, 4-(N-tert-butoxycarbonyl-hydrazino)-4-oxo-butyric acid, was 
prepared as previously described.37 4-Formylbenzoic acid was further purified 
by recrystallization from boiling water with addition of decolorizing carbon. 
Dry tetrahydrofuran (THF) and diethyl ether were obtained directly from 
Glass Contour’s Solvent Dispensing System. Acetone was dried by distillation 
over potassium carbonate. 
 
1H NMR was recorded on a Bruker Avance 300 MHz or 500 MHz model. 
Chemical shifts are reported in parts per million relative to residual solvent 
peaks.45 Electrospray ionization mass spectra (ESI-MS) were obtained on a 
Thermo Finnigan MAT ESI-MS system. UV-vis spectra were recorded on a 
Shimadzu UV-1800 UV-vis spectrophotometer. Analytical HPLC was 
conducted either on a Agilent 1200 series DAD using Phenomenex Luna 
C18(2) column (5 m, 100 Å, 250 x 4.60 mm, 1.0 mL/min flow) or on 
Shimadzu Prominence using Shimpack VP-ODS column (5 m, 120 Å, 150 x 




on the Shimadzu Prominence using a gradient elution of 20-80% B over 15 
min followed by 80% B for a further 5 min where solvent A is aq. NH4OAc 
buffer (10 mM, pH 5.5) and solvent B is MeCN. Semi-preparative HPLC was 
performed on a Shimadzu Prominence using YMC-Pack Pro C18 column (5 
m, 120 Å, 250 x 10 mm, 2.0 mL/min flow). 
 
Synthesis of 4-formylbenzoyl chloride. Catalytic amount of DMF (20 µL) 
was added to a vigorously stirred solution of 4-formylbenzoic acid (1000 mg, 
6.67 mmol) dissolved in THF (15 mL) and cooled in an ice bath. Oxalyl 
chloride (687 µL, 7.99 mmol) was then added dropwise to the reaction 
mixture which was further stirred for 6 h before gradually allowing it to warm 
to room temperature. Unreacted oxalyl chloride was removed by evaporation 
in vacuo to yield a white residue. Trace amount of oxalyl chloride was 
removed by repeated washings in ether (3 x 10 mL) followed by evaporation 
in vacuo. The crude product, obtained in quantitative yield, was used directly 
in the next without further manipulation. 
 
Synthesis of cis,cis,trans-diamminedichlorobis(4-
formylbenzoate)platinum(IV) 1. 4-Formylbenzoyl chloride (1124 mg, 6.68 
mmol) dissolved in acetone (40 mL) was added dropwise to a vigorously 
stirred suspension of cis,cis,trans-diamminedichloro-dihydroxoplatinum(IV) 
(100 mg, 0.30 mmol) and pyridine (723 µL, 8.98 mmol) in acetone (20 mL). 
The reaction mixture was refluxed for 5 h and left at r.t. for a further 8 h. The 
reaction mixture was treated with water (100 mL) and cooled at 4°C for 12 h. 




decanted. The residue was washed with water (3 x 50 mL) and ether (3 x 60 
mL) to yield an off-white powder. The product was purified by dissolution in 
minimal DMF and precipitating with equivolume of ethyl acetate (EA). The 
desired product remained as a homogenous solution initially but gradually 
precipitates after 2-3 h as an off-white powder. To maximize the yield, the 
filtrate was evaporated to dryness, redissolved in minimal DMF, 
supersaturated with H2O and recrystallized again by adding EA to slowly 
precipitate an additional crop of the desired product. Combined yield: 135 mg 
(75%). C16H16Cl2N2O6Pt.1DMF (671.4.): calc. C 33.99, H 3.45, N 6.26; found 
C 34.15, H 3.68, N 6.1 1H NMR (acetone-d6, 300.13 Hz): 10.14 (s, 2H, CHO), 
8.16 (d, 4H, Ar-H, 3JHH = 8.2 Hz), 7.98 (d, 4H, Ar-H, 
3JHH = 8.2 Hz), 6.74 (m, 
6H, NH3, 
1JHN = 53.9 Hz, 
2JHPt = 52.3 Hz); ESI-MS (-ve mode, m/z): 596.8 
[M-H]-; Purity (HPLC): 1 peak at 254 and 280 nm. 
 
General procedure for synthesis of platinum(IV)-imine conjugates. In 
general, the platinum(IV)-imine conjugates were prepared by treating 1 with 
5-10 times stoichiometric excess of the desired hydrazide/aminooxy-
functionalised substrate in an aq. buffer solution containing 50% v/v DMF. 
Progress of the reactions was followed by RP-HPLC at periodic intervals. The 
reaction mixture was lyophilised, washed and dried to yield the final product. 
 
Synthesis of platinum(IV)-benzhydrazide bis-conjugate (2a). 
Benzhydrazide (45.0 mg, 334 µmol) was stirred with 1 (20 mg, 33 µmol) in 
50% v/v DMF/ H2O for 24 h. The crude reaction mixture was lyophilized to 




mg (95%). 1H NMR (DMSO-d6, 300.13 Hz): 8.51 (s, 2 x 1H, imine proton), 
8.00-7.91 (m, 2 x 4H, ArH), 7.81-7.78 (m, 2 x 2H, ArH), 7.50-7.53 (m, 2 x 
3H, ArH), 6.79 (br m, 2 x NH3); ESI-MS (-ve mode, m/z): 833.0 [M-H]
-; 
Purity (HPLC): 96% at 254 nm. 
 
Synthesis of platinum(IV)-methoxybenzhydrazide bis-conjugate (2b). 4-
methoxybenzhydrazide ( 55.5 mg, 334 µmol) was stirred with 1 (20 mg, 33 
µmol) in 50% v/v DMF/aq. MES (0.1 M, pH 5.5) for 20 h. The crude reaction 
mixture was then lyophilized to yield an off-white residue and washed with 
H2O (4 x 5 mL). Depending on the quality of 4-methoxybenzhydrazide used, it 
was sometimes necessary to wash further with 30% DMF/H2O (2 x 1 mL) and 
EA (1 x 1 mL). Yield: 28.9 mg ( 97 %). 1H NMR (DMSO-d6, 300.13 Hz): 
11.85 (s, 2 x 1H, NH), 8.50 (s, 2 x 1H, imine proton), 7.98 (d, 2 x 2H, ArH, 
3JHH = 8.4 Hz), 7.92 (d, 2 x 2H, ArH, 
3JHH = 8.73 Hz), 7.78 (d, 2 x 2H, ArH, 
3JHH = 7.7 Hz), 7.08 (d, 2 x 2H, ArH, 
3JHH = 8.85 Hz), 6.79 (br m, 2 x NH3), 
3.84 (s, 2 x 3H); ESI-MS (-ve mode, m/z): 893.0 [M-H]-; Purity (HPLC):  95 
% at 254 nm. 
 
Synthesis of platinum(IV)-tyrosine hydrazide bis-conjugate (2c). l-
Tyrosine hydrazide (39.1 mg, 200 µmol) was stirred with 1 (24 mg, 40 µmol) 
in 50% DMF/aq. NaOAc (2 M, pH 4.8). The crude reaction mixture was 
lyophilized after 4 h to yield a pale yellow solid which was then washed with 
cold H2O (4 x  1 mL). Yield: ca.  32.4 mg (  85 %).
 1H NMR (DMSO-d6, 
500.13 Hz): 9.18 and 9.12 (s, 2 x 1H, NH amide), 8.27 (s, 2 x 1H, imine), 




2H, ArH), 6.78 (br, 2 x NH3), 6.67 – 6.61 (m, 2 x 2H, ArH), remaining protons 
were not observed or obscured by solvent; ESI-MS (-ve mode, m/z): 951.1 
[M-H]-, Purity (HPLC): 94% at 254 nm. 
 
Synthesis of platinum(IV)-Girard’s reagent D. 2HCl (2d). Girard’s reagent 
D dihydrochloride (31.8 mg, 167 µmol) was stirred with 1 (20 mg, 33 µmol) 
in 50% DMF/aq. p-anisidine (100 mM). The crude reaction mixture was 
lyophilized after 12 h to give a brownish residue and washed with chilled H2O 
(2 x 1 mL), ethanol (2 x 1 mL) and ethyl acetate (1 x 0.5 mL) to yield a white 
precipitate. Yield: 24.5 mg (85%). 1H NMR (DMSO-d6, 300.13 Hz): 12.14 (s, 
1H, NH), 8.11 (s, 2 x 1H, imine proton), 7.97-7.95 (d, 2 x 2H, ArH), 7.80-7.77 
(d, 2 x 2H, ArH), 6.79 (br m, 2 x NH3), 4.52 (s, 2 x 2H, CH2), 2.87 (s, 2 x 3H, 
CH3); ESI-MS (+ve mode, m/z): 797.0 [M-H]
+;  Purity (HPLC): 95% at 254 
nm. 
 
Synthesis of platinum(IV)-Girard’s reagent T. 2Cl (2e). Girard’s reagent T 
(28.1 mg, 167 µmol) was stirred with 1 (20 mg, 33 µmol) in 50% DMF/ aq. p-
anisidine (100 mM). The work-up was performed in the same manner as 2d. 
Yield: 20.0 mg (67%). 1H NMR (DMSO-d6, 300.13 Hz): 8.11 (s, 2 x 1H, 
imine proton), 7.98-7.95 (m, 2 x 2H, ArH), 7.81-7.79 (m, 2 x 2H, ArH), 6.81 
(br m, 2 x NH3), 4.81 (s, 2 x 2H, CH2), CH3 obscured by solvent; ESI-MS 






Synthesis of platinum(IV)-benzylhydroxylamine (2f) bis-conjugate. o-
Benzylhydroxylamine hydrochloride (53.3 mg, 334 µmol) was stirred with 1 
(20 mg, 33 µmol) in 50% DMF/aq. NaOAc (2 M, pH 4.8). The crude reaction 
mixture was lyophilized after 24 h to yield an off-white precipitate which was 
then washed with H2O (4 x 5 mL). Yield: 25.0.1 mg (93%).
 1H NMR (DMSO-
d6, 300.13 Hz): 8.34 (s, 2 x 1H, (E) imine proton, 8.32 (s, 2 x 1H, (Z) imine 
proton, 7.94-7.91 (d, 2 x 2H, ArH), 7.68-7.65 (d, 2 x 2H, ArH), 7.44-7.29 (d, 2 
x 5H, ArH), 6.77 (br m, 2 x NH3), 5.21 (s, 2 x 2H, CH2) ; ESI-MS (-ve mode, 
m/z): 807.0 [M-H]-; Purity (HPLC): 87.4% EE and 10.2% EZ stereoisomers at 
254 nm. 
 
Synthesis of hydrazide linker-functionalised AMVSEF peptide. 4-(N-tert-
butoxycarbonyl-hydrazino)-4-oxo-butyric acid (116.1 mg, 500 µmol) was 
treated with N,N'-diisopropylcarbodiimide (63.1 mg, 500 µmol) and N-
hydroxysuccinimide (57.5 mg, 500 µmol) in DMF (0.5 mL) for 10 min. The 
emulsion was then added to the AMVSEF peptide resin (100 mg, ca. 100 
µmol) and stirred at room temperature for 2 h. The resin was washed 
repeatedly with DMF, DCM and 1:1 v/v DCM/MeOH and dried thoroughly. 
Subsequently, the resin was incubated with a freshly prepared TFA cocktail 
(5% thioanisole, 3% EDT and 2% anisole v/v added as scavengers) for 1.5 h 
and filtered. The filtrate was added dropwise to cold ether (15 mL) to yield a 
white precipitate which was collected by centrifugation and washed with cold 
ether (3 x 5 mL). The residue was dissolved in glacial acetic acid and 
lyophilized to yield the crude hydrazide-functionalised peptide. The crude 




semi-preparative RP-HPLC (Shimadzu) using a 5-29% gradient elution system 
with aq. NH4OAc buffer (10 mM, pH 7) (solvent A) and MeCN (solvent B) 
over 40 min at 2.0 mL/min; ESI-MS (-ve mode, m/z): 797.1 [M+H]+. 
 
Synthesis of platinum(IV)-AMVSEF peptide bis-conjugate (3). Pt-
benzaldehyde 1 (ca. 0.1 mg, 0.167 µmol) was stirred with hydrazide-
functionalised AMVSEF peptide (ca. 1 mg, 1.17 µmol) in 20% DMF/H2O 
(1.75 mL). The reaction mixture was monitored by RP-HPLC (Agilent) over 
24 h using a gradient of 5-15% B in the first 10 min followed by 15-80% B for 
20 min where solvent A is aq. NH4OAc buffer (10 mM, pH 5.5) and solvent B 
is MeCN. The bis-conjugated product was subsequently purified by RP-HPLC 
(Shidmadzu) using a gradient elution system of 5-15% B for 10 min followed 
by 15-80% for the next 20 min where solvent A is aq. NH4OAc buffer (10 
mM, pH 7) and solvent B is MeCN; ESI-MS (-ve mode, m/z):  1076.8 [M-
2H]2-; Purity (HPLC): 1 peak at 254 nm. 
 
Catalysis at physiological pH by p-anisidine. Benzhydrazide (4.15 mg) was 
added to 3.5 mL of a stock solution of 1 (0.263 mM) in 50 % DMF/H2O. The 
reaction mixture was divided equally into two portions and p-anisidine (21.5 
mg) was added to one portion. The final reaction mixture comprises 0.263 mM 
1 and 8.71 mM benzhydrazide, with the catalysed reaction containing an 
additional 100 mM p-anisidine. Both reactions were agitated and monitored at 
periodic intervals using RP-HPLC. The consumption of 1 and formation of the 
bis-conjugated product 2a was quantified by integration at 254 and 280 nm. 




consecutive reversible reaction using the chemical reactions module of 
Berkeley Madonna (Macey & Oster, UCLA). The experiment was repeated 
with 0.117 mM 1 and 27.7 mM benzhydrazide. Further details are described in 
SI.  
 
Stability of Pt-Girard’s reagent T (2e) under physiological conditions. 1 
M solution of 2e was prepared by sequential dilution in aq. sodium 
phosphate buffer (0.1 M, pH 7.4). Its UV absorbance was measured from 250 
to 800 nm at hourly intervals at 37 C.  
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Figure S2.3. RP-HPLC assessment of purity of Pt-benzaldehyde 1 dissolved 
in DMF/ H2O. Elution conditions for both spectra (A) and (B): 20 - 80% 
gradient elution system with aq. NH4OAc buffer (10 mM, pH 5.5) (solvent A) 
and MeCN (solvent B) over 15 min at 1.0 mL/min. Columns used are: A) 
Phenomenex Luna C18(2) (250 x 4.60 mm i.d) B) Shimpack VP-ODS column 




































































































































































Figure S2.4. 1H NMR spectra of platinum(IV)-benzhydrazide conjugate (2a) 



























































































































































































































































Figure S2.5. 1H NMR spectra of of platinum(IV)-methoxybenzhydrazide 











1H NMR spectra of Pt-tyrosine hydrazide 2c. The asymmetry of the 
aromatic protons observed in the 1H NMR spectra of 2c was initially puzzling 
as the protons Ha/ Ha
1,  Hb/ Hb
1 and Hd/ Hd
1 exhibited greater magnetic 
inequivalence than was observed with the other Pt(IV)-imine conjugates 
where the same protons (though magnetically inequivalent) had closely 
overlapping chemical shifts. Consequently, in order to rule out the possibility 
of asymmetry of the axial ligands (eg. one side having E stereoisomerism with 
the other side being Z), we synthesized the purely organic hydrazone 
conjugate between 4-carboxylbenzaldehyde and tyrosine hydrazide for 
comparison. As shown in Figure S6, the organic hydrazone displayed the same 
asymmetry of the aromatic protons. We postulated that this asymmetry arose 
due to slow rotation of the N=CH-Ph double bond in the NMR timescale, 
resulting in more distinctive magnetic inequivalence of Hb vs Hb
1. 
  
Synthesis of hydrazone conjugate between 4-carboxylbenzaldehyde and l-
tyrosine hydrazide as NMR reference. 4-carboxylbenzaldehyde (21.5 mg, 
0.143 mmol) was added to a solution of l-tyrosine hydrazide (140 mg, 0.716 
mmol) in 50% DMF/ H2O (3 mL). The reaction mixture was lyophilized after 
24 h and washed with H2O to yield a white precipitate. See Figure S6 for 
1H 















































































































































































































































Org. tyrosine hydrazide + benzaldehyde (reprocessed)
















Figure S2.6. Similarities between 1H NMR spectrum of (A) Pt-tyrosine 
hydrazide (2c) and (B) the purely organic hydrazone ligation between 4-
carboxylbenzaldehyde and tyrosine hydrazide. The 3D visual illustration is 


































max = 303 nm
 
Figure S2.7. Only slight hydrolysis of Pt-Girard’s reagent T 2e was observed 
at pH 7.4 and 37 C over 24 h; the max of the spectra was at 303 nm, 
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Figure S2.8. (A) RP-HPLC reaction monitoring of formation of Pt-AMVSEF 
peptide 3 at 214 nm. Elution conditions: 5 – 15% over 10 min followed by 15 
– 80% from 10 to 30 min aq. NH4OAc buffer (10 mM, pH 5.5) (solvent A) 
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Figure S2.9. ESI-MS of Pt-AMVSEF peptide 3 in negative mode showing the 










Catalysis at physiological pH by p-anisidine.  The reaction between Pt-
benzaldehyde 1 (A) and benzhydrazide to form the mono-ligated Pt-
benzhydrazide (B) and bis-ligated Pt-benzhydrazide 2a (C) product follows 
pseudo 1st order reaction kinetics in the presence of excess hydrazide and may 








Figure S2.10. Illustration of imine ligation between Pt-benzaldehyde 1 (A) 
and benzhydrazide to yield the mono-ligated product (B) and the bis-ligated 
product 2a (C). 
 
The consumption of 1 and formation of the bis-conjugated product 2a at 
hourly intervals was quantified by integration at 254 and 280 nm. In order to 
obtain a smooth plot of [1] and [2a] as a function of time, the experimental 
data was curve-fitted to model the chemical equilibriums as shown in Figure 
S10 using the chemical reactions module of Berkeley Madonna, a commercial 
graphical differential equation solver. 
 
In order to account for differences in molar absorptivity, the fraction of Pt-
benzaldehyde (A) at any one point in time (t) was calculated as the current 
amount of A over the initial amount of A as quantified by HPLC integration. 




calculated as the current amount of C over the maximum amount of C 
produced at the end of the reaction. Since it was difficult to extrapolate the 
maximum amount of mono-ligated product (B) from the experimental data, 
the fraction of B at any one point in time was calculated by substracting from 
the fraction of A and C. This is summarized as the follows: 
 
Fraction of A = Average of   at 254 and 280 nm 
Fraction of C = Average of  at 254 and 280 nm 
Fraction of B =  
Hours 
Fraction at 254nm /mAU Fraction at 280nm /mAU Average Fraction of 254 and 280 nm 
1  Mono Bis 1 Mono Bis 1 Mono Bis 
0.00 1.00 0.00 0.00 1.00 0.00 0.00 1.00 0.00 0.00 
0.17 0.97 0.03 0.00 0.94 0.06 0.00 0.95 0.05 0.00 
1.00 0.86 0.14 0.00 0.80 0.20 0.00 0.83 0.17 0.00 
2.08 0.76 0.24 0.00 0.77 0.23 0.00 0.76 0.24 0.00 
3.17 0.69 0.31 0.00 0.67 0.33 0.00 0.68 0.32 0.00 
4.25 0.71 0.29 0.00 0.72 0.28 0.00 0.72 0.28 0.00 
5.33 0.62 0.38 0.00 0.63 0.36 0.01 0.63 0.37 0.00 
6.42 0.56 0.44 0.01 0.52 0.47 0.01 0.54 0.45 0.01 
7.50 0.50 0.48 0.01 0.46 0.52 0.01 0.48 0.50 0.01 
8.50 0.45 0.53 0.02 0.41 0.57 0.02 0.43 0.55 0.02 
20.50 0.18 0.71 0.11 0.18 0.71 0.11 0.18 0.71 0.11 
25.50 0.16 0.67 0.17 0.19 0.64 0.17 0.18 0.66 0.17 
Table S2.1. Representative summary of experimental data for curve fitting. 
Data shown is for 100 mM p-anisidine catalysed reaction with 0.263 mM Pt-
















Probing the Platinum(IV) Prodrug Hypothesis. Are 























Amongst the metallopharmaceuticals in development, platinum(IV) 
complexes are unique because they are native prodrugs of clinically-relevant 
platinum(II) pharmacophores such as cisplatin and oxaliplatin (Fig. 3.1) These 
platinum(II) drugs are some of the most effective anticancer agents in clinical 
use and the first line treatment for many malignancies today (Fig. 3.1).1-3 The 
general consensus is that these platinum(IV) prodrug complexes are 
themselves pharmacologically inactive and must undergo reductive 
elimination by endogenous reductants to release the active square-planar 
platinum(II) core with concomitant dissociation of the axial ligands (Fig. 
3.2).1-3 As such, the axial ligands confers unique possibilities of tuning the 
pharmacokinetic parameters such as lipophilicity and solubility as well as the 
attaching any targeting groups or synergistic co-drugs without altering the 
cellular mechanism of action of the innate platinum(II) pharmacophore.1-3 
 
Figure 3.1. Top: cisplatin and oxaliplatin are two platinum(II) agents in 
clinical use today. Bottom: Satraplatin is a promising platinum(IV) anticancer 
prodrug under clinical trials. Complexes 1 and 2 are newly synthesized 
asymmetrical platinum(IV) complexes bearing a benzaldehyde moiety for 
facile imine ligation to any therapeutically-relevant substrate.  
 
The key impetus driving this study is the uncertainty whether asymmetrical 
aryl platinum(IV) complexes bearing a cisplatin-type scaffold (cis,cis-




applications for, are indeed prodrugs of cisplatin.4 Based on the literature, 
there have been mixed evidence for and against the hypothesis that cisplatin-
type platinum(IV) complexes are prodrugs of cisplatin. The strongest support 
for prodrug hypothesis appeared to be extrapolated from extensive in vitro and 
in vivo studies from satraplatin5, 6 and iproplatin7 which bear the cis-
am(m)ine(cyclohexylamine) and cis-diisopropylamine core respectively (Fig. 
3.1). These studies showed that that the expected platinum(II) congener was 
indeed the predominant product of reduction via HPLC. However to date, the 
same has never been shown from a cisplatin-type platinum(IV) scaffold. 
Indeed, subtle variation of the equatorial ligands, such as equatorial 
replacement of 1,2-DACH (diaminocyclohexane) with a 1,4-DACH ligand can 
have a profound and unexpected influence on the reduction behaviour of 
platinum(IV) complexes.8 It was also observed that trans-analog of satraplatin 
bearing trans-dichloro ligands favored an inner-sphere reduction mechanism, 
resulting in retention of the diacetate ligands and loss of the chloride ligands.9 
Another study suggested that reduction of certain classes of cis-platinum(IV) 
complexes including satraplatin may actually proceed via multiple pathways 
leading to the loss of any combination of axial carboxylate and equatorial 
chloride ligands.10, 11 Consequently, 4 different reduction products were 
formed instead of the expected sole product. 
 
Validation of the platinum(IV) prodrug hypothesis is important because it is 
the underlying working assumption behind much effort which has been 
directed towards the design of platinum(IV)-conjugates in recent years.3 Very 
diverse examples of platinum(IV)-conjugates have been reported including 




macromolecular delivery vehicles.17-20 Invalidation of this central hypothesis 
would bear negative implications against this burgeoning field. For instance, 
we reported a method of hydrophobic entrapment to encase strongly 
hydrophobic platinum(IV) complexes bearing axial aryl carboxylates within 
multiwalled carbon nanotubes via hydrophobic-hydrophobic interactions.20 
The premise was that hydrophilic cisplatin would be released as a result of 
drastic hydrophobic reversal upon reduction. Such a strategy hinged upon the 
release of the axial benzoyl ligands rather than the chloride ligands. In 
addition, asymmetric acylation of platinum(IV) complexes has gained 
substantial interest recently given its potential to significantly expand the 
current paradigm.4, 21, 22 However, the reduction of such mono- and bis-
functionalised asymmetrical platinum(IV) complexes, particularly aryl 
complexes 1 and 2 which represents useful scaffolds for facile imine ligation 
to therapeutically relevant biomolecules,23 have scarcely been studied.  
 
 
Figure 3.2. The platinum(IV) prodrug hypothesis: reductive elimination of 
platinum(IV) prodrugs occurs with the release the active platinum(II) core as 
well as both axial carboxylate ligands.  
 
Thus far, the formation of cisplatin has mostly been demonstrated indirectly 
through the ability of the reduction product to form 1,2-GG-Pt adducts with 
DNA which was detected either by HPLC,20 electrophoresis gel mobility24 or 
antibody staining.15 The drawback of detection by DNA-binding is that any 
platinum(II) product bearing diam(m)ine ligand would also bind to DNA in 




formation of cisplatin from platinum(IV) complexes but the insensitivity of 
this method makes it difficult to detect the formation of any other plausible 
by-products.25 One way of detecting cisplatin directly is by hydrophillic 
interaction liquid chromatography (HILIC) which is an useful approach to 
separate and quantify hydrophilic cisplatin both ex-vitro and ex-vivo,26, 27 but 
has not yet been applied to study the reduction of platinum(IV) complexes. In 
this study, we employed a combination of HILIC and RPLC (reversed-phase 
liquid chromatography) to probe the reduction of model platinum(IV) 
complexes 1 and 2 as well as satraplatin by ascorbic acid in order to establish 
whether they are true prodrugs of their platinum(II) congeners. Our results 
demonstrate that asymmetric aryl platinum(IV) complexes are indeed prodrugs 
of cisplatin upon reduction and that it is the predominant reduction product. In 
addition, we also observed that reduction rate of complex 1 and 2 contradicted 
established trends because reduction of complex 1 (bearing an axial OH) was 
unexpectedly faster compared to complex 2 (bearing an axial OAc). 
 
Results & Discussion 
Experimental design considerations. The prevailing hypothesis holds that 
platinum(IV) complexes are prodrugs which are activated via reduction 
elimination of the axial ligands to yield the pharmacologically active square-
planar platinum(II) centre. In order to probe this hypothesis, we followed the 
reduction of platinum(IV) complexes by employing both conventional RPLC 
(silica-C18) and ZIC-HILIC since the two techniques exhibit orthogonal 
retention. Cisplatin, which has little to no retention on RPLC, is well separated 




use of these two orthogonal separation techniques allows screening for 
possible reduction products across a breadth of polarities. This strategy 
ensured that all possible reduction products, which may otherwise co-elute 
using a single technique, were well-resolved. 
 
Since our goal was to study the direct and immediate reduction product(s) of 
platinum(IV) without interference from subsequent ligand exchange reactions 
of the labile platinum(II) products, we chose a relatively simple reducing 
environment. Ascorbic acid in an aqueous phosphate buffered system was 
used as a model of an outer-sphere reductant,2 over more realistic ex vivo 
reducing conditions such as blood or whole cell extracts. The intracellular 
half-life of cisplatin has been estimated to be only about 75 to 120 min due to 
rapid aquation followed by displacement of the labile chloride ligands by 
numerous high molecular weight cytoplasmic nucleophiles.28, 29 The multitude 
of products formed would obscure study of the direct reduction product(s). 
Other outer-sphere reducing agents such as cytochrome c and haemoglobin 
have been strongly implicated as biologically significant reducing agents for 
satraplatin.5, 30 As these are macromolecular reducing agents where the 
electron is transferred through space from the reducing center to the acceptor, 
the immediate reduction outcome should the same, regardless of outer-sphere 
reductants. Reduction experiments were done in the presence of 137 mM NaCl 
in order to suppress aquation of the platinum(II) reduction product. In the 
absence of chloride ions, we and others have observed very rapid aquation of 




Reduction outcome and conversion yield. Reduction of 1 is expected to 
yield cisplatin alongside concomitant dissociation of the axial 4-
carboxylbenzaldehyde ligand. The starting reactants, 1 and ascorbic acid, as 
well as the expected reduction products could be efficiently separated within 
20 min via HILIC chromatography using a 70% ACN/ aq. NH4OAc (20 mM, 
pH 6.4) isocratic eluent system. The identity of all peaks was ascertained by 
LC-MS and by comparison of retention time against authentic standards 
obtained commercially. In particular, the retention time (12.3 min) and LC-
ESIMS (m/z 318, Pt(Cl2)(NH3)2 + NH4
+ adduct) of cisplatin coincide with an 
earlier published report by Nygren et al using nearly identical separation 
condition.26 On RPLC, only unreacted complex 1 and 4-carboxylbenzaldehyde 
could be observed but not cisplatin. 
 
HPLC monitoring indicated that the reduction outcome was indeed consistent 
with the reduction hypothesis. At the start of the reaction, 3 peaks 
corresponding to unreacted 1 (5.1 min), dehydroascorbic acid (6.6 min) and 
ascorbic acid (8.6 min) were observed via HILIC (Fig. 3.3). Observable 
amounts of dehydroascorbic acid were already initially present in 
commercially obtained ascorbic acid due to air-oxidation. With time, 1 
decreased in tandem with the appearance of 2 new emergent peaks 
corresponding to the axial release of 4-carboxylbenzaldehyde (4.2 min) and 
cisplatin (12.3 min). Complex 1 was stable in PBS and in the absence of 
ascorbic acid, no reduction was observed. Oddly, the peak attributable to 
dehydroascorbic acid did not increase visibly. This may be due to the low 




rapidly hydrolyzed to weakly UV-absorbing diketogulonic acid under 
physiological pH.32 On RPLC, the release of cisplatin was not observed 
because it co-eluted with ascorbic acid at void retention. Nonetheless, it was 
clear that a decrease in 1 (11.6 min) was in tandem with a release of 4-
carboxylbenzaldehyde (5.0 min). More significantly, the RPLC chromatogram 
supports the hypothesis that reduction of 1 occurred primarily via axial 
dissociation since no other platinum(II) by-products were observed. Plausible 
side-products retaining the benzaldehyde axial ligand would be fairly 
hydrophobic, UV-absorbing and therefore visible. One such reduction product, 
cis-Pt(NH3)2(Cl)(carboxylbenzaldehyde), was separately synthesized and 
isolated via semi-preparative HPLC (See SI). This platinum(II) complex, 




Figure 3.3. Top left and top right: HILIC (230 nm) and RPLC (214 nm) 
chromatograms respectively of the reduction of 1 by ascorbic acid. Legend: a 
– 4-carboxylbenzaldehyde b – 1 c – dehydroascorbic acid d – ascorbic acid e – 
cisplatin. Bottom: Release profile of cisplatin over time. Legend:  - 1  - 











































cisplatin. Note that figures show representative experiments conducted at 
different times using different initial concentrations of 1. 
 
At the crux of the issue, we wanted to establish if cisplatin was indeed the 
predominant reduction product of 1 and not simply a minor side-product. The 
conversion yield of complex 1 to cisplatin was calculated to be 89.5  2.0 % 
(SE) based on peak area against a calibration curve under HILIC. Like 1, 
complex 2 which has an OAc axial ligand instead of OH, was reduced to form 
cisplatin and 4-carboxylbenzaldehyde with a conversion yield of 92.6   10.1 % 
(SE) (see SI). These results showed convincingly that the class of highly 
potent asymmetrical platinum(IV) aryl complexes under development are 
indeed true prodrugs of cisplatin. However, since the measured yields were 
<100 %, we cannot discount the possibility of other side-products which may 
be weakly UV-absorbing and therefore undetectable by the UV-vis detector on 
the HPLC. In this regard, hyphenation of HILIC to ICP-MS may be revealing. 
We also observed the formation of small peaks at 15.6 min and 20.1 min upon 
prolonged standing of the reduction mixture. These were likely due to 
aquation of cisplatin rather than a direct result of reduction because they were 
also observed when a solution of cisplatin alone was left standing for 12 h. 
The latter peak at 20.1 min could be identified via LC-MS as the mono-
aquated species [Pt(NH3)2(Cl)(MeCN)]
+ (m/z 305.9) with the aqua-ligand 
substituted by the HPLC eluent. 
 
We studied the reduction of satraplatin to its postulated reduction product, 
JM118 cis-Pt(NH3)(cyclohexylamine)Cl2, using both RPLC and HILIC to 
validate our protocol. Unlike cisplatin, JM118 is hydrophobic and could be 




attributable to satraplatin decreased over time and was accompanied by an 
increase in JM118 (Fig. 3.4). The reduction was quantitative and no other 
major by-products could be observed on both RPLC and HILIC, an 
observation consistent with the platinum(IV) reduction hypothesis. The 
conversion yield to JM118 which was calculated independently on both RPLC 
and HILIC were 83.2  0.8 % (SE) and 86.2%   3.4 % (SE) respectively, 
demonstrating that JM118 was indeed the predominant reduction product of 
satraplatin. 
 
Figure 3.4. Top left and top right: HILIC (214 nm) and RPLC (214 nm) 
chromatograms respectively of the reduction of satraplatin by ascorbic acid. 
Legend: a – satraplatin b – JM118 c– ascorbic acid. Bottom: Release profile of 
JM118 over time. Legend:  - satraplatin  - JM118. Note that figures show 
representative experiments conducted at different times using different initial 
concentrations of satraplatin. 
 
Comparison of reduction rate. To date, it is generally agreed upon that the 
reduction potentials and reduction rates of platinum(IV) complexes are 
positively correlated.2, 33, 34 For complexes bearing the same equatorial ligands, 
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based on the axial ligands as follows, OH < carboxylates < Cl, with hydroxido 
being reduced the slowest. In contrast, we observed a very pronounced and 
unexpected difference in the reduction rate of 1 (bearing an axial 
benzaldehyde and OH ligand) versus 2 (bearing an axial benzaldehyde and 
OAc ligand) (Figure 3.5). In order to accurately compare the reduction rate of 
all three platinum(IV) complexes, we monitored the decline of the parent 
platinum(IV) peak by RPLC in ascorbic acid using a higher buffering capacity 
phosphate buffer (200 uM of complex dissolved in pH 7.4 200 mM phosphate 
buffer + 137 mM NaCl). This higher capacity buffer was necessary to 
maintain a constant pH since reduction rate by ascorbic acid is very pH-
sensitive.35 The experimentally determined half-lives of 1 and 2 in 2 mM 
ascorbic acid were significantly different at ca. 2 min and 2.50 h, respectively. 
In 4 mM ascorbic acid, the half-lives of both complexes decreased to ca. 1 min 
and 1.48 h, respectively. Intriguingly, the simple acetylation of the axial OH 
ligand from 1 to 2 resulted in a vast improvement in terms of reduction 
resistance by a factor of 67 to 89 folds as well as aqueous kinetic solubility in 
PBS by 10 folds (see SI). This vindicated the utility of the asymmetrical 
approach in the design of platinum(IV) anticancer prodrugs recently advocated 














86.2  3.4 % 
RPLC - - 83.2  0.8 % 
Table 3.1. Conversion yields of 1 and 2 to cisplatin as well as satraplatin to 
JM118. Values are reported as mean with standard error. a) Reduction in PBS 
(10 mM phosphate, 137 mM NaCl and 2.7 mM KCl) b) Reduction in 200 mM 





Figure 3.5. Rate of reduction of 180 uM of 1, 2 and satraplatin dissolved in 
200 mM phosphate buffer + 137 mM NaCl in the presence of 2 mM ascorbic 
acid (left) or 4 mM ascorbic acid (right). ). Curve was fitted using Graphpad 
Prism 5. 
 
The reduction rates we obtained were consistent with work reported by Gibson 
and Hambley studying platinum(IV) prodrug complexes bearing an oxaliplatin 
template, Pt(dach)(oxalate). It was observed that cis,cis,trans-
Pt(dach)(oxalate)(OH)(OAc) was reduced faster than cis,cis,trans-
Pt(dach)(oxalate)(OAc)2 by ascorbic acid despite having a more negative 
reduction potential.37 It was postulated that in the absence of a bridging 
chloride ligand (as typical of a cisplatin-type scaffold), hydroxido groups were 
much better bridging ligands to facilitate electron transfer compared to acetyl 
carboxylates. Our results extend their experimental findings from an 
oxaliplatin-type scaffold bearing [PtN2O2]-motif to cisplatin-type scaffolds 
bearing [PtN2Cl2]. Our results suggest that a bridging hydroxido ligand 
promotes reduction, with or without the presence of a bridging chloride ligand. 
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To the best of our knowledge, this is the first reported study done on the 
relative reduction rate of asymmetrical platinum(IV) complexes bearing a 
cisplatin-type scaffold. Our results when taken together with Gibson and 
Hambley’s reports highlights the importance of critically re-examining some 
of the commonly accepted assumptions guiding the platinum(IV) prodrug 
development since trends applicable to symmetrical platinum(IV) complexes 




Despite the large body of work pursuing the use of platinum(IV) complexes as 
prodrugs of cisplatin, there has yet been a conclusive study demonstrating that 
these complexes would yield cisplatin upon reduction and not merely any 
DNA-reactive platinum(II) species. Our results showed unambiguously that 
asymmetrical platinum(IV) aryl carboxylates bearing the cisplatin-type 
template are indeed such prodrugs and they chemically reduce to form 
predominantly cisplatin. We further observed that reduction of asymmetric 
mono-carboxylate 1, bearing an axial OH, was unexpectedly faster than 
asymmetric bis-carboxylate 2, bearing an axial OAc, illustrating important 




Chemicals & reagents. Satraplatin and JM118 were purchased from Merlin 




diamminedichlorodihydroxoplatinum(IV) were synthesized and purified as per 
literature procedures.38, 39 Succinimidyl 4-formylbenzoate was synthesized as 
reported by Philips et al.40 All other chemicals and reagents were purchased 
from commercial vendors and used without further purification. 
 
Instrumentation. 1H NMR was recorded on a Bruker Avance 300 MHz. 
Chemical shifts are reported in parts per million relative to residual solvent 
peaks. Electrospray ionization mass spectra (ESI-MS) were obtained on a 
Thermo Finnigan LCQ ESI-MS system. Elemental analysis was carried out on 
a Perkin-Elmer PE 2400 elemental analyzer by CMMAC (National University 
of Singapore). Platinum concentrations of stock solutions were measured 
externally by CMMAC (National University of Singapore) on an Optima ICP-
OES (Perkin-Elmer). HPLC was performed on either an Agilent 1200 series 
DAD or a Shimadzu Prominence system. LC-MS was conducted on a Bruker 
AmaZonX ion-trap coupled to a Dionex Ultimate 3000 RSLC system. HILIC 
was performed using a SeQuant ZIC-HILIC column (150 × 2.1 mm i.d., 5 μm, 
200 Å) at a 0.1 mL/min flow rate with 214, 230 and 305 nm UV detection. 
RPLC was performed using a Shimpack VP-ODS column (150 x 4.60 mm i.d., 




diamminedichlorodihydroxoplatinum(IV) (300 mg, 0.898 mmol) was 
suspended in dry DMSO (120 mL). NHS-activated-ester, succinimidyl 4-




suspension. The reaction mixture was stirred vigorously at r.t. for 72 h and 
subsequently filtered through celite to remove unreacted cis,cis,trans-
diamminedichlorodihydroxoplatinum(IV) and metallic platinum. The filtrate 
was reduced in volume to about 0.5 - 1 mL in a lyophilizer before being 
precipitated by addition of DCM (60 mL) and diethyl ether (20 mL). It was 
essential to prevent the filtrate from being lyophilized completely. The crude 
product was then washed sequentially by sonication with DCM (3 x 10 mL), 
water (3 x 5 mL) and acetone (3 x 5 mL) to yield the desired product as a 
white-colour precipitate. At each rinsing step, the washing was continued until 
the rinsing solvent turned from pale yellow to colourless. Yield: 180 mg (43%) 
1H NMR (DMSO-d6, 300.13 Hz): δ 10.07 (s, 1H, CHO), 8.05 (d, 2H, Ar-H, 
3JHH = 8.04 Hz), 7.95 (d, 2H, Ar-H, 
3JHH = 8.04 Hz), 6.05 (m, 6H, NH3, 
1JHN = 
52.4 Hz, 2JHPt = 52.1 Hz); ESI-MS (−): m/z 464.9 [M-H]-; Anal. Calcd, 
C8H12Cl2N2O4Pt (466.18): C, 20.61; H, 2.59; N, 6.01. Found: C, 20.88; H, 
2.58; N, 5.75. Purity (HPLC): 97% at 254 nm. 
 
Synthesis of cis,cis,trans-diamminedichloro(acetato)(4-
formylbenzoate)platinum(IV) (2). Acetic anhydride (8 μL, 0.0848 mmol) 
was added to a solution of 1 (20 mg, 0.0429 mmol) dissolved in dry DMF (1 
mL) and stirred vigorously for 48 h. The solution was evaporated to oil and 
precipitated with diethyl ether (5 mL). The precipitate was washed with DCM 
(5 mL). The crude product was then dissolved in acetone (10 mL) and filtered 
to remove insoluble unreacted complex 1. This process of evaporation, 
precipitation with ether, washing with DCM, reconstitution in acetone and 




THF (10 mL) and filtered. Likewise, the process was repeated. After drying, 
the crude product was washed with minimal cold water (0.5 mL) and the 
desired water-soluble product was isolated from insoluble impurities by 
extracting with water (3 x 15 mL). The combined water portions were pooled 
and evaporated to yield an off-white powder. Yield: 11 mg (50%) 1H NMR 
(DMSO-d6, 300.13 Hz): δ 10.08 (s, 1H, CHO), 8.05 (d, 2H, Ar-H, 3JHH = 8.04 
Hz), 7.96 (d, 2H, Ar-H, 3JHH = 8.04 Hz), 6.65 (br m, 6H, NH3), 1.95 (s, 3H, 
CH3); ESI-MS (−): m/z 506.8 [M-H]-; Purity (HPLC): 97% at 254 nm. 
 
Monitoring reduction outcome of platinum(IV) complexes via HILIC. 
Stock solutions (ca. 1 mM) of 1, 2 and satraplatin were prepared in phosphate 
buffer. Complexes 1 and 2 were dissolved in PBS pH 7.4 (containing 10 mM 
phosphate, 137 mM NaCl and 2.7 mM KCl) while satraplatin was dissolved in 
a higher capacity pH 7.4 phosphate buffer (200 mM phosphate buffer, 137 
mM NaCl). The reductant, ascorbic acid, was then added to a 2 mL portion of 
the stock solutions to give 2-4 mM in the reduction mixture. The aqueous 
reaction mixture was monitored at periodic intervals as follows: 120 μL of 
reaction mixture was aliquoted and diluted with an equivolume of MeCN to 
form a 50% aqueous/MeCN injection mixture which was analyzed via HILIC 
(10 μL injection). An isocratic 70% MeCN/ aq. NH4OAc (20 mM, pH 6.4) 
elution condition was employed. We observed that sonication of the injection 
mixture prior to injection helped to level the solvent baseline at 214 nm. 
Freshly prepared stock solutions containing both parent complexes and their 
reduction products (cisplatin and JM118) at varying concentrations were 




Concentrations of stock solutions were adjusted to [Pt] determined by ICP-
OES. Complexes 1 and 2 were monitored at 214, 230 and 305 nm while 
satraplatin was monitored at 214 and 230 nm only. Initial concentration of 
platinum(IV) complexes were determined from the master stock solutions 
before addition of ascorbic acid using both the calibration curve and ICP-OES 
determination. The reduction yield (cisplatin and JM118) was determined at 
the point in time when the respective peak area plateau out. The identity of all 
the starting materials & reduction products were established by comparing the 
retention time against authentic standards as well as by LC-MS. Experiment 
was repeated in at least duplicates. 
 
Monitoring reduction outcome of platinum(IV) complexes via RPLC. 
Reduction monitoring on RPLC was carried out in a similar manner as HILIC 
with appropriate modifications. Briefly, a reduction mixture contained approx. 
500 μM platinum(IV) complex with 4 mM ascorbic acid in phosphate buffer 
was prepared. At periodic intervals, the aqueous reduction mixture was 
injected directly and monitored via RPLC (20 μL injection) using a gradient 
elution of 5 - 15 % B over 8 min followed by 15 – 50 % B for a further 10 min 
and finally 80 % B from 20 min onwards where solvent A is aq. NH4OAc 
buffer (10 mM, pH 7) and solvent B is MeCN. Reduction yield of satraplatin 
was determined using an established calibration curve by peak area. It was not 
possible to quantify the reduction yield of complexes 1 and 2 as polar cisplatin 





Comparing reduction rate of platinum(IV) complexes. Stock solutions of 1, 
2 and satraplatin (200 μM dissolved in pH 7.4 200 mM phosphate buffer + 
137 mM NaCl) were prepared from master stock solutions of known 
concentrations calibrated by ICP-OES. For each of the three platinum(IV) 
complexes, 900 μL of complex was added to 100 uL of ascorbic acid (40 mM 
in pH 7.4 200 mM phosphate buffer + 137 mM NaCl). For all 3 complexes, 
the final concentration of the reaction mixture was 180 μM complex and 4 
mM ascorbic acid at pH 7.4. The decline of the parent peak area was then 
monitored at periodic intervals by RPLC using the same gradient elution as 
described earlier. Initial peak area was determined by adding 900 μL of 
complex to 100 μL of buffer alone. The experiment was repeated at 2 mM 
final ascorbic acid concentration. 
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formylbenzoate) platinum(II). Pt(NH3)2(Cl)2 
(50 mg, 0.167 mmol) and AgNO3 (26.89 mg, 
0.158 mmol) was stirred vigorously in H2O (1 mL), heated at 40 C for 2 h. 
The reaction suspension was filtered using a syringe filter to give a clear 
filtrate. Sodium formylbenzoate (31.55 mg, 0.183 mmol) was added to the 
filtrate and the reaction mixture was heated at 40 C for 5 h. The resulting 
yellowish-white ppt was washed with H2O (3 x 1 mL). At this stage, the pale-
green crude product contained a mixture of bis-acylated cis-diamminebis(4-
formylbenzoate) platinum(II) and the desired mono-acylated cis-
diamminechloro(4-formylbenzoate) platinum(II). This was then dissolved in 
70% MeCN/ H2O and purified by semi-preparative HPLC.  
 
Figure S3.1. Semi-preparative trace of the crude 







Figure S3.2. ESI-MS of the isolated Pt(II)(NH3)2(Cl)(carboxylbenzaldehyde). 
m/z 411.8 [M-H]-. 
 
 
Figure S3.3. Aquation of cisplatin to form an unidentified product. HILIC 
chromatograms of A) cisplatin in PBS (containing 139 mM Cl-) after leaving 
to stand and B) cisplatin in 50 mM phosphate buffer pH 7 (without Cl-) after 1 
h. C) The DAD-UV-vis spectrum of the peak at 15.6 min showed an absence 
of any chromophores, excluding the possibility that it was a reduction product 
containing a carboxylbenzaldehyde moiety since the latter has a characteristic 








Figure S3.4. Left and right: HILIC (230 nm) and RPLC (214 nm) 
chromatograms respectively of the reduction of 2 by 2 – 4 mM ascorbic acid. 
Legend: a – 4-carboxylbenzaldehyde b – 2 c – dehydroascorbic acid d – 
ascorbic acid e – cisplatin.  
 
 
Figure S3.5. Representative calibration curves. A fresh calibration curve was 
plotted per experiment. Top row: Calibration curves for cisplatin and 1 
respectively at 230 and 305 nm. Bottom row: Calibration curve for JM118 and 
satraplatin respectively at 214 nm.  
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JM118 calibration (214 nm)


























Satraplatin calibration (214 nm)





























Measurement of maximum aqueous kinetic solubility in PBS. Solid 
samples of 1, 2 and satraplatin were continuously added to PBS (pH 7.4) with 
sonication for about 20 min until the point of turbidity. The suspension was 
then syringe-filtered to obtain the corresponding saturated solution. Maximum 















Table S3.1.  Maximum solubility of 1 and 2 and satraplatin in PBS (pH 7.4). 













Induction of Targeted Necrosis with HER2-targeted 
Platinum(IV) Anticancer Prodrugs  





























Molecularly-targeted chemotherapeutics have made considerable 
progress in the clinical outcomes for many malignancies.1 The 
recognition that certain molecular pathways are critical to carcinogenesis 
and continued tumour progression, and may therefore represent an 
Achilles’ heel, has triggered a revolution in cancer drug development. 
However, drug resistance continue to be a significant challenge and it is 
well-recognized that the failure of many chemotherapeutics arises due to 
an inability to induce apoptosis at a cellular level.2, 3 Most cancers 
progressively acquire a myriad of pro-survival adaptations such as a 
mutated p53 tumor suppressor gene and upregulation of the anti-
apoptotic Bcl-2 signal which render them refractory to treatment. 
Although a number of experimental strategies to restore apoptosis 
sensitivity has been explored, these approaches have been severely 
challenged by the vast heterogeneity within the same tumor mass and 
accumulation of multiple unrelated pro-survival mutations 
simultaneously which frustrate molecularly-targeted approaches.4 
Conversely, necrotic cell death has traditionally been shunned in favor 
of apoptosis because the abrupt release of intracellular contents in the 
extracellular space triggers an unintended inflammatory response. Yet it 
has been recognized in recent years as a regulated mode of cell death, 
distinct from apoptosis, which may be harnessed to circumvent defects 





The HER2 receptor tyrosine kinase is a clinically-validated molecular 
target responsible for the initiation, progression and metastasis of a 
variety of cancers.8 It is an epidermal growth factor receptor which is 
highly over-expressed on the cell surface of around 20–30% of breast8 
and 20% of gastric cancers9 and has been associated with poorer 
prognosis. The first FDA-approved clinical agent to exploit HER2 over-
expression is the monoclonal anti-HER2/neu antibody trastuzumab 
(Herceptin®). It has been proposed that trastuzumab antagonizes the 
downstream growth signalling pathway of HER2/neu by inhibiting 
HER2 dimerization as well as promotes immune-mediated killing 
through antibody-dependent cellular cytotoxicity.10 In contrast to the 
full-length antibody (ca. 150 KDa), a shorter peptidomimetic could 
retain comparable targeting capability while displaying superior tissue 
penetration. A family of short exocyclic peptides designed to mimic the 
CDR-H3 recognition loop of trastuzumab, named AHNP (anti-
HER2/neu peptide), have been shown to bind HER2 with high affinity.11, 
12  
 
In order to achieve highly selective Pt drugs, we developed a HER2-
targeted Pt agent by tethering an anti-HER2/neu peptide (AHNP) 
targeting sequence to Pt(IV) prodrug scaffolds of both cisplatin (CDDP) 
or oxaliplatin (OXP) via chemoselective oxime ligation (Fig. 4.1a).13 
The Pt(IV) scaffolds are native prodrugs which can be activated by 
intracellular reduction to release their cytotoxic Pt(II) payload with 




Here in this work, we report that Pt(IV)-AHNP conjugates exhibit an 
unique biphasic mode of action which is profoundly different from their 
clinically used Pt(II) counterparts. The first phase involves rapid killing 
via targeted necrosis instead of apoptosis, due to massive Pt influx. The 
surviving cell population, although still viable, exhibited a phenomenon 
of delayed cell death, possibly due to mitotic catastrophe. The Pt(IV)-
AHNP conjugates were also more selective against HER2-amplified 
cells while sparing normal HER2 expressing cells. Although the concept 
of targeted necrosis has often been advocated, there have been very few 
actual proof of concepts reported in literature.6 We offer evidence 
supporting targeted necrosis as a viable alternative to conventional 
apoptosis-inducing agents, while precluding potential non-specificity 
associated with the necrotic death pathway. 
 
 
Fig. 4.1 Synthesis of HER2-targeted Pt(IV)-AHNP conjugate 
consisting of an AHNP motif tethered to a cytotoxic Pt pharmacophore. 
The AHNP motif was separated with a small tripeptide spacer (GGK) 








lysine residue. Peptide sequence: H2N-
YC*DGFYAC*YMDVGGKK(aminooxy)-CONH2 (* - linked disulfide 
bridge). 
 
Results & Discussion  
Design and synthesis of HER2-targeted Pt(IV)-AHNP conjugates. 
We postulated that a Pt(IV) prodrug scaffold conjugated to the HER2-
targeting AHNP peptide could selectively deliver CDDP or OXP into 
HER2 over-expressing cells while reducing collateral toxicity. We 
previously showed that the asymmetrical Pt(IV)-benzaldehyde-bearing 
scaffold, based on CDDP, was reduced with dissociation of the axial 
ligands to yield CDDP predominately.16 The CDDP-based Pt(IV) 
scaffold 1 was synthesized as previously described starting from 
oxoplatin, by reacting with a N-hydroxysuccinimide-ester of 4-
formylbenzoic acid followed by acetylation with acetic anhydride (Fig. 
4.1b).16 The OXP-based Pt(IV) scaffold 2 was synthesized via a different 
route in order to take advantage of the synthetically accessible trans-
OXP-(OH)(OAc) precursor17 by acylation with 4-formylbenzoyl 
chloride in the presence of pyridine as an organic base. The crude 
product was subsequently purified by flash column chromatography. 
Acetal formation due to the reactive aldehyde moiety was readily 
observed in the presence of MeOH and can be resolved by excluding it 
entirely. Pt(IV)-AHNP conjugates, based on CDDP and OXP, 3a and 4a 
were synthesized via a chemoselective oxime ligation strategy.13, 16 
Pt(IV)-dAHNP conjugates 3b and 4b, bearing a non-binding peptide 
altered at 3 key residues on ANHP, were prepared as controls. In 




desired (aminooxy)acetylated peptide with slight stoichiometric deficit 
of 1 or 2 in 60% v/v DMSO. The oxime ligation proceeded quickly and 
was usually completed within 2 h with minimal side-products observed. 
The crude products were purified by semi-preparative HPLC with 
moderate yields between 19–51% after isolation. Characterization of the 
conjugates was carried out using ESI-MS and their purities were 
ascertained to be between 94–98% purity by analytical HPLC (SI). 
 
Pt(IV)-AHNP conjugates exhibits rapid and massive drug uptake 
and selectively kills HER2(+) cells in coculture. We evaluated whether 
Pt(IV)-AHNP could enhance cellular uptake and deliver their cytotoxic 
payload through the HER2-targeting motif in line with our design 
strategy. Enhanced uptake of 3a and 4a was observed, following short-
term drug exposure to highly HER2-expressing NCI-N87 gastric cancer 
cell-line for 4 h and subsequent analysis of whole cell and nuclear 
uptake by ICP-MS (Fig. 4.2a).18 Although extracellular reduction of 
Pt(IV) in cell-culture media may occur, this was not expected to be a 
significant factor within the short 4 h duration.19 CDDP and OXP 
exhibited similar whole cell uptake of 170.23.5 and 170.16.4 pmol per 
106 cells respectively. The targeted CDDP-AHNP (3a) and OXP-AHNP 
(4a) conjugates presented dramatically higher whole-cell uptakes of 
4246450 and 1598138 pmol per 106 cells respectively which was ca. 
25-fold and 9-fold greater than their parental drug (p < 0.01). 
Accordingly, nuclear uptake of 3a and 4a was 3-fold and 12-fold higher 




untargeted Pt(IV) precursors, 1 and 2, as well as control Pt(IV)-dAHNP 
conjugates, 3b and 4b, were not as readily taken into NCI-N87. Since 
control peptide dAHNP differed minimally from AHNP, mainly by 
substitution of L to D-isomer amino acids, and is expected to have 
similar polarity, the superior uptake of 3a and 4a suggest selective 
uptake mediated by HER2 receptors rather than by passive diffusion. In 
agreement, both 3a and 4a were cytotoxic while the control conjugates 
3b and 4b were effectively non-cytotoxic (IC50 > 100 M) based on 
MTT metabolic activity assays after 72 h exposure (Figure S4.2). We 
reasoned that the massive and rapid uptake of the targeted Pt agents 
relative to their parental drugs within a short time frame could explain 
for the conjugates’ unique killing profile. 
 
In line with our hypothesis of selective targeting, we further 
evaluated if 3a and 4a could selectively kill HER2 positive cells while 
sparing cells with basal HER2 levels. We utilized a co-culture model 
comprising NCI-N87, with high HER2 expression, and A2780 ovarian 
carcinoma, with significantly lower but still detectable levels of HER2.20 
A co-culture of NCI-N87 (unstained) and A2780 (pre-stained with 
CellTrackerTM Green as a tracer) was drug-treated for 24 h before 
staining with propidium iodide (PI) to determine cell viability by flow 
cytometry analysis. A ratio of 4:1 NCI-N87 (48 h doubling time) to 
A2780 (13 h doubling time) was seeded 24 h prior to drug treatment so 
that both cell lines were at approximately equal proportions at the point 




A2780 ovarian cancer cell-line was chosen rather than healthy primary 
cultures as a more challenging co-culture model because both CDDP and 
OXP already feature modestly favourable therapeutic index, killing 
cancer cells over normal healthy cells in most cases. The results indicate 
that 3a and 4a not only demonstrated superior killing of NCI-N87 but 
were more selective compared to the untargeted CDDP and OXP (p < 
0.001) (Fig. 4.2b). CDDP and OXP treatment of the co-culture did not 
discriminate between NCI-N87 and A2780. In contrast, the trend was 
sharply reversed with 3a and 4a which killed a significantly higher 
percentage of NCI-N87 relative to A2780 (p < 0.001). 
 
Fig. 4.2. (a) Pt(IV)-AHNP conjugates are much more efficiently taken 
up into cells. Whole cell (left) and nuclear (right) uptake after drug 
treatment (20 M) for 4 h in NCI-N87 as measured by ICP-MS. 
Statistical analysis by unpaired Student’s t test. (b) Pt(IV)-AHNP 
conjugates selectively kill HER2 over-expressing  NCI-N87 over the 
normal HER2 expressing A2780. A co-culture of NCI-N87 and A2780 
(pre-stained with CellTracker™ Green) was drug-treated for 24 h before 
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Bonferroni post-tests. Means ± s.e.m. (* p < 0.05, ** p < 0.01, *** p < 
0.001) 
 
Distinctly different cell-killing profile of Pt(IV)-ANHP conjugates 
via targeted necrosis. Clinical Pt(II) agents namely CDDP, carboplatin 
and OXP induce tumor cell death through DNA-damage mediated 
apoptosis.3, 21 We therefore employed the Annexin V apoptosis assay in 
order to evaluate the mode of cell death induced by Pt(IV)-AHNP 
conjugates 3a and 4a. Cells were exposed to the Pt agents for 24 h 
before staining with Annexin V-EGFP and PI. Annexin V binds to 
surface-exposed phosphatidylserine residues, which migrates from the 
inner plasma membrane leaflet towards the outer leaflet during 
apoptosis.22, 23 To facilitate comparison, the complexes were tested at 
equi-concentrations (15 M), close to the clinically relevant peak plasma 
CDDP concentration of 13.03  4.70 M after a standard intravenous 
dosage (100 mg/m2).17 As expected, both CDDP and OXP-treated NCI-
N87 cells displayed appreciable apoptotic cell populations in early 
(Annexin V+/PI-) and late-stage apoptosis (Annexin V+/PI-) which 
increased in a dose-dependent manner (Fig. 4.3a and 4.3b (left)). In stark 
contrast, both 3a and 4a-treated NCI-N87 shown predominately cell 
death via primary necrosis (Annexin V-/PI+), indicating that the plasma 
membrane has been compromised without phosphatidylserine exposure 
(Fig. 4.3a and 4.3b(left)). 
 
In agreement, the morphology of OXP-treated NCI-N87 cells displayed 
characteristic features of apoptotic cell death (cell rounding and 




fragmentation of DNA) (Fig. 4.4a).24 On the other hand, 4a-treated NCI-
N87 did not show the same defining morphology and instead presented 
irregular nuclear fragmentation (both karyolysis and karyorrhexis) as 
well as the appearance of dead de-nucleated cell-debris, still attached to 
the substrate, bearing the same polygonal morphology as healthy cells. 
The exposure of phosphatidylserine is an early event in the apoptotic 
process which precedes many other characteristic features such as cell-
shrinkage and nuclear condensation.22, 23 Although Pt(IV)-AHNP 
conjugates displayed higher nuclear Pt levels than their Pt(II) congeners 
(Fig. 4.1a), therefore more DNA platination, only minimal apoptosis was 
observed in the former. This suggest that the Pt(IV)-AHNP conjugates 
induced very rapid membrane permeabilization before the apoptotic 
cascade of events could be initiated by DNA-damage recognition 
proteins.  
 
As reactive oxygen species (ROS) is a well-known stimulus of necrosis, 
we further investigated if the observed necrosis was ROS-mediated. 
Cellular ROS on NCI-N87 was measured using 2’,7’–
dichlorofluorescein diacetate (DCFDA), a redox sensitive probe, 1 and 4 
h after drug-treatment (Fig. S4.1). After 4 h, 3a and 4a gave a 1.7-fold 
and 1.3-fold signal increase respectively over non-treated control cells. 
In comparison, the AHNP peptide alone led a signal increase of 1.6-fold. 
Since the AHNP peptide was by itself a modest effector of ROS with 
associated necrotic cell death (Fig. 4.3b), a non-passive role of the 




levels of 3a and 4a-treated cells was not correlated with its cell-killing 
ability and it is thus probable that ROS was not the sole factor in 
inducing necrotic cell death here. 
 
 
Fig. 4.3.  Apoptosis was evaluated by AnnexinV/ PI staining of 
drug-treated cells after 24 h. (a) Scatter plot of treated NCI-N87 cells (15 
M drug) (b) Barchart of apoptosis-sensitive NCI-N87 (left) and 
apoptosis-resistant BT-474 (right) after 24 h exposure. Each bar depicts 
% of cells at either early-stage apoptosis, late-stage apoptosis or 
necrosis. Tabulated data in Table S4.1. 
 
The loss of a functional p53 is a well-established biomarker for Pt-
associated apoptotic resistance both in vitro and in vivo which arises due 
to consequent failure in enacting the apoptotic cell death machinery in 









































































































































































































































































is resistant to apoptosis on the basis of its temperature-sensitive p53 
status that is defective at 37C.25 In keeping with NCI-N87, BT-474 cells 
exhibit high HER2 expression levels.26 Pt(IV)-AHNP conjugates were 
more potent in both apoptosis-sensitive NCI-N87 and apoptosis-resistant 
BT-474 cells compared to their parental drug following 24 h exposure 
(Fig. 4.3b). AHNP peptide alone displayed only modest cell-killing. In 
NCI-N87, about 31.6% and 34.5% of cells were non-viable (Annexin 
V+ or PI +) following 15 M drug exposure of 3a and 4a compared to 
15.8% and 18.8% with CDDP and OXP treatment, respectively. Against 
p53-dysfunctional BT-474 cells, no signs of early apoptosis (Annexin 
V+/PI-) were observed regardless of drug-treatment. Both CDDP and 
OXP-treated cells fared no better than untreated control cells (Fig. 4.3b). 
In contrast, Pt(IV) conjugates 3a and 4a surpassed their parental drugs at 
22.5% and 47.2%, respectively, through induction of necrosis. Taken 
together, these results suggest that 3a and 4a can overcome apoptotic 
resistance through HER-2 targeted necrosis. 
 
Surviving tumour cell population exhibit delayed cell death and 
suppression of long-term proliferation. We observed a curious 
biphasic killing mechanism on NCI-N87 cells by Pt(IV)-AHNP 
conjugates which was hinted at by visual monitoring of drug-treated 
cells under conventional microscopy (Fig. 4.4b and S4.3). The first 
phase comprised a rapid killing of between 30–35% of cells via necrosis 
(as ascertained by Annexin V), continued proliferation of the surviving 




death (Fig. S4.3). This sharp discernible two-phase rate of killing was 
not apparent with the free parental drugs. The surviving population of 
Pt(IV)-AHNP treated cells were still viable and retained limited 
proliferation capacity in the short term (but not long term). The 
surviving population of 3a and 4a-treated NCI-N87 cells were 
significantly more metabolically active compared to CDDP and OXP-
treated cells after an intermediate 3-day period (Fig. S4.2). The MTT 
assay, which measures oxidoreductase activity, was used to assess 
metabolic activity of treated cells relative to non-treated cells after 72 h. 
3a and 4a-treated cells (15 M) displayed higher metabolic activities of 
48.22.3% and 49.02.1% compared to 25.04.3% and 21.04.3% with 
CDDP and OXP, respectively. This result suggested that there were 
more viable cells following treatment of 3a and 4a as compared to 
parental CDDP and OXP despite the more rapid induction of necrotic 
cell death by the conjugates. Yet the MTT assay cannot distinguish 
between cell-killing and the inhibition of cell proliferation (cytostasis) 
since both these factors could contribute to the measured metabolic 
activities. 
 
One of the hallmarks of cancer is the capacity for indefinite growth and 
replication.27 In order to track the long-term proliferation ability of the 
surviving cell population, we employed a combination of confocal 
microscopy and clonogenic assay to monitor the fate of treated cells (15 
M for 24 h) which were subsequently allowed to recover in fresh media 




cells undergo modest cellular expansion but displayed increasingly 
severe nuclear fragmentation 1–6 d after treatment (Fig. 4.4b). The 
nuclear morphology at 24 h (when 4a was aspirated) was still relatively 
intact, indicating that subsequent nuclear deformation was independent 
of the acute necrotic phase. We hypothesized that the abnormal nuclear 
morphology observed with concomitant delayed cell death was due to 
mitotic catastrophe, a consequence of aberrant mitosis.5, 28 4a-treated 
cells displayed micro-nucleation, multiple nuclei as well as enlarged 
irregular nuclei which are morphological features suggestive of mitotic 
catastrophe (Fig. 4.4a-b).5, 28 4a-treated cells gave rise to abnormal 
progeny suggesting that the mitotic defect, presumably due to a 
combination of DNA damage and impairment to the mitotic machinery, 
was durable even after the compound was removed. By day 6, all 4a-
treated cells were either dead (de-nucleated) or exhibited severely 
abnormal nuclear morphology implying that continued long-term 
proliferation was unviable. On the contrary, the few surviving cell 
population in OXP-treated NCI-N87 displayed a healthy-looking nuclear 
morphology which may suggest a capacity for re-growth if allowed to 
recover further (Fig. 4.4a). The cell cycle analysis of 4a-treated NCI-
N87 over 72 h indicated a transient G0/G1 arrest which occurred between 
the 27th to 49th hour followed by progression into the S phase and 
abrogation of the G2/M mitotic checkpoint between the 49
th to 72th h 
(Fig. S4.4). This mitotic entry of the cell despite cellular damage, and 
without an apoptotic response, is consistent with a hypothesis of 




treated cells indicated a markedly different DNA content profile, 
implying a different mechanistic action (Fig. S4.4). There was a slight 
accumulation into the early S phase (but not late S phase), paralleled by 
a sharp increase in the sub-G0 phase (DNA laddering) which implied 
that cellular apoptosis was induced shortly after initiation of DNA 
synthesis. 
 
Fig. 4.4.  (a) Representative overlaid microscopy images of control 
and treated NCI-N87 (15 M drug for 24 h and allowed to recover in 
fresh media for a week). Differences in nuclear morphology were 
visualized by Hoechst 3342 staining. Untreated cells were shown at day 
1 while drug-treated cells were shown at day 6. (b) 4a-treated NCI-N87 
undergoes short-term proliferation 24 h after drug treatment but display 
increasing severe nuclear fragmentation over 7 d (left to right). (c) 
Clonogenic assay of NCI-N87 (left) and BT-474 (right) to assess the 
long-term proliferation ability of single cells drug-treated for 24 h and 
allowed to recover in fresh complete media. Representative image of 
AHNP-treated NCI-N87 colonies shown in the inset. Statistical analysis 
by unpaired Student’s t test against non-treated control. Means ± s.e.m. 

















































































































































Although the surviving population of 4a-treated cells were more 
metabolically-active compared to OXP-treated cells and in fact exhibited 
transient cellular expansion, the progressively distorted nuclear 
morphology of 4a-treated cells and its progeny suggested that long-term 
cellular division was unlikely. Thus, a clonogenic assay was performed 
in order to substantiate this hypothesis. The clonogenic assay measures 
the ability of single cells to divide through at least six generations 
(forming colonies  50 cells). In both NCI-N87 and BT-474, pre-treating 
the cells for 24 h was sufficient to induce a near complete abolishment 
of colony forming units with CDDP, OXP and the Pt(IV)-AHNP 
conjugates (p < 0.001) but not with free AHNP (Fig. 4.4c and S4.5). In 
NCI-N87, any significant differences between the free parental drug and 
conjugates 3a and 4a were not observed because both cell cycle arrest 
and cell death precluded colony formation. Furthermore, although the 
concentration tested of both CDDP and OXP were ineffective in 
triggering apoptosis in the resistant BT-474 cell-line, it was still 
sufficient to inhibit long-term proliferation. In contrast, free AHNP 
peptide was effective in directly killing both cell-lines (Fig. 4.3b) but 
was unable to halt long-term proliferation (Fig. 4.4c), indicating that 
these events are not necessarily correlated.  
 
Taken together, our results indicate that the Pt(IV)-AHNP conjugates 
were mechanistically very different from their Pt(II) counterparts, and of 






Unlike molecular targeted therapy, non-specific alkylating agents like 
CDDP and OXP may have multiple modes of action arising from 
different biological targets including DNA.29, 30 A broader spectrum of 
action could be therapeutically favorable because it potentially 
circumvents multi-factorial apoptosis-resistance signaling pathways. We 
investigated two potent HER2-targeted Pt(IV)-AHNP agents based on 
the clinically-used Pt(II) drugs CDDP and OXP. Despite being prodrugs, 
conjugation of a HER2-targeting peptide drastically altered the mode of 
cell death, presumably via massive and rapid Pt influx. These conjugates 
exhibited a unique biphasic mode of action and selectively killed highly 
HER2-expressing cells under co-culture conditions, even against 
phenotypes that are resistant to apoptosis. Our work highlights targeted 
necrosis as a viable alternative cell death modality that can be harnessed 
to overcome defective apoptosis hampering many conventional chemo- 
and targeted anticancer agents.  
 
Materials and Methods 
General reagents. Unless otherwise stated, all starting reagents are 
commercially available. Cisplatin,4 cis,cis,trans-
diamminedichloro(hydroxido)(4-formylbenzoate)platinum(IV) 1,16 
oxaliplatin,31 and trans-acetato[(1R,2R)-cyclohexane-1,2-diamine-






Peptides. The HER2/neu binding peptide (AHNP) and control non-binding 
peptide (dAHNP) were custom-synthesized by ChinaPeptides (Shanghai) and 
modified with an (aminooxy)acetic acid linker at the ε-amino group of the 





Instrumentation. 1H NMR was recorded on a Bruker Avance 300 MHz or 
400 MHz. Chemical shifts are reported in parts per million relative to residual 
solvent peaks.32 Electrospray ionization mass spectra (ESI-MS) were obtained 
on a Thermo Finnigan LCQ ESI-MS system. Elemental analysis was carried 
out on a Perkin-Elmer PE 2400 elemental analyzer by CMMAC (National 
University of Singapore). Platinum concentrations of stock solutions were 
measured externally by CMMAC (National University of Singapore) on an 
Optima ICP-OES (Perkin-Elmer). In some cases, platinum concentrations 
were also measured on an Agilent 7500 Series ICP-MS. Analytical UV-vis 
absorbance was measured on a Shimadzu UV-1800 UV-vis spectrophotometer. 
Analytical reversed phase HPLC (RPLC) was conducted on a Shimadzu 
Prominence or an Agilent 1200 series DAD using Shimpack VP-ODS column 
(5 μm, 120 Å, 150 × 4.60 mm, 1.0 mL min-1 flow). Semi-preparative HPLC 
was performed on a Shimadzu Prominence using YMC-Pack Pro C18 column 







formyl-benzoyl chloride (111.8 mg, 0.663 mmol) dissolved in dry acetone (2 
mL) was added dropwise to a suspension of trans-acetato[(1R,2R)-
cyclohexane-1,2-diamine-N,N'](ethanedioato-O,O')hydroxidoplatinum(IV) 
(105.1 mg, 0.222 mmol) and pyridine (680 L, 8.44 mmol) in dry acetone (15 
mL). The reaction mixture was stirred vigorously and refluxed overnight to 
give a pale yellow suspension. The solvent was evaporated in vacuo and the 
precipitate was dissolved in minimal MeCN and precipitated with chilled 1:1 
DCM/diethyl ether. The crude mixture was left at 4 C for 1 h to promote 
further precipitation. The crude precipitate was then triturated with DCM, 
redissolved in acetonitrile and purified by flash silica gel chromatography (1:1 
DCM/MeCN and 0.01% AcOH; Rf = 0.4) to yield a yellow powder. Yield: 
14.2 mg (10.6 %) 1H NMR (DMSO-d6, 300.13 Hz): δ 10.08 (s, 1H), 8.4 (br m, 
4H), 8.05 (d, 2H), 7.97 (d, 2H), 2.66 (br m, 2H), 2.16 (m, 2H), 1.99 (s, 3H), 
1.52 (m, 4H), 1.11 (m, 2H); ESI-MS (-ve): m/z 604.0 [M-H]-; 
C18H22N2O9Pt.2H2O (641.5 g/ mol) calc: C 33.70, H 4.09, N 4.37; found C 
33.36, H 3.91, N 4.38. Purity (HPLC): 1 peak at 254 and 280 nm.  
 
General procedure for synthesis of platinum(IV)-peptide conjugates. In 
general, the platinum(IV)-peptide conjugates (3a-b and 4a-b) were prepared 
by treating the desired (aminooxy)acetylated peptide with slight stoichiometric 
deficit of 1 or 2 in 60 % v/v DMSO. All reagents were pre-dissolved in DMSO 
to form stock solutions. Concentrations of the free peptide was determined by 




Reaction was generally completed within 2 – 4 h as determined by analytical 
HPLC. The desired products were subsequently isolated by semi-preparative 
HPLC using a gradient elution of 10 – 30 % solvent B for the first 25 min 
followed by 30 % B for another 17 min. Purity of the conjugates was assessed 
on an analytical column assessed using a gradient elution of 8 – 30 % B for the 
first 10 min, 30 % B for another 8 min and finally 30 – 80 % B for 7 min. 
Solvent A is aq. NH4OAc buffer (10 mM, pH 7) and solvent B is MeCN. 
 
Cisplatin(IV)-AHNP conjugate (3a). Complex 1 (50.5 uL of a 60.19 mM 
stock solution, 3.04 mol) was added to aminooxy-functionalized AHNP 
peptide (150 L of a 23.76 mM stock solution, 3.56 mol) in 1.4 mL 60 % v/v 
DMSO. The reaction mixture was agitated for 2 h before purification by semi-
preparative HPLC. Yield: ca.1.5 mg (21 %); ESI-MS(-): m/z 1188.6 [M - 
2H]2-; Purity (HPLC): 98 % at 280 nm. 
 
Cisplatin(IV)-dAHNP conjugate (3b). Synthesis of 3b was similar to 3a. 
Yield: ca. 43 %; ESI-MS(-): m/z 1180.9 [M – 2H]2-; Purity (HPLC): 97 % at 
280 nm. 
 
Oxaliplatin(IV)-AHNP conjugate (4a). Synthesis of 4a was similar to 3a but 
using 2 as the platinum(IV) scaffold instead. Yield: ca.19 %; ESI-MS(-): m/z: 





Oxaliplatin(IV)-dAHNP conjugate (4b). Synthesis of 4b was similar to 4a. 
Yield: ca. 51 %. ESI-MS(-): m/z 1229.6 [M – 2H]2-; Purity (HPLC): 96 % at 
280 nm.  
 
Cell culture. The HER2/neu over-expressing human gastric cancer cell-line 
NCI-N87 and breast cancer cell-line BT474 were obtained from ATCC. The 
A2780 human ovarian cancer cell line was obtained from EACC. All cell-lines 
were cultured in complete RPMI 1640 medium containing 10 % fetal bovine 
serum (FBS) and maintained in a humidified of 5 % CO2 at 37 C. 
 
Annexin-V apoptosis assay (24 h). Apoptosis induced by drug treatment was 
assessed by double staining drug-treated cells with Annexin V-EGFP (abcam) 
and PI. Briefly, 2 x 105 cells were seeded per well in 12-well plates in 
complete media (1 mL) and allowed to adhere overnight. The test compounds 
were then diluted in complete medium and added to the cells at the 
concentrations indicated for 24 h. The old drug-containing media was then 
collected and the cells were harvested by trypsinzation and subsequently 
combined with the old media to deactivate trypsin. 2 x 105 cells per well were 
counted, pelleted and resuspended in 500 µL of Annexin-V binding buffer (10 
mM HEPES/NaOH (pH 7.4), 140 mM NaCl and 2.5 mM CaCl2) containing 1 
x Annexin V-EGFP protein and PI (1 µg/mL). Samples were kept in the dark 
and analysed immediately on a flow cytometer (BD LSRFortessa). 





MTT assay for evaluating intermediate-term cellular metabolic activity 
(72 h). The indicated cell-lines were harvested from culture flasks by 
trypsinization and seeded at a density of 4.0 × 103 cells/well in 100 µL 
aliquots into flat-bottomed 96-well tissue-culture plates. Cells were allowed to 
adhere in drug-free complete media with 10 % FBS for 24 h, followed by the 
addition of dilutions of drug in 100 µL/well complete media and further 
incubated for 72 h. At the end of exposure, medium was replaced by 100 
µL/well MTT solution (0.5 mg/mL in PBS). After incubation for 4 h, MTT 
was aspirated and substituted with 100 µL/well DMSO. UV-vis absorbance 
was measured at 570 nm using a microplate reader (Biotek). Experiments were 
performed in sextuplicates for each drug concentration and carried out 
independently in triplicates. Metabolic activity was evaluated with the 
reference to the absolute IC50 value. IC50 values were calculated from 
concentration-response curves (cell viability against log of drug concentration) 
obtained in repeated experiments and adjusted to the actual concentration of Pt 
administered as measured by ICP-OES. 
 
Clonogenic assay for evaluating long term reproductive viability (11 to 15 
d). The cells were harvested by trypsinization into a single-cell suspension and 
subsequently the indicated number of cells, in complete media (2 mL), was 
seeded per well into a 6-well plate. Cells were allowed to adhere for 4 h, 
followed by addition of drug diluted to the indicated concentrations in 
complete media for 24 h. After 24 h, the cells were refreshed with fresh media 
(4 mL) and the cells was incubated for an additional 11 (BT-474) or 15 d 




was then rinsed carefully with PBS (2 x 3 mL), fixed with 3 : 1 v/v MeOH: 
AcOH for 5 min, stained with crystal violet (0.5 % w/v ddH2O) for an 
additional 15 min before rinsing thoroughly with water. Colonies containing 
greater than 50 cells were counted. 
 
Drug targeting assay via co-culture of NCI-N87 and A2780. A2780 and 
NCI-N87 were cultured separately in T75 tissue culture flasks. A2780 was 
stained with CellTracker™ Green (2 uM) (Molecular Probes) in RPMI for 30 
min. The media was aspirated and the cells were subsequently incubated with 
complete RPMI for a further 30 min. Both cell-lines were harvested by 
trypsinization and subsequently A2780 (2.5 x 104 cells / well) was co-cultured 
with unstained NCI-N87 (1 x105 cells / well) in a 12-well plate. The cells were 
rested overnight before drug-treatment for 24 h. After 24 h, the old cell culture 
media (containing detached cells) was kept to deactivate the trypsin 
downstream. Trypsin-EDTA (300 µL) added to the adherent cells for 5 min 
and the harvested cells were transferred to the old culture media to deactivate 
(mostly A2780). Fresh trypsin-EDTA (300 µL) was added for a further 10 min 
and pooled together with the old culture media to deactivate (mostly NCI-
N87). The combined cell fraction was washed with PBS (1 x 500 µL) and 
finally resuspended in PI (1 µg/mL) before analysis on a flow cytometer (BD 
LSRFortessa). 
 
Intracellular platinum accumulation. For whole platinum accumulation, 
NCI-N87 (4 x 105 cells / sample) was drug treated for 4 h at 37 C. After 4 h, 




(2 x 500 µL). The cells was then centrifuged down and the cell pellet was 
digested by heating with 65 % ultrapure HNO3 (300 µL) at 90 C overnight. 
The acid was boiled off and the cellular residue was re-dissolved by sonicating 
in 2 % HNO3 (500 µL) for analysis by ICP-MS. Nuclear platinum 
accumulation was carried out as reported previously.34 All values were 
reported as pmol per 106 cells. 
 
Measurement of intracellular ROS. 2 x 105 cells was seeded in clear-bottom 
black 96 well plate and allowed to adhere overnight. After 24 h, the cells was 
washed with HBSS (1 x 100 µL) and prestained with 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA) (15 M in 100 µL HBSS) 
for 45 min at 37 C. After washing with HBSS (1 x 100 µL), the cells were 
drug treated for the indicated duration. Drug were diluted in supplemented 
HBSS (containing 10 % FBS). At the indicated time and without washing, the 
fluorescence signal on the plate bottom (Ex: 485 nm / Em: 535 nm) was read 
using a microplate reader (Biotek), taking into account background 
fluorescence. 
 
Cell cycle analysis. 2 x 105 cells were seeded per well in 12-well plates in 
complete media (1 mL) and allowed to adhere overnight. The test compounds 
were then diluted in complete medium and added to the cells at the 
concentrations indicated. At various time intervals, the culture media 
(containing detached cells) was removed and kept to deactivate trypsin 
downstream. The adherent cells was washed with trypsin-EDTA (500 µL) and 




cells was then pooled together with the old culture media. The combined cell 
fraction was washed with chilled PBS (1 x 500 µL), followed by dropwise 
addition of chilled 70 % v/v EtOH/ water (500 µL) with constant mixing. 
After 1 h at 4C, the fixed cells were washed with PBS (1 x 500 µL) and 
finally resuspended in RNase (MpBio, 500 µL of a 100 ug/ mL in PBS) and PI 
(50 ug/mL in PBS) for 1 h at r.t before analysis in a flow cytometer (BD 
LSRFortessa). 
 
Visualisation of cellular morphology via fluorescence microscopy. 1 x 105 
cells were seeded per well in 24-well plates in complete media (500 L) on 
poly-L-lysine coated coverslips and allowed to adhere overnight. The cells 
were drug treated in complete media at the indicated concentrations for 24 h. 
After 24 h, the drug-containing media was replaced with fresh com. RPMI (1 
mL). At various time intervals, the 90 % of the old media was aspirated, 
leaving just sufficient to cover the cells and fixed with an equiv.-volume of 3 : 
1 v/v MeOH/ AcOH for 5 min. The fixative was carefully aspirated and fresh 
fixative (300 L per well) was added for another 10 min before washing with 
PBS (1 x 500 uL). Finally, the cells was stained with Hoescht 3342 (2 g/ mL 
in PBS) for about 15 min at r.t and the coverslips was mounted onto slides for 
analysis on a confocal microscopy (FV1000, Olympus) 
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Scheme S4.1. Synthesis of platinum(IV)-AHNP conjugates. Reaction 
conditions: (I) succinimidyl 4-formylbenzoate, in DMSO, r.t. (II) acetic 
anhydride in DMF, r.t. (III) H2O2 in acetic acid, r.t. (IV) 4-formyl-benzoyl 
chloride in acetone, pyridine, reflux. AHNP: H2N-
YC*DGFYAC*YMDVGGKK(aminooxy)-CONH2; dAHNP: 




Table S4.1.  Tabulated data of apoptosis as evaluated by AnnexinV/ PI 
staining of drug-treated NCI-N87 or BT-474 cells after 24 h. Each cell 




ANXV+/PI- ANXV+/PI+ ANXV-/PI+ ANXV+/PI- ANXV+/PI+ ANXV-/PI+
No drug 1.8 6.2 0.8 0.5 4.0 3.0
CDDP 3 uM 1.9 6.3 1.3 - - -
CDDP 15 uM 6.6 7.4 1.9 0.3 4.5 3.0
OXP 3 uM 2.3 7.1 1.0 - - -
OXP 15 uM 7.3 11.5 0.6 0.3 4.0 2.6
AHNP only 3 uM 1.6 6.3 1.1 - - -
AHNP only 15 uM 1.5 7.2 6.9 0.5 4.9 7.3
3a 3 uM 1.4 6.4 7.3 - - -
3a 15 uM 1.8 6.0 23.8 0.4 5.8 16.3
4a 3 uM 1.7 8.4 5.7 - - -
4a 15 uM 1.8 6.4 26.2 0.4 5.0 37.4
NCI-N87 BT-474






Figure S4.1. Measurements of cellular ROS on NCI-N87 after drug-treatment 
using 2’,7’–dichlorofluorescein diacetate (DCFDA) which measures general 
oxidative stress. In some cases, cells were co-treated with butylated 
hydroxyanisole (BHA), an antioxidant. t-butyl hydroperoxide-treated cells was 














































































































































Compound AHNP only CDDP 1 3a 3b 
IC50 (µM) > 60 2.9  0.3 23.1  2.9 15.5  2.4 > 100 
 
Figure S4.2. Intermediate-term potency of the drug conjugates as determined 
by MTT measurements of cellular metabolic activity after 72 h drug treatment 
against the NCI-N87 gastric cancer cell line. (a) Representative dosage-
response curves (b) Table of absolute IC50 (µM). Platinum concentrations 














































































































































































Compound OXP 2 4a 4b 






Figure S4.3. Visual flouresence microscopy monitoring of drug-treated NCI-
N87 over time. NCI-N87 was drug-treated (15 M for 24 h and then allowed 
to recover in fresh media). Nuclear morphology were visualized by Hoechst 
3342 staining. There were substantial floating dead cells in drug-treated cells 
in the initial 24 h drug-treatment period (not shown here). When allowed to 
recover after 24 h drug-treatment, 4a-treated cells undergoes a transient phase 
of cell-profileration, as evidenced by a decrease in empty space at 144 h. The 
cells exhibited increasingly abnormal nuclear morphology over time, implying 











Figure S4.4. Cell-cycle distribution of drug-treated NCI-N87 cells over time. 
Drug-treated cells were permeabilized with 70 % v/v ethanol and stained with 
propodium iodide to determine DNA content. 
  












No drug – 72 h












AHNP only – 72 h

















































































OXP – 27 h 49 h 72 h

























G0/G1 = 68.8 %
S = 11.2 %
G2/M = 14.3 %
G0/G1 = 70.1 %
S = 10.3 %
G2/M = 10.7 %
G0/G1 = 40.5 %
S = 25.1 %
G2/M = 9.6 %
G0/G1 = 35.7 %
S = 20.1 %
G2/M = 6.5 %
G0/G1 = 36.9 %
S = 20.0 %
G2/M = 10.0 %
G0/G1 = 50.8 %
S = 13.7 %
G2/M = 13.0 %
G0/G1 = 60.5 %
S = 11.9 %
G2/M = 4.7 %
G0/G1 = 37.3 %
S = 21.2 %





Figure S4.5. Representative photos of clonogenic assay on NCI-N87 to assess 
the long-term proliferation ability of drug-treated cells. Single cells were 
seeded in a 6-well plate, drug-treated for 24 h and allowed to recover in fresh 
complete media for a further 15 d before counting the number of colonies 


































        
**Cyclohexane ring 


























Figure S4.6b. ESI-MS (-) characterisation of 2: Fullscan, zoom scan (isotopic 




















Figure S4.6c. RP-HPLC purity assessment of 2 dissolved in MeCN-H2O 
using Shimpack VP-ODS column (150 x 5.60 mm i.d). Elution condition: 8–
30 % solvent B for 10 min, 30 % solvent B for 8 min and finally 30-80 % 






Fig. S4.7a. ESI-MS (-) characterisation of cisplatin(IV)-AHNP conjugate 3a: 





















Fig. S4.7b. HPLC chromatogram of cisplatin(IV)-AHNP conjugate 3a. The 
purity of the compound was assessed using Shimpack VP-ODS column (150 x 
5.60 mm i.d). Elution Condition: 8–30 % solvent B for 10 min, 30 % solvent 














Fig. S4.8a. ESI-MS (-) characterisation of cisplatin(IV)-dAHNP conjugate 3b: 










Fig. S4.8b. HPLC chromatogram of cisplatin(IV)-dAHNP conjugate 3b. The 
purity of the compound was assessed using Shimpack VP-ODS column (150 x 
5.60 mm i.d). Elution Condition: 8–30 % solvent B for 10 min, 30 % solvent 







Fig. S4.9a. ESI-MS (-) characterisation of oxaliplatin(IV)-AHNP conjugate 4a: 

















Fig. S4.9b. HPLC chromatogram of oxaliplatin(IV)-AHNP conjugate 4a. The 
purity of the compound was assessed using Shimpack VP-ODS column (150 x 
5.60 mm i.d). Elution Condition: 8–30 % solvent B for 10 min, 30 % solvent 







Fig. S4.10a. ESI-MS (-) characterisation of oxaliplatin(IV)-dAHNP conjugate 













Fig. S4.10b. HPLC chromatogram of oxaliplatin(IV)-dAHNP conjugate 4b. 
The purity of the compound was assessed using Shimpack VP-ODS column 
(150 x 5.60 mm i.d). Elution Condition: 8–30 % solvent B for 10 min, 30 % 
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For the longest time, the contribution of the immune system in chemotherapy 
has been disregarded as cytotoxic drugs are generally believed to be 
immunosuppressive.1-5 Consequently, evaluation of new chemotherapeutic 
agents involved screening of drug candidates upon xenografted tumors in 
immunodeficient mice which neglects any possible immune contribution. 
However, a substantial body of recent work has challenged this assumption. 
There is now a growing consensus that a number of chemotherapeutics do 
stimulate the innate and/or the adaptive immune system and that at least part 
of the observed clinical therapeutic efficacy of these agents actually hinges on 
its off-target immunostimulating mechanisms.1-5 Despite this, there has been 
surprisingly little development in the rational design of chemotherapeutic 
agents with the aim of combining both direct cytotoxicity and 
immunostimulation. Indeed, a multi-pronged immune-chemotherapeutic 
approach would not only shrink tumours but more importantly, reactivate 
dormant immune response against malignancies, therefore conveying long-
term immunity and preventing cancer relapse. 
 
Platinum(II) drugs such as cisplatin, carboplatin and oxaliplatin are some of 
the most effective and widely adopted anti-cancer agents in clinical use 
today.6-8 They form the first line of treatment for many malignancies including 
testicular, ovarian, bladder and non-small cell lung cancer.9, 10 Although 
formation of covalent platinum-DNA adducts is generally accepted as the 
principal mode of action,11 classical platinum agents like cisplatin have also 




immunomodulators of both the innate and adaptive immune system.12 
Platinum agents can indirectly promote immune-mediated killing of cancer 
cells through its action on cancer cells by 1) triggering an immunogenic mode 
of tumor cell death via exposure of specific “eat-me” signals,13 2) increasing 
tumour-cell susceptibility for T-cell killing,14, 15 and 3) by down-regulating 
immunosuppressive PD-L2 in a STAT6-dependent manner on tumour cells 
leading to enhanced recognition by T-cells.16 In addition, platinum agents can 
also directly engage immune effector functions by 1) stimulating both 
monocyte and natural killer (NK) cell mediated cytotoxicity,17-21 2) promoting 
antigen-presenting capacity of dendritic cells,22, 23 and 3) by reversing 
immunosuppressive tumour microenvironments by downregulating PD-L2 on 
dendritic cells16 and by selective depletion of inhibitory myeloid-derived 
suppressor cells (MDSC) and Treg cells.
24 As far back as 1970s, the 
immunostimulating potential of cisplatin had already been recognised by 
Rosenberg, who discovered the antineoplastic properties of cisplatin.25 Since 
then, there has been more compelling empirical evidence corroborating the 
immunomodulating capacity of platinum-based therapy with favourable 
chemotherapy outcomes.13, 24, 26 Nonetheless, the immune-mediating activity 
of platinum-based agents has been neglected in the development of new 
therapeutics which has focused primarily on the principle of targeting DNA 
within tumour cells.  
 
In this work, we designed a novel immune-chemotherapeutic agent by 
tethering a dual-purpose peptide sequence, which behaves as both a FPR1/2-
targetting moiety and an immune adjuvant, to a platinum(IV) prodrug scaffold 




complexes are native prodrugs which are themselves pharmacologically 
inactive and must undergo reductive elimination by endogenous reductants to 
release cisplatin with concomitant dissociation of the axial ligands.6-8 Formyl 
peptide receptors (FPRs), a family of GPCRs which includes FPR1 and FPR2 
(formally designated as FPR and FPRL1 respectively), are selectively 
overexpressed in certain tumors such as breast cancers,28 ovarian cancers29 and 
glioblastomas30, 31 and has been implicated with a more invasive and 
maglignant phenotype owing to its role in mediating metastasis.30, 31 At the 
same time, FPR1/2-binding ligands like WKYMVm and fMLF are also potent 
immunostimulators, activating innate effectors such as monocytes, dendritic 
cells and natural killer (NK) cells, leading to increased cytolytic activity, 
phagocytosis, chemotaxis, cytokine production and superoxide generation.32-34 
FPR1/2 ligands can thus act as both a targeting moiety to deliver cisplatin to 
FPR1/2 overexpressing cancer cells and immune cells35, 36 via rapid receptor-
mediated internalization37 as well as a potent immune adjuvant to provoke an 
immune anticancer response.38 Our work is the first attempt of a rationally-
designed platinum-based anticancer agent combining chemotherapy with 
immunotherapy to achieve therapeutic synergy. Herein, we report a proof-of-
concept to demonstrate the feasibility of this approach which may encourage 
future systematic evaluation of immuno-chemotherapeutic agents. 
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Results & Discussion  
Design & synthesis of FPR1/2-targeted platinum(IV)-peptide conjugates. 
In this two-pronged approach, we postulated that a cisplatin prodrug scaffold 
tethered to a FPR1/2 targeting peptide could simultaneously exert direct 
cytotoxicity against metastatic cancers overexpressing FPR1/2 receptors as 
well as to activate both FPR1/2 expressing monocytes and NK cells with the 
platinum(IV)-peptide adjuvant. From a design standpoint, the platinum(IV) 
scaffold was essential to preserve the immunomodulating cisplatin 
pharmacophore while accommodating the additional peptide group. Otherwise, 
direct conjugation of the peptide to cisplatin at either the ammine or chloride 
ligand positions would inadvertently alter its core structure. The asymmetrical 
mono-functionalised platinum(IV) scaffold 1 was synthesized via a new N-
hydroxysuccinimide(NHS)-ester activated carboxylic acid route which gave 
the mono-carboxylated product preferentially over the di-carboxylated product. 
Presumably, the NHS-activated acid was insufficiently reactive to react with 
the second hydroxido group which is less nucleophilic than the first.39 This 
method is similar to a technique using carbodiimide coupling reagents 
reported by Zhang et al39 but with the added advantage of using an easily 
isolatable activated NHS-ester instead of in situ formation of the activated acid. 






Figure 5.2. Synthesis of cis,cis,trans-diamminedichlorohydroxy(4-
formylbenzoate) platinum(IV) (1), cis,cis,trans-diamminedichloro(acetato)(4-
formylbenzoate) platinum(IV) (2) and subsequent oxime ligation with various 
peptides. 
 
The platinum(IV)-peptide conjugate was synthesized via an chemoselective 
oxime ligation strategy we previously reported,27 which exploited the facile 
and stable bond formed between an aromatic aldehyde group with an 
aminooxy-functionalised peptide. Four different peptide agonists of FPR1/2 
were conjugated to the platinum(IV) scaffold. Annexin1 2-12 (ANXA1 2-12), 
Annexin1 2-26 (ANXA1 2-26), WKYMVm and formyl-MLFK (Figure 5.3). 
The ANXA1 2-12 and 2-26 sequences were reported to have a moderate 
binding affinity to both FPR1 and FPR2 (M range).40, 41 WKYMVm has high 
binding affinity to both FPR1 and FPR2 (nm range) while fMLFK 
preferentially binds to FPR1 (nm range) over FPR2 (M range).34, 41 FPR1/2 
agonists activate phagocytes through a G-protein mediated pathway, leading to 
increased chemotaxis, phagocytosis and cytokine production.32-34 
 
Treatment of a slight excess of the platinum(IV) scaffold 1 and 2 with the 




3a ANXA1 (2-12) OH







yielded the platinum(IV)-peptide drug conjugates, 3a - d and 4, quantitatively 
which were subsequently isolated by semi-preparative HPLC and 
characterised by ESI-MS (mass spectral analysis). The products were stable in 
aqueous solution for over one week as ascertained by HPLC. 
 
FPR-targeted platinum(IV)-peptide prodrugs are selectively cytotoxic 
against FPR1/2 overexpressing tumor cells. The effects of the FPR-targeting 
platinum(IV)-peptide drug conjugates, 3a – d and 4, on in vitro proliferation 
against three FPR1/2 overexpressing tumor cell-lines were assessed via MTT 
assay which measures cell viability (Figure 5.3). U-87MG is a highly 
malignant human glioblastoma cancer whose invasive behaviour has been 
linked to FPR1 overexpression.30, 31 The two human breast cancer lines, MCF-
7 and MDA-MB-231, overexpress both FPR1 and FPR2 receptors.28 The cell 
viability of treated cells were measured after 72 h incubation and the dose-
response curve obtained was used to determine the absolute IC50, defined as 
the drug concentration required to inhibit cell viability by 50%. Cisplatin and 
1 were included for comparison. For accuracy, drug concentrations were 
calibrated to platinum concentrations measured by inductively coupled plasma 
optical emission spectrometry (ICP-OES). 
 
In general, all drug conjugates, with the exception of 3d (fMLFK conjugate), 
exhibited a comparable, if not slightly better, dose-dependent response 
compared to cisplatin across all three cell-lines tested. The IC50 values 
followed a general trend: 1 << 3c (WKYMVm) < cisplatin  3b (ANXA1 2-





Figure 5.3. Cytotoxicity IC50 of FPR1/2-targeted platinum(IV)-peptide 
prodrugs against FPR1/2 overexpressing cell-lines. The cell-viability of drug-
treated cells was measured after 72 h incubation to plot a dose-response curve 
and determine the absolute IC50. Drug concentrations were calibrated to 
platinum measurements via ICP-OES. Means ± s.e.m. (* p < 0.05, *** p < 
0.0001; Student's t test) 
 
MCF-7, 1 was the most cytotoxic followed by 3c which was marginally more 
efficacious than cisplatin, 3b and 3a. Complex 3d was effectively non-
cytotoxic (IC50 > 100 M). Against MDA-MB-231, 1, cisplatin and 3c all bear 
similar IC50. Since the WKYMVm conjugate 3c was the most potent of the 
peptide series, we further evaluated the cytotoxicity of related WKYMVm 
conjugate 4. The IC50 values of 3c and 4 were similar across all 3 cell-lines, 
indicating that the differences in reduction rate between the parent scaffolds 
did not affect observed cytotoxicity in vitro. The precursor scaffold 1 was the 
most potent against MCF-7 and U-87MG but comparable to cisplatin on the 









































































Cisplatin 24.8 24.2 30.8
1 6.5 8.8 34.2
3a 25.5 25.9 ND
3b 19.3 25.5 ND
3c 18.6 22.4 40.9
3d non cytotoxic non cytotoxic ND





attributable to non-specific uptake by passive diffusion rather than by active 
targeting. In contrast to MCF-7 and U-87MG, increased accumulation of 
platinum was not likely to improve cytotoxicity on the cisplatin-resistant 
MDA-MB-231 due to its impaired p53 status.42 We postulate that the 
unexpectedly poor cytotoxicity of the short fMLFK conjugate 3d was most 
likely due to the loss of binding affinity due to close proximity to the platinum 
scaffold. 
 
The specificity of uptake of the platinum(IV)-WKYMVm conjugate 4 was 
further investigated by pre-treating U-87MG cells with increasing 
concentrations of free competitive WKYMVm peptide in order to pre-saturate 
the FPR1/2 receptors. Thereafter, the cells were exposed to 4 for 4 h, before 
being harvested for platinum uptake studies using ICP-MS. Pre-treatment with 
1-, 2- and 5-fold excess of the free WKYMVm peptide led to a corresponding 
decrease in mean platinum accumulation of 4 in the treated cells to 
approximately 76%, 64% and 35%, respectively (Figure S5.1). The reduction 
of platinum uptake by FPR1/2 ligands was attributable to competitive binding 
and consistent with studies conducted with other FPR1/2 targeted agents.36, 43 
Some non-specific binding may account for the fact that complete inhibition 
of uptake was not observed regardless of stoichiometric excess of free 
WKYMVm.36 The uptake inhibition by free WKYMVm was consistent with a 
model of selective drug uptake mediated by FPR1/2 receptors. 
 
To date, only a handful of targeted platinum(IV)-peptide drug conjugates have 
been reported.44-47 Although these targeted prodrugs demonstrated improved 




possibly due to sequestration of active cisplatin away into lysosomal 
organelles. In general, most platinum(IV) prodrugs which achieved greater 
potency than its platinum(II) congener do so by virtue of increased drug 
uptake via passive diffusion due to increased lipophilicity complexes rather 
than by active targeting.48-50 The potential of FPR1/2-targetting peptides as 
vectors for selective drug delivery to immune cells has been already been 
borne out with several examples in literature such as the delivery of anti-HIV 
and anti-inflammatory agents to macrophages.51-53 In particular, internalisation 
of the peptide drug conjugates was found to be rapid and specific.53 Here, we 
show that FPR1/2-targeted drug conjugates can be used for cancer therapy as 
well. We have demonstrated that 3c and 4 had comparable, if not slightly 
better cytotoxicity, compared to cisplatin which suggest active-targeting since 
platinum(IV) complexes tend to be less potent than their platinum(II) congener. 
This is reinforced by the observation that 3d (fMLFK) was effectively non-
cytotoxic implying that the targeting sequence plays a crucial role. Finally, 
drug uptake was FPR1/2-mediated could be inhibited by free competitive 
agonists in a dose-dependent manner. Complexes 3c and 4 were selected for 
further studies due to their favourable cytotoxicity profile. While the in vitro 
cytotoxicity of both complexes were similar, 4 which has a slower reduction 
rate, may be a better candidate due to its increased stability against a 
premature extracellular reducing environment. 
 
Platinum(IV)-WKYMVm drug conjugates activates PBMCs towards a 
tumoricidal stage. The cell-mediated cytotoxicity of drug-activated peripheral 




evaluated by adapting a MTT-based assay described by Loosdrecht et al.54 
Briefly, PBMCs were pre-treated with 10 M each of the compounds for 24 h, 
washed, and co-cultured with pre-seeded tumor cells at a 10:1 ratio for a 
further 72 h. MTT was used to determine the percentage of residual viable 
tumor cells post-incubation. Both tumor cells and PBMCS alone were plated 
as control groups.  
 
The cell-mediated cytotoxicity of PBMCs incubated in suspension for 24 h 
with drugs were significantly enhanced against MCF-7 and MDA-MB-231 but 
not against U-87MG (Figure 5.4). In the absence of drugs, PBMCs incubated 
in medium alone exerted a basal cytotoxicity with a mean cell-viability of 
70.0 %, 87.5% and 70.1 % against MCF-7, MDA-MB-231 and U-87MG 
respectively with reference to tumour cells cultured in the absence of PBMCs. 
Encouragingly, the FPR-targeted platinum(IV)-WKYMVm conjugates, 3c and 
4, were more potent than the positive control cisplatin (Figure 5.4). It is 
unclear why complex 4 was slightly more potent than 3c but we postulate that 
this could be due to the slower rate of reduction of 4 in RPMI (containing 
strongly reducing gluthathione), shielding complex 4 from getting reduced 
prematurely in the extracellular milieu before drug uptake can occur. Free 
WKYMVm peptide alone did not exert significant cell-mediated cytotoxicity 
despite reportedly being a potent activator of monocytes and NK cells.32-34 The 
levels of the extracellular proinflammatory cytokines, tumour necrosis factor 
 (TNF-) and interferon  (IFN-), were also measured to assess monocyte 
and NK cell activation (Figure 5.5). Drug treatment of PBMCs with 4, 




treated PBMCs (p < 0.0001) and the positive control cisplatin (p < 0.0001). 
While cisplatin treatment alone significantly increased both TNF- and IFN- 
secretion compared to non-treated PBMCs (p < 0.01 and p < 0.0001 
respectively), the levels of the cytokines secreted were much lower as 
compared to PBMCs treated with the FPR1/2-targeted complex 4, consistent 
with the results of the cell-mediated cytotoxicity assay. 
 
 
Figure 5.4. Summary of drug induced cell-mediated cytotoxicity. Average cell 
viability (%) of U-87MG, MCF-7 and MDA-MB-231 when co-incubated with 
drug-treated PBMCS after 72 h. Means ± s.e.m. (*** p < 0.0001; Student's t 














































































































































































































Cisplatin is a potent activator of monocytes17, 55 and NK cells19, 21, 55 both in 
vitro and in vivo. Tumoricial activity due to cisplatin activation is believed to 
be due to a combination of two closely intertwined mechanisms due to 1) 
secretion of the proinflammatory messenger cytokines TNF-, IFN- and 
interleukin1 (IL-1),56 which dramatically potentiates the cytolytic capacity of 
monocytes and NK cells, and 2) triggering of a contact-dependent cell death 
by a torrent of reactive oxygen species (ROS), nitric oxide (NO), Fas-FasL, 
TNF–TNFR1 and TRAIL mediated cell death. Briefly, cisplatin-exposed 
macrophages lead to a significant enhancement of iNOS-mediated cell death.20, 
57 This may be a direct result of cisplatin-treatment in a cytokine-independent 
pathway57 or indirectly through a cytokine-dependent pathway mediated by 
TNF- and IFN- secretion.20 Contact-mediated apoptosis of tumor cells, 
expressing the membrane-bound death receptors Fas, TNFR and/or TRAIL-
receptor, may also occur due to a cytokine-dependent monocyte membrane-
bound exposure of the corresponding apoptosis inducing ligands (FasL, TNF-
 and TRAIL) after cisplatin treatment.58, 59 
 
In this work, the platinum(IV)-WKYMVm conjugate, 4, was identified as a 
potent activator of innate immune effectors. Complex 4 was more effective 
than 3c, cisplatin and the free WKYMVm peptide in triggering cell-mediated 
cytotoxicity of MDA-MB-231 and MCF-7 but not U-87MG. This trend was 
corroborated by the extracellular secretion of TNF- and IFN- of drug-
treated PBMCs. These pro-inflammatory cytokines are key mediators of the 
innate immune system, are themselves cytotoxic and can also induce several 




described earlier. It is unknown why treated PBMCs were ineffective against 
U-87MG but this immune evasion may be due to dysregulation of contact-
mediated apopotosis pathways. Intriguingly, we observed a disconnect on the 
susceptibility of the various cell-lines to immune-mediated cytotoxicity and 
direct cytotoxicity. MCF-7 was vulnerable to both mechanisms of cell death 
while U-87MG was vulnerable to DNA-damage induced cell death only. The 
p53 mutant, MDA-MB-231, was resistant to DNA-damage triggered cell death 
but was the most susceptible to immune-mediated cytotoxicity. This 
observation supports the ultility of a multi-pronged immuno-chemotherapy 
approach in the treatment of drug-resistant tumors. 
 
 
Figure 5.5. Secretion of the extracellular cytokines, IFN- and TNF-, after 
treatment of the complex 4, free WKYMVm peptide and cisplatin for 24 hr, as 
determined by sandwich ELISA of the cellular supernatant. Means ± s.e.m. 
(** p < 0.01, *** p < 0.0001; Student's t test) 
 
Conclusion  
Over the last decade, there has been substantial evidence supporting the 
pivotal role of the immune system inducing tumour regression following 
conventional chemotherapy. Even though platinum-based agents dominate 








































































































chemotherapies combinations,60 there has been little interest neither in 
deciphering the molecular mechanism of platinum-mediated 
immunomodulation nor the design of combined immuno-chemotherapeutic 
platinum drugs. We have demonstrated here the feasibility of a rationally-
designed immuno-chemotherapeutic platinum-based agent in achieving 
selective cancer cell-targeting as well as eliciting an immune-response. This 
approach complements conventional chemotherapy with the aim of destroying 
micro-metastasis. We believe that this work could spur for the development of 
clinically-useful immuno-chemotherapeutic platinum-based agents with 
improved therapeutic outcomes.  
 
Methods  
General reagents. Cisplatin and cis,cis,trans-
diamminedichlorodihydroxoplatinum(IV) were synthesized and purified as per 
literature procedures.61, 62 Succinimidyl 4-formylbenzoate was synthesized as 
reported by Philips et al.63 All other chemicals and reagents were purchased 
from commercial vendors.  
 
Peptides. All peptides were modified with the (aminooxy)acetic acid linker at 
either the N terminal or to a lysine residue as specified. The four 
(aminooxy)acetylated peptides ANXA1 (2-12) aminooxy–Ala–Met–Val–Ser–






D–Met–NH2 and fMLFK formyl–Met–Leu–Phe–Lys(aminooxy)–COOH were 
custom-synthesized by ChinaPeptides (Shanghai).   
 
Instrumentation. 1H NMR was recorded on a Bruker Avance 300 MHz or 
400 MHz. Chemical shifts are reported in parts per million relative to residual 
solvent peaks.64 Electrospray ionization mass spectra (ESI-MS) were obtained 
on a Thermo Finnigan LCQ ESI-MS system. Elemental analysis was carried 
out on a Perkin-Elmer PE 2400 elemental analyzer by CMMAC (National 
University of Singapore). Platinum concentrations of stock solutions were 
measured externally by CMMAC (National University of Singapore) on an 
Optima ICP-OES (Perkin-Elmer). In some cases, platinum concentrations 
were also measured on an Agilent 7500 Series ICP-MS. Analytical UV-vis 
absorbance was measured on a Shimadzu UV-1800 UV-vis spectrophotometer. 
Analytical reversed phase HPLC (RPLC) was conducted on a Shimadzu 
Prominence or an Agilent 1200 series DAD using Shimpack VP-ODS column 
(5 μm, 120 Å, 150 × 4.60 mm, 1.0 mL min-1 flow). Semi-preparative HPLC 
was performed on a Shimadzu Prominence using YMC-Pack Pro C18 column 
(5 μm, 120 Å, 250 × 10 mm, 2.0 mL min-1 flow). Analytical hydrophilic 
interaction liquid chromatography (HILIC) was performed using a SeQuant 
ZIC-HILIC column (150 × 2.1 mm i.d., 5 μm, 200 Å) at a 0.1 mL/min flow 
rate with 214, 230 and 305 nm UV detection. LC-MS was conducted on a 







diamminedichlorodihydroxoplatinum(IV) (300 mg, 0.898 mmol) was 
suspended in dry DMSO (120 mL). NHS-activated-ester, succinimidyl 4-
formylbenzoate (300 mg, 1.347 mmol) was then added slowly to the 
suspension. The reaction mixture was stirred vigorously at r.t. for 72 h and 
subsequently filtered through celite to remove unreacted cis,cis,trans-
diamminedichlorodihydroxoplatinum(IV) and metallic platinum. The filtrate 
was reduced in volume to about 0.5 - 1 mL in a lyophilizer before being 
precipitated by addition of DCM (60 mL) and diethyl ether (20 mL). It was 
essential to prevent the filtrate from being lyophilized completely. The crude 
product was then washed sequentially by sonication with DCM (3 x 10 mL), 
water (3 x 5 mL) and acetone (3 x 5 mL) to yield the desired product as a 
white-colour precipitate. At each rinsing step, the washing was continued until 
the rinsing solvent turned from pale yellow to colourless. Yield: 180 mg (43%) 
1H NMR (DMSO-d6, 300.13 Hz): δ 10.07 (s, 1H, CHO), 8.05 (d, 2H, Ar-H, 
3JHH = 8.04 Hz), 7.95 (d, 2H, Ar-H, 
3JHH = 8.04 Hz), 6.05 (m, 6H, NH3, 
1JHN = 
52.4 Hz, 2JHPt = 52.1 Hz); ESI-MS (−): m/z 464.9 [M-H]-; Anal. Calcd, 
C8H12Cl2N2O4Pt (466.18): C, 20.61; H, 2.59; N, 6.01. Found: C, 20.88; H, 
2.58; N, 5.75. Purity (HPLC): 97% at 254 nm. 
 
Synthesis of cis,cis,trans-diamminedichloro(acetato)(4-
formylbenzoate)platinum(IV) (2). Acetic anhydride (8 μL, 84.8 μmol) was 
added to a solution of 1 (20 mg, 42.9 μmol) dissolved in dry DMF (1 mL) and 
stirred vigorously for 48 h. The solution was evaporated to oil and precipitated 
with diethyl ether (5 mL). The precipitate was washed with DCM (5 mL). The 




insoluble unreacted 1. This process of evaporation, precipitation with ether, 
washing with DCM, reconstitution in acetone and filtration was then repeated 
again. The crude product was then redissolved in THF (10 mL) and filtered. 
Likewise, the process was repeated. After drying, the crude product was 
washed with minimal cold water (0.5 mL) and the desired water-soluble 
product was isolated from insoluble impurities by extracting with water (3 x 
15 mL). The combined water portions were pooled and evaporated to yield an 
off-white powder. Yield: 11 mg (50%) 1H NMR (DMSO-d6, 300.13 Hz): δ 
10.08 (s, 1H, CHO), 8.05 (d, 2H, Ar-H, 3JHH = 8.04 Hz), 7.96 (d, 2H, Ar-H, 
3JHH = 8.04 Hz), 6.65 (br m, 6H, NH3), 1.95 (s, 3H, CH3); ESI-MS (−): m/z 
506.8 [M-H]-; Purity (HPLC): 97% at 254 nm. 
 
General procedure for synthesis of platinum(IV)-peptide conjugates. In 
general, the platinum(IV)-peptide conjugates (3a-d and 4) were prepared by 
treating the desired (aminooxy)acetylated peptide with 2x stoichiometric 
excess of 1 or 2 in an aq. buffered solution containing 50 % v/v DMSO. All 
reagents were pre-dissolved in DMSO to form stock solutions. Concentrations 
of the free peptides were measured by UV at 280 nm in 50 mM pH 7 
phosphate buffer.65 Reaction progress was followed by analytical HPLC over 
24 h using a gradient elution of 5–30 % B in the first 15 min followed by 30–
80 % B for 10 min. The desired products were subsequently isolated by semi-
preparative HPLC. Purity of the conjugates was assessed using a gradient 
elution of 20-80 % B over 20min. Unless otherwise stated, solvent A is aq. 




Information for detailed synthetic procedure, characterization and semi-
preparative separation conditions of 3a-d and 4. 
 
Cell lines and cell culture. Human glioblastoma (GBM) cell line U-87MG 
and adenocarcinoma cell lines MCF-7 and MDA-MB-231 were obtained from 
ATCC. All cells were grown in high glucose Dulbecco’s modified Eagle 
medium (DMEM) containing 10 % fetal bovine serum (FBS) and maintained 
in a 5 % CO2 incubator at 37 °C.  
 
Cell viability assay of platinum(IV)-peptide conjugates on FPR1/2 over-
expressing tumors. The indicated cell-lines were harvested from culture 
flasks by trypsinization and seeded at a density of 6.0 × 103 cells/well in 100 
µL aliquots into flat-bottomed 96-well tissue-culture plates. Cells were 
allowed to adhere in drug-free complete DMEM with 10 % FBS for 24 h, 
followed by the addition of dilutions of drug in 100 µL/well complete media 
and further incubated for 72 h. At the end of exposure, medium was replaced 
by 100 µL/well MTT solution (0.5 mg/mL in PBS). After incubation for 4 h, 
MTT was aspirated and substituted with 100 µL/well DMSO. UV-vis 
absorbance was measured at 570 nm using a microplate reader (Biotek). 
Experiments were performed in sextuplicates for each drug concentration and 
carried out independently in triplicates. Cytotoxicity was evaluated with the 
reference to the absolute IC50 value. IC50 values were calculated from 
concentration-response curves (cell viability against log of drug concentration) 
obtained in repeated experiments and adjusted to the actual concentration of Pt 




Cellular platinum accumulation of complex 4 in the presence of free 
competitive WKYMVm. U-87MG was seeded in 35 mm tissue-culture 
petridishes in DMEM supplemented with 2% FBS (5 x 105 cells in 2 mL 
media) and incubated for 24 h. To inhibit uptake of complex 4, the tumor cells 
were pre-treated with increasing concentrations of free WKYMVm or DMSO 
vehicle control and incubated for a further 1 h. The media was aspirated and 
the cells were subsequently treated with complex 4 (10 uM in 1 mL DMEM) 
and incubated for a further 8 h. The cells were then washed carefully with PBS 
and harvested by scraping into microtubes. The cells were centrifudged and 
washed again twice with PBS to remove residual drug. The number of U-
87MG in each microtube was counted accurately followed by acid digestion 
(by heating in 300 uL 65 % ultrapure nitric acid at 90 oC overnight, boiling to 
dryness and re-dissolving the residue in 500 uL 2 % nitric acid) for platinum 
quantification by ICP-MS. The measured platinum levels were adjusted to 
pmol Pt/ 106 cells for comparison. 
 
Cytotoxicity of drug-activated human peripheral blood mononuclear cells 
(PBMCs) against tumor cell-lines. Prior to activation, frozen PBMCs 
(AllCells LLC, USA) were thawed and washed twice with complete RPMI to 
remove freezing medium. 4.1 ×  106 PBMCs were incubated in 5 mL of 
complete RPMI for 24 h at 37 °C. Suspension cultures of PBMCs were drug 
activated by incubating 4.8 × 105 PBMCs with either 10 µM of cisplatin, 3c or 
4 each respectively in an Eppendorf tube in 1 mL of complete RPMI for 24 h 
with gentle shaking periodically at 37 °C. After activation, PBMCs were 




in 1.2 mL of complete DMEM. PBMCS were then co-cultured with the 
indicated tumor cells (pre-seeded 24 h beforehand at a density of 4.0 × 103 
cells/well in 100 µL aliquots into flat-bottomed 96-well tissue-culture plates) 
at an 10:1 effector to target ratio and incubated for 72 h. At the end of 
exposure, medium was replaced by 100 µL/well MTT solution (0.5 mg/mL in 
PBS). After incubation for 4 h, MTT was aspirated and substituted with 100 
µL/well DMSO. UV-vis absorbance was measured at 570 nm using a 
microplate reader (Biotek). Experiments were performed in triplicates for each 
drug-activated PBMCs and carried out independently for three times. Cell 
viability was calculated from the absorbance value of the tumor cells cultured 
with drug-activated PBMCs and non-activated PBMCs (A), the absorbance 
value of PBMCs only (B), the absorbance value of DMSO only (C), and the 
absorbance value of the tumor cells only (D) as follows; 
(𝐴−𝐶) −(𝐵−𝐶)
𝐷 − 𝐶
× 100 %.  
 
Measurements of TNF and IFNγ via ELISA. The amount of the cytokines, 
TNF- and IFN-γ, secreted by drug-treated PBMCS after 24 h into the 
complete RPMI supernatant was measured using the commercially available 
human TNF- and IFN-γ sandwich ELISA screening kits (Pierce) as per the 
manufacturer’s protocol. Calibration standards provided by the kits were 
reconstituted and diluted in complete RPMI. Readings were adjusted to pg/ 
106 cells for comparison. 
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Figure S5.1. Platinum uptake studies of platinum(IV)-WKYMVM conjugate 
4 in FPR1/2-expressing U-87MG cells after 4 h of incubation following pre-
incubation with increasing concentrations of free competitive WKYMVm. 
ICP-MS readings were adjusted to pmol Pt per 106 cells.  
 













































































































































































































































Pt-mono-benzaldehyde (DMF method, heat 55 degrees, 2x NHS, 24 hr)
     Ha 
 Hc    Hb
 
  Hd 






Figure S5.3. ESI-MS (Methanol, -ve mode) characterization of complex 1: 
Fullscan, MS/MS and zoomscan (top to bottom): m/z: found: 464.9 [M-H]-, 
















Figure S5.5. ESI-MS (Methanol, -ve mode) characterization of complex 2: 
Fullscan, zoomscan and MS/MS (top to bottom): m/z: found: 506.82 [M-H]-, 
calculated: 508.2  
 
D:\Student\...\Pt-Ac-benzaldehyde 9/6/2012 5:22:17 PM Pt-Ac-benzaldehyde
Pt-Ac-benzaldehyde #151-156 RT: 2.24-2.31 AV: 6 SB: 5 2.16-2.21 NL: 5.19E5
T: - c ESI Full ms [200.00-800.00]



































556.84 568.67472.82 488.63 684.14 706.90 780.76674.97526.94428.75 791.68754.76744.70634.46 688.24603.73460.77 647.03413.50 440.76 720.02 772.28736.59
Pt-Ac-benzaldehyde #182-200 RT: 2.69-2.96 AV: 19 NL: 1.10E4
T: - p ESI Z ms [503.00-513.00]




































503.87 509.92 511.85510.99 512.85506.05 507.99 509.13507.03 510.58505.57503.07 511.67504.41 512.03509.59503.69 512.68
Pt-Ac-benzaldehyde #235 RT: 3.69 AV: 1 SB: 5 2.16-2.21 NL: 2.17E4
T: - c ESI Full ms2 508.00@cid20.00 [200.00-800.00]





































Figure S5.6. RP-HPLC assessment of purity of Pt-Ac-benzaldehyde 2 
dissolved in MeCN-H2O. Elution conditions for both spectra (A) and (B): 20 – 
80 % gradient elution system with aq. NH4OAc buffer (10 mM, pH 7) (solvent 
A) and MeCN (solvent B) over 20 min at 1.0 mL/min. Column used is: 
Shimpack VP-ODS column (150 x 4.60 mm i.d). 
 
Figure S5.7. HPLC spectra of crude reaction mixture of Pt(IV)-OH-
aminooxy-2-12 (3a) at 295nm. Elution conditions: 8 – 45 % B for 30 min 
followed by 90 % B for the next 10 min. NH4OAc buffer (10 mM, pH 7) 






Figure S5.8.  RP-HPLC assessment of purity of Pt(IV)-OH-aminooxy-2-12 
(3a) dissolved in MeCN-H2O. Elution conditions: 20 – 80 % gradient elution 
system with aq. NH4OAc buffer (10 mM, pH 7) (solvent A) and MeCN 
(solvent B) over 20 min at 1.0 mL/min. Column used is: Shimpack VP-ODS 






















D:\Student\Daniel Wong\Pt-2-12 8/7/2012 9:23:31 AM Pt-2-12
Pt-2-12 #50-61 RT: 1.24-1.53 AV: 12 SB: 15 0.41-0.76 NL: 1.02E6
T: + c ESI Full ms [500.00-2000.00]

































1394.43949.66 1478.52740.20 903.38528.86 999.39810.84620.65 1088.99 1138.01 1850.291197.38 1380.84654.94573.42 1278.98 1437.45 1517.25 1600.09 1724.281670.43 1891.71 1944.961797.11
Pt-2-12 #86-114 RT: 1.88-2.22 AV: 29 NL: 4.91E4
T: + p ESI Z ms [1826.00-1836.00]


































1831.831830.871828.64 1834.65 1835.551833.851829.771826.40 1832.721827.38 1828.191826.70
Pt-2-12 #150-153 RT: 2.96-3.04 AV: 4 SB: 15 0.41-0.76 NL: 9.23E5
T: + c ESI Full ms2 1831.00@cid23.00 [500.00-2000.00]

























































Figure S5.9. ESI-MS (Methanol, +ve) characterization of conjugate 3a: 
fullscan, zoomscan and MS/MS (top to bottom): m/z: found: 915.6 [M+2H]2+ 
and 1831.3 [M+H]+; calculated: 1830.7 
 
Figure S5.10. HPLC spectra of crude reaction mixture of Pt(IV)-OH-
aminooxy-2-26 (3b) at 295nm. Elution conditions: 8 – 45 % B for 38 min, 45 
– 80 % B for 2 min followed by 90 % B for the next 10 min. NH4OAc buffer 

















Figure S5.11. RP-HPLC assessment of purity of Pt(IV)-OH-aminooxy-2-26 
(3b) dissolved in MeCN-H2O. Elution conditions: 20 – 80 % gradient elution 
system with aq. NH4OAc buffer (10 mM, pH 7) (solvent A) and MeCN 
(solvent B) over 20 min at 1.0 mL/min. Column used is: Shimpack VP-ODS 
column (150 x 4.60 mm i.d). 
 
 
Figure S5.12. ESI-MS (Methanol, +ve) characterization of conjugate 3b: 
fullscan, zoomscan and MS/MS (top to bottom): m/z: found: 1784.2 [M+2H]2+; 
calculated: 3568.6 
D:\Student\Charmian Yeo\Pt-mono-2-26 8/21/2012 3:27:42 PM Pt-mono-2-26
Pt-mono-2-26 #74-75 RT: 1.53-1.55 AV: 2 SB: 13 0.78-1.00 NL: 7.39E5
T: + c ESI Full ms [1000.00-2000.00]































1252.801153.88 1864.121449.00 1659.251057.84 1081.631020.43
1355.101329.14 1928.981708.371524.26 1777.491270.80 1631.631500.44 1960.011398.12 1608.221548.53 1737.55
Pt-mono-2-26 #108-114 RT: 2.03-2.10 AV: 7 NL: 5.41E4
T: + p ESI Z ms [1780.00-1790.00]



































1782.06 1788.49 1788.751781.561780.62 1789.43 1789.871782.571781.131780.21
Pt-mono-2-26 #141-143 RT: 2.60-2.64 AV: 3 SB: 13 0.78-1.00 NL: 1.73E5
T: + c ESI Full ms2 1785.00@cid25.00 [1000.00-2000.00]







































Figure S5.13. HPLC spectra of crude reaction mixture of Pt(IV)-OH-
aminooxy-WKYMVm (3c) at 295nm. Elution conditions: 8 – 50 % B for 45 
min followed by 90 % B for the next 15 min. NH4OAc buffer (10 mM, pH 7) 
(solvent A) and MeCN (solvent B) at 2.0 mL/min. 
 
Figure S5.14. RP-HPLC assessment of purity of Pt(IV)-OH-aminooxy-
WKYMVm (3c) dissolved in MeCN-H2O. Elution conditions: 20 – 80 % 
gradient elution system with aq. NH4OAc buffer (10 mM, pH 7) (solvent A) 
and MeCN (solvent B) over 20 min at 1.0 mL/min. Column used is: Shimpack 












Figure S5.15. ESI-MS (Methanol, +ve) characterization of conjugate 3c: 
fullscan, zoomscan and MS/MS (top to bottom): m/z: found: 1376.9 [M+H]+; 
calculated: 1375.4 
 
Figure S5.16. HPLC spectra of crude reaction mixture of Pt(IV)-OH-
aminooxy-fMLFK (3d) at 295nm. Elution conditions: 8 – 45 % B for 30 min 
followed by 90 % B for the next 10 min. NH4OAc buffer (10 mM, pH 7) 
(solvent A) and MeCN (solvent B) at 2.0 mL/min. 
 
D:\Student\Charmian Yeo\Pt-mono-w-pep 9/27/2012 3:33:10 PM Pt-mono-w-pep
Pt-mono-w-pep #18-22 RT: 0.31-0.38 AV: 5 SB: 14 0.02-0.24 NL: 1.32E6
T: + c ESI Full ms [500.00-1500.00]
































539.11 848.81687.48 776.64 1251.57
796.40 989.20892.12752.58
1493.521324.80 1399.111081.841037.68 1437.00948.49802.77 1177.371135.98 1239.96 1301.45
Pt-mono-w-pep #50-109 RT: 0.84-1.60 AV: 60 NL: 1.77E4
T: + p ESI Z ms [1372.00-1382.00]





































1381.971376.46 1377.831372.08 1373.14 1380.441378.611373.68 1374.00 1379.561372.87 1381.391374.61
Pt-mono-w-pep #125 RT: 2.00 AV: 1 SB: 14 0.02-0.24 NL: 1.20E5
T: + c ESI Full ms2 1377.00@cid20.00 [500.00-1500.00]








































Figure S5.17. RP-HPLC assessment of purity of Pt(IV)-OH-aminooxy-
fMLFK (3d) dissolved in MeCN-H2O. Elution conditions: 20 – 80 % gradient 
elution system with aq. NH4OAc buffer (10 mM, pH 7) (solvent A) and 
MeCN (solvent B) over 20 min at 1.0 mL/min. Column used is: Shimpack VP-














Figure S5.18. ESI-MS (Methanol, -ve) characterization of conjugate 3d: 





Pt-mono-FMLFK_121015150112 10/15/2012 3:01:12 PM Pt-mono-FMLFK
Pt-mono-FMLFK_121015150112 #7-8 RT: 0.15-0.17 AV: 2 SB: 3 0.64-0.68 NL: 1.06E5
T: - c ESI Full ms [300.00-1500.00]






























885.16 1003.55 1067.12 1278.08969.28937.26 1134.31432.86 774.05
1207.99 1371.09807.30 899.63 1342.21878.29
677.09511.95 769.26 1380.971247.86560.59356.88 1472.24601.08 1316.19854.82490.53
1406.78630.04 708.91402.82318.79
Pt-mono-FMLFK_121015150112 #7-8 RT: 0.15-0.17 AV: 2 SB: 3 0.64-0.68 NL: 1.06E5
T: - c ESI Full ms [300.00-1500.00]






























885.16 1003.55 1067.12 1278.08969.28937.26 1134.31432.86 774.05 1207.99 1371.09807.30 899.63 1342.21878.29
677.09511.95 769.26 1380.971247.86560.59356.88 1472.24601.08 1316.19854.82490.53
1406.78630.04 708.91402.82318.79
Pt-mono-FMLFK_121015150112 #7-8 RT: 0.15-0.17 AV: 2 SB: 3 0.64-0.68 NL: 1.06E5
T: - c ESI Full ms [300.00-1500.00]






























885.16 1003.55 1067.12 1278.08969.28937.26 1134.31432.86 774.05
1207.99 1371.09807.30 899.63 1342.21878.29
677.09511.95 769.26 1380.971247.86560.59356.88 1472.24601.08 1316.19854.82490.53
1406.78630.04 708.91402.82318.79
 
D:\Student\Charmian Yeo\Pt-mono-FMLFK 10/15/2012 2:49:36 PM Pt-mono-FMLFK
Pt-mono-FMLFK #198-211 RT: 3.84-4.08 AV: 14 NL: 5.33E3
T: - p ESI Z ms [1080.00-1090.00]






























1080.84 1081.26 1086.801082.74 1084.69 1085.771080.15 1088.501087.451082.10 1089.641083.791081.73
Pt-mono-FMLFK #266-275 RT: 5.52-5.80 AV: 10 NL: 2.26E2
T: - c ESI Full ms2 1085.00@cid30.00 [295.00-1500.00]


































Figure S5.19. HPLC spectra of crude reaction mixture of Pt(IV)-Ac-
aminooxy-WKYMVm (4) at 295nm. Elution conditions: 8 – 50 % B for 45 
min followed by 90 % B for the next 15 min. NH4OAc buffer (10 mM, pH 7) 
(solvent A) and MeCN (solvent B) at 2.0 mL/min. 
 Figure S5.20. RP-HPLC assessment of purity of Pt(IV)-Ac-aminooxy-
WKYMVm (4) dissolved in MeCN-H2O. Elution conditions: 20 – 80 % 
gradient elution system with aq. NH4OAc buffer (10 mM, pH 7) (solvent A) 
and MeCN (solvent B) over 20 min at 1.0 mL/min. Column used is: Shimpack 













Figure S5.21. ESI-MS (Methanol, +ve) characterization of conjugate 4: 




General procedure for synthesis of platinum(IV)-peptide conjugates. In 
general, the platinum(IV)-peptide conjugates (3a-d and 4) were prepared by 
treating the desired (aminooxy)acetylated peptide with 2x stoichiometric 
excess of 1 or 2 in an aq. buffered solution containing 50 % v/v DMSO. All 
reagents were pre-dissolved in DMSO to form stock solutions for addition. 
Concentrations of the free peptides were measured by UV at 280 nm in 50 
mM pH 7 phosphate buffer. Reaction progress was followed by analytical 
HPLC over 24 h using a gradient elution of 5–30 % B in the first 15 min 
followed by 30–80 % B for 10 min. The desired products were subsequently 
isolated by semi-preparative HPLC. Purity of the conjugates was assessed 
F:\Student\Charmian Yeo\Pt-Ac-WKYMVm 12/11/2012 12:42:19 PM Pt-Ac-WKYMVm
Pt-Ac-WKYMVm #51-56 RT: 0.89-0.93 AV: 5 NL: 1.76E5
T: + p ESI Z ms [1414.00-1424.00]
































1417.04 1423.411420.471416.111415.38 1417.47 1422.991414.27 1419.59 1421.931416.40 1418.53
Pt-Ac-WKYMVm #177-180 RT: 2.87-2.93 AV: 4 SB: 8 0.02-0.14 NL: 3.45E5
T: + c ESI Full ms2 1419.00@cid25.00 [500.00-1500.00]


































1225.10 1373.20 1419.781314.17 1385.301346.83
Pt-Ac-WKYMVm #34-40 RT: 0.58-0.68 AV: 7 SB: 24 0.14-0.53 NL: 2.43E7
T: + c ESI Full ms [500.00-1500.00]

























928.47 977.34885.21728.71 771.85 1212.55 1404.531099.371019.30 1061.27 1256.16 1300.61840.34800.46 1463.111124.48 1184.62 1360.72
[M+H]+ 




using a gradient elution of 20-80 % B over 20min. Unless otherwise stated, 
solvent A is aq. NH4OAc buffer (10 mM, pH 7) and solvent B is MeCN 
 
Platinum(IV)-peptide conjugate of 1 and ANXA1(2-12) (3a). Complex 1 
(50 µL of a 75.1 mM stock solution) was added to aminooxy-functionalized 
ANXA1 (2-12) peptide (50 µL of a 35 mM stock solution) in 1 mL 50 % 
DMSO–NaOAc (50 mM, pH 5.5) and stirred overnight. The mono-conjugated 
product was subsequently purified by semi-preparative HPLC using a gradient 
elution system of 8–45 % B for 30 min followed by 90 % B for the next 10 
min; ESI-MS (+): m/z 915.6 [M+2H]2+ 1831.3 [M+H]+; Purity (HPLC): 99 % 
at 254 nm. 
 
Platinum(IV)-peptide conjugate of 1 and ANXA1(2-26) (3b). Synthesis was 
similar to 3a but in 1 mL DMSO–KH2PO4 (50 mM, pH 7.5). The mono-
conjugated product was subsequently purified by semi-preparative HPLC 
using a gradient elution system of 8–45 % B for 38 min, 45-80 % B for 2 min 
followed by 90 % B for the next 10 min where solvent A is aq. NH4OAc 
buffer (20 mM, pH 7); ESI-MS (+): m/z 1784.2 [M+2H]2+; Purity (HPLC): 
95 % at 254 nm. 
 
Platinum(IV)-peptide conjugate of 1 and WKYMVm (3c). Synthesis was 
as 3a. The mono-conjugated product was subsequently purified by semi-
preparative HPLC using a gradient elution system of 8–50 % B in the first 45 
min followed by 90 % B for 15 min. ESI-MS (+): m/z 1376.9 [M+H]+; Purity 




Platinum(IV)-peptide conjugate of 1 and fMLFK (3d). Synthesis was as 3a. 
The mono-conjugated product was subsequently purified by semi-preparative 
HPLC using a gradient elution system of 8–45 % B for 30 min followed by 
90 % for the next 10 min; ESI-MS (−): m/z 1084.1 [M-H]-; Purity (HPLC): 
87 % at 254 nm. 
 
Platinum(IV)-peptide conjugate of 2 and WKYMVm (4). Synthesis was 
similar to 3c but with complex 2. ESI-MS (+): m/z 1419.1 [M+H]+; Purity 
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There is growing evidence that conventional chemotherapeutics can modulate 
the immune system and trigger an immune response which sustains a long 
term durable therapeutic outcome.1, 2 It has been proposed that the therapeutic 
efficacy of certain agents (eg. anthracyclines, taxanes and gemcitabine) 
depends, at least partially, on such off-target immune effects.1, 3 Accordingly, 
higher densities of tumor-infiltrating lymphocytes following chemotherapy 
has been correlated with significantly better survival outcomes in colorectal 
and breast cancers.4, 5 One of several ways in which chemotherapeutics engage 
a tumor-specific immune response is by triggering immunogenic cell death 
(ICD) whereby the dying cancer cells initiate a robust immune response, 
acting as a de facto anticancer vaccine.6, 7 Thus, immunocompetent (but not 
immunodeficient) mice vaccinated with dying cancer cells pre-treated with 
ICD inducers (eg. anthracyclines, shikonin and hypericin-PDT) are protected 
against subsequent challenges with live cancer cells.8 Retrospective analysis of 
multiple cancers suggest that human patients treated with chemotherapy 
together with digoxin, an ICD-promoting agent, had improved overall survival, 
especially when the chemotherapy cocktail does not already contain an ICD 
inducer.9 
The ICD-inducing capacity of anticancer drugs has been tied with their 
capacity to elicit endoplasmic reticulum (ER) stress and associated reactive 
oxygen species (ROS) (Figure 6.1).6, 7, 10 It is believed that cancer cells dying 
in response to ROS-mediated ER stress emit a combination of three distinct 
spatiotemporally-defined “danger” signals, which are recognized by the 




established as the biochemical hallmarks of ICD, are: (i) translocation of ER-
resident calreticulin (CRT) to the cell surface during early apoptosis (ii) active 
secretion of ATP and (iii) extracellular secretion of nuclear high-mobility 
group box 1 protein  (HMGB1) at late-stage apoptosis. Cell-surface CRT, the 
dominant pro-phagocytotic “eat me” signal,11 promotes the engulfment of 
cancer cells by professional macrophages such as dendritic cells (DCs) for 
tumour antigen presentation.8 Secreted ATP acts as a “find me” signal as well 
as stimulating purinergic P2RX7 receptors on DCs, triggering production of 
IL-1ß, a pro-inflammatory cytokine which is required for IFN-γ production by 
tumour-specific cytotoxic T cells.6, 7, 10  Finally, HMGB1 binds to toll-like 
receptor 4 (TLR4) on DCs, triggering a myeloid differentiation primary 
response gene 88 (MYD88)-dependent signalling cascade, which promotes 
antigen processing and presentation to T cells.6, 7, 10  Thus, a dysfunctional 
P2RX7 or TLR4 has been correlated with negative therapeutic outcomes in 
both mice and human studies with ICD-inducing chemotherapeutics such as 
doxorubicin, highlighting the immune component as an essential contribution 
to the efficacy of these agents.6, 7, 10 
 

























Although a mainstay of chemotherapy, there has not been a systematic attempt 
to screen both existing and upcoming Pt agents for ICD. It has been reported 
that oxaliplatin but not cisplatin, could induce ICD.12 We evaluated a library 
of Pt agents (Figure 6.2) containing compounds which are either clinically-
relevant or of upcoming interest, as well as structurally-related analogues. The 
library includes cisplatin, oxaliplatin and carboplatin, all of which are in 
clinical use.13 Pt(1R,2R-DACH)Cl2 is a structural analogue of oxaliplatin. 
Picoplatin, satraplatin and phenantriplatin are examples of novel Pt 
compounds either in clinical trials or pre-clinical development while JM118 is 
the active PtII species of satraplatin.14-16 Pt-NHC is an unique cyclometalated 
complex which selectively localizes in the ER and induces ER stress.17 The 
remaining complexes are PtIV prodrugs of cisplatin and oxaliplatin.  
Figure 6.2. Structures of platinum agents used in this study. 
 
Results & Discussion  
Identification of ICD inducers from an in vitro phagocytosis assay. Since a 
critical step for ICD is the engulfment of dying cancer cells by professional 
macrophages,8 we first applied an in vitro phagocytosis assay18 to identify 





CellTracker Orange) were treated briefly (4 h) before co-incubation (2 h) with 
murine J774 macrophages (pre-stained with CellTracker Green). Double-
stained macrophages indicated phagocytosis (Figure 6.3b). With the exception 
of Pt-NHC, which was both very cytotoxic and fluorescent above 10 M, all 
other Pt agents were screened at 50 M. Pt-NHC (5 M) sharply increased 
tumour cell phagocytosis over non-treated controls (38.2 ± 3.5 % vs 12.8 ± 0.2 
%, p < 0.0001) followed distantly by phenantriplatin (20.1 ± 3.6 %), cisplatin 
(20.0 ± 1.0 % at 100 M only), satraplatin (18.8 ± 0.9 %) and picoplatin (17.6 
± 2.8 %) (Figure 6.3a). In contrast, none of the clinically-used Pt drugs nor 
their related analogues promoted phagocytosis at 50 M. Our results diverged 
from a recent work which found oxaliplatin could induce ICD as we observed 
neither increased phagocytosis nor ER-ROS (Figure S6.1).12 Nonetheless, 
there was a certain concentration dependence observed with cisplatin (50 and 
100 M) and Pt-NHC (1 and 5 M), which correlated well with qualitative 
measurements of ER ROS (Figure S6.1). The addition of 2 axial acetato 
ligands to JM118 elevated phagocytosis in satraplatin, which could reflect 
differences in subcellular localisation or accumulation. Phagocytosis was 
corroborated by fluorescence microscopy which shows cytosolic mixing of the 










Figure 6.3. Phagocytosis screening: (a) Orange-stained CT-26 cells were 
drug-treated (4 h) before co-incubating (2 h) with green-stained J774 
macrophages and analysed by flow cytometry. The phagocytosis % was 
calculated from the no. of double-stained macrophages over total no. of 
macrophages. Inset: Fluorescence microscopy of J774 macrophages (green) 
engulfing CT-26 (red) as evident by mixing of the dyes. (b) Representative 
flow cytometry scatter plots showing increased phagocytosis (top right 
quadrant) with Pt-NHC over control. (c) Coating CT-26 with rCRT enabled 
phagocytosis while co-incubation with a CRT blocking peptide abolished 
phagocytosis. Means ± s.e.m. (* p < 0.05, ** p < 0.01, *** p < 0.0001; 
Student's t test). 
 
We determined that the observed phagocytosis was indeed mediated by cell-
surface exposure of CRT. Although other recognition ligands had been 




mediator of immunogenicity in cancer cells.11, 20 CRT, normally located in the 
ER, would be translocated to the outer surface of the plasma membrane in 
response to ER-stress.7 This was then recognized by low-density lipoprotein-
related protein (LRP) receptors on macrophages. Coating the cell surface with 
recombinant murine CRT to CT-26 without drug or treated with 50 M 
cisplatin, resulted in a significant increase in tumor cell phagocytosis over 
basal levels (Figure 6.3c). On the other hand, blocking the CRT-LRP 
interactions via a CRT blocking peptide abolished phagocytosis of Pt-NHC-
treated CT-26 (Figure 6.3c). Hence, these results underscored the requirement 
of ecto-CRT on tumor cells for inducing phagocytosis in our screening 
methodology. 
 
Pt-NHC elicits biochemical hallmarks of ICD. We proceeded to evaluate 
the capacity of Pt-NHC to elicit the distinct biochemical hallmarks of ICD, 
namely CRT exposure, ATP secretion and extracellular HMGB1 release. 
Surface immunostaining under non cell-permeabilising conditions indicated 
that CRT exposure with Pt-NHC (5 M) was a rapid process, detectable as 
soon as 1 h after drug-exposure (Figure 6.4a, b). Furthermore, surface-CRT 
was detected on treated-cells with intact membrane integrity and also before 
phosphatidylserine exposure, implying that the translocation occurred at an 
early stage of apoptosis (Figure 6.4b). Under identical conditions, no immuno-
detectable CRT was observed on the surface of non-treated cells. Confocal 
microscopy analysis of both Pt-NHC (5 M) and cisplatin (100 M) treated 
cells revealed that ecto-CRT was distributed in uneven clusters, which was 




It was proposed that the uneven distribution reflected the segregation of CRT 
away from CD47 (the “don’t-eat-me” signal) and thus promoting 
phagocytosis.20 The release of both ATP and HMGB1 was also clearly evident 
with Pt-NHC treatment (5 M). ATP secretion into the supernatant after 24 h 
treatment was measured via a luciferase-based assay (Figure 6.4c). The 
extracellular release of nuclear HMGB1 was detected as an absence of nuclear 
fluorescence after staining (with Triton-X permeabilisation) of treated cells 
(24 h) with an anti-HMGB1-Dy488 antibody and subsequent analysis by both 
confocal microscopy (Figure 6.4a) and flow cytometry (Figure 6.4c). In 
contrast, the presence of nuclear HMGB1 was clearly evident in non-drug 
treated controls. Thus, Pt-NHC fulfilled all three molecular hallmarks of ICD, 
a feature unique to all other validated ICD inducers such as UVC irradiation, 
anthracyclines and cardiac glycosides.6, 7, 9  
 
Figure 6.4. (a) Left: Rapid patch-like surface exposure of CRT observed by 
confocal microscopy after drug-treatment (1 h) of CT-26 followed by surface 
immuno-fluorescence staining with anti-CRT mAb. Right: HMGB1 release 
from the nuclei of CT-26 after 24 h drug-exposure (permeabilised and stained 
with both anti-HMGB1-Dy488 mAb and PI). (b) Pt-NHC enhanced ecto-CRT 
exposure in live cells (red shaded) compared to non-treated control (dotted 
line). CT26 cells were treated for 1 h (gated against PI- cells) and 4 h (gated 
against AnnexinV- cells) and surface-stained with an anti-CRT-PE mAb (c) 






































































































































































Left: Extracellular release of ATP (left) and HMGB1 (right) of CT-26 after 24 
h exposure.  Means ± s.e.m. (* p < 0.05, ** p < 0.01; Student's t test). 
 
 
Pt-NHC triggers ROS-mediated ER stress. It is believed that ER stress, 
either in tandem with or in parallel to an over-generation of ROS, plays a 
prominent role in ICD. The ER stress response elicited by ICD-inducers would 
ignite a cascade of danger signalling pathways, including the activation of 
protein kinase-like ER kinase (PERK), which is mandatory for CRT exposure 
and possibly ATP secretion.6, 7, 10, 22 Nonetheless, not all ER-stressors (eg. 
tunicamycin) are ICD-inducers but the converse was a pre-requisite.10 ICD-
inducers have been classified into two categories: Type I inducers which 
triggers ER stress via off-target secondary mechanisms, and Type II inducers 
which selectively triggers focused ROS-mediated ER stress and shown to be 
more efficient in emitting danger signals.7, 21, 23 Type II ICD inducers are 
believed to be superior to the more common Type I inducers, which only 
induce collateral ER stress.7, 24 Till date, only a handful of Type II ICD-
inducers had been identified (eg. photodynamic therapy with hypericin, an 
ER-specific photosensitizer, and certain oncolytic viruses).7 Pt-NHC, which 
had minimal DNA-binding affinity, was previously reported to specifically 
localize in the ER and induced an ER stress response via PERK activation.17  
In this context, we sought to demonstrate that the ER stress response was in 
fact ROS-mediated, qualifying Pt-NHC as a Type II ICD inducer. ROS 
production was tracked after short-term drug exposure (4 h) using 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA) as a general ROS 
indicator,25 and ER being visualized by ER-Tracker Red, which bind to 




colocalisation of ROS with the ER (89.2 % as determined by Costes method26) 
with Pt-NHC (1 M) (Figure S6.1). At 5 M Pt-NHC, ER exhibited severe 
deformation and ROS was correspondingly more diffuse and less colocalised, 
possibly as a consequence of increased ER membrane permeability associated 
with ER-stress induced apoptosis.27 In CT-26, ROS was only observed with 5 
M Pt-NHC but not at 1 M. In keeping with MDA-MB-231, the observed 
ROS was relatively diffuse. The absence of ROS with Pt-NHC at a lower 
concentration (1 M) corresponded to significantly lower phagocytosis, ATP 
secretion and HMGB1 release, implying that ROS played a key role in Pt-
NHC associated ICD. Likewise, phagocytosis was only observed with 
cisplatin at 100 M (where intense ROS was observed in a subpopulation of 
cells) but not at 50 M (a concentration where ROS was not observed). In 
general, all Pt compounds which promoted phagocytosis had measurable ROS 
production (Figure S6.1). Phagocytosis induced by Pt-NHC was significantly 
reduced when tumour cells were co-incubated with trolox, an antioxidant 
which quenches ROS (Figure 6.5). Thus, oxidative ER-stress triggered by Pt-
NHC plays a crucial role in ICD. 
 
Traditionally, new platinum agents were evaluated primarily by direct 
cytotoxicity against cancer cell lines. We observed no correlation between the 
propensity of Pt agents to trigger tumor cell phagocytosis and cytototoxicity 
(Figure 6.6, evaluated by Annexin V assay) suggesting that ICD is 
independent of cytotoxicity. It was demonstrated that the therapeutic efficacy 
of anthracyclines (ICD-inducer) was negated in mice models when the host 




in some models of cancer, it was the immune-modulating capacity of 
chemotherapeutics, and not cytotoxicity, which was important. In keeping 
with this strategy, we recently reported platinum(IV)-peptide agents that 
directly activated macrophages as another pathway of eliciting an anticancer 
immune response.29  
 
Figure 6.5.  The anti-oxidant, trolox, quenches cellular ROS and this in turn 
inhibits phagocytosis. CT-26 was first pre-treated with trolox (30 min) prior to 
drug exposure and later co-treated with trolox and Pt-NHC (4 h). (a) Trolox 
quenched Pt-NHC induced ROS as analysed by flow cytometry. (b) Co-
incubation of Pt-NHC with trolox significantly inhibited tumour cell 
phagocytosis. Means ± s.e.m. (* p < 0.05, ** p < 0.01; Student's t test). 
 
 
Figure 6.6. Cytotoxicity of Pt agents via Annexin V apoptosis assay. CT-26 
cells were treated for 24 h and stained with AnnexinV-eGFP and propidium 





































































































Over the last decade, there has been substantial evidence supporting the 
pivotal role of the immune system in inducing tumour regression following 
conventional chemotherapy.1, 2 It is probable that many highly promising 
immunogenic and/or immune-stimulating Pt candidates might have been 
neglected. This work, which represents one of the very first few attempts to 
exploit the immune-modulating properties of Pt agents, could pave the way for 
the development of combined Pt-based immuno-chemotherapeutics. 
 
Methods  






(OAc)(OBz),32 picoplatin,34 phenathraplatin14 and Pt-NHC17 were synthesized 
and characterized as previously reported in literature. Complexes oxaliplatin, 
carboplatin, satraplatin and JM118 were purchased from commercial vendors. 
Stock solutions of cisplatin, Pt(1R,2R-DACH)Cl2, picoplatin, satraplatin and 
JM118 were dissolved in 0.9 % NaCl. Complexes oxaliplatin, carboplatin, cP-
(OAc)2, oX-(OH)2, oX-(OAc)2 and phenathraplatin were dissolved in H2O. 
Complexes cP-(OAc)(OBz) and Pt-NHC were dissolved in DMSO. Platinum 
concentrations of stock solutions were measured externally by CMMAC 
(National University of Singapore) on an Optima ICP-OES (Perkin-Elmer). 
 
Cell lines and cell culture. The murine colon cancer cell-line CT-26 and 
murine macrophages J774A.1 were kind gifts of Dr Ian Cheong (Temasek Life 




Singapore) respectively. Human breast cancer cell-line MDA-MB-231 was 
obtained from ATCC. CT-26 cells were cultured in Roswell Park Memorial 
Institute (RPMI) 1640 medium. J774A.1 and MDA-MB-231 cells were 
cultured in Dulbecco's Modified Eagle Medium (DMEM). All media were 
supplemented with 10 % heat-deactivated Fetal Bovine Serum (FBS) and the 
cells were maintained in a 5 % CO2 incubator at 37 °C. 
 
Reagents and antibodies. CellTracker Orange CMTMR (5-(and-6)-(((4-
Chloromethyl)Benzoyl)Amino)Tetramethylrhodamine), CellTracker Green 
CMFDA (5-Chloromethylfluorescein Diacetate), 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA) and ER-Tracker Red were 
purchased from Life Technologies. Annexin V-Enhanced Green Fluorescent 
Protein (EGFP) Apoptosis Detection Kit (ab14153), Phycoerythrin-conjugated 
mouse monoclonal anti-calreticulin antibody (ab83220), rabbit polyclonal 
anti-calreticulin antibody (ab2907), Dy488-conjugated rabbit monoclonal anti-
HMGB1 antibody (epr3506) and secondary FITC-conjugated anti-rabbit 
mouse monoclonal antibody (ab99700) were purchased from Abcam. Murine 
recombinant CRT was purchased from MyBioSource. CRT blocking peptide 
was bought from MBL International. 
 
In vitro phagocytosis assay. J774 cells were seeded at 5 x 104 cells/ well in a 
24-well plate in heat deactivated complete DMEM for 48 h. On the same day, 
adherent CT-26 cells were seeded in heat deactivated complete RPMI in a T75 
flask such that 80 % confluency would be achieved 48 h later. 2 d later, CT-26 




by trypsin-EDTA and counted. Exactly 5 x 105 cells were transferred to each 
1.5 mL Eppendorf microtube and treated with indicated drug for 4 h in an 
Eppendorf shaker at 37 °C. Simultaneously, J774 cells was labelled with 1 µM 
Celltracker Green (492 nm/516 nm). 4 h later, orange-labelled CT-26 cells 
were washed 3 times with heat deactivated complete DMEM while green-
labelled J774 cells were washed twice with PBS. CT-26 was co-cultured with 
J774 at a 1 : 10 effector-target ratio for 2 h. 2 h later, cells were harvested with 
1 mM cold EDTA followed by scraping. Cold Hanks' Balanced Salt solution 
(HBSS) buffer was added to the cells to deactivate EDTA activity before the 
cells were fixed with 4 % formaldehyde for 15 min at r.t. Phagocytosis was 
assessed by a flow cytometer (BD LSRFortessa cell analyser) using Summit 
software. At least 10,000 macrophages were analysed for each sample. 
Phagocytosis % refers to the number of double positive macrophages over the 
total number of macrophages analyzed. In some experiments CT-26 were pre-
treated with Trolox for 30 min before they were co-treated with indicated drug 
and Trolox for 4 h at 37 °C to quench cellular ROS. To restore ecto-CRT 
expression, CT-26 were treated with rCRT as previously described. 8 In other 
experiments, 8 µg/ mL CRT blocking peptide was co-incubated with CT-26 
and J774 to block ecto-CRT. In some experiments, J774 cells were plated on 
poly-L-lysine coated cover slips and 1 x 105 CT-26 cells were added to J774 at 
a 1:2 effector: target ratio. 2 h later, cells were washed once with PBS and 
fixed with 1 % paraformaldehyde for 15 min. Cover-slips were washed gently 
in ultrapure H2O before they were mounted onto slides and analysed with a 
fluorescence microscope. Flourescent and brightfield images were taken 




Visualization of production of ROS in the ER by confocal microscopy. 
CT-26 cells were plated at 2 x 105 cells/ well on poly-L-lysine coated cover 
slips in 12-well plates in heat deactivated complete RPMI. Cells were treated 
with drugs for 4 h before they were washed thrice with pre-warmed HBSS and 
incubated with 25 µM pre-warmed H2DCFDA (488 nm/ 515 nm) for 15 min at 
37 °C. 15 min later, H2DCFDA was removed from the cells and 1 µM pre-
warmed ER-Tracker Red (587 nm/ 615 nm) was added to the cells for 15 min. 
After the incubation time, cells were washed thrice with HBSS before the 
cover slips were washed with ultrapure water, mounted onto slides and 
analysed with confocal microscopy (FV1000, Olympus) immediately. Images 
were taken using 10x and 60x objective lens and processed using Olympus 
FLUOVIEW Viewer.   
 
Measurement of cellular reactive oxygen species by flow cytometry. 2 x 
105 CT-26 cells were pre-treated with Trolox for 30 min before they were co-
treated with indicated drug and Trolox for 4 h at 37 °C. 4 h later, cells were 
washed twice with pre-warmed HBSS before they were incubated with 25 µM 
pre-warmed H2DCFDA for 30 min at 37°C. Cells were then washed once with 
HBSS before they were analysed immediately on a flow cytometer (BD 
LSRFortessa cell analyser). Quantitative analysis was performed using 
Summit software.  
 
Visualization of cell surface CRT by confocal microscopy. 2 x 105 CT-26 
cells were treated with drug for 1 h, washed with cold PBS twice before they 




min on ice. Cells were then washed with cold PBS twice, then incubated with 
a secondary FITC-conjugated anti-rabbit mouse monoclonal antibody (diluted 
in cold 2 % FBS in PBS) for 30 min on ice. Cells were washed once with cold 
PBS, fixed with 4 % paraformaldehyde for 15 min, then mounted onto slides. 
Cells were visualized with confocal microscopy (FV1000, Olympus) 
immediately. Images were taken using 60x objective lens and processed using 
Olympus FLUOVIEW Viewer.   
 
Flow cytometric analysis of cell surface CRT. 2 x 105 CT-26 cells were 
treated with drug, washed twice with cold 2 % FBS in PBS before they were 
incubated with PE-conjugated anti-CRT (diluted in cold 2 % FBS in PBS) for 
30 min. Cells were washed once with cold 2 % FBS in PBS, pelleted, 
resuspended in PBS containing 1 µg/ mL 7-AAD and analysed immediately 
on a flow cytometer (BD LSRFortessa cell analyser). Quantitative analysis 
was performed using Summit software.   
 
Visualization of HMGB1 by confocal microscopy. CT-26 cells were plated 
at 1 x 105 cells/ well on poly-L-lysine coated cover slips in 12-well plates in 
heat deactivated complete RPMI. The next day, cells were drug-treated for 24 
h and washed with PBS. The cells was then fixed with 4 % paraformaldehyde 
for 10 min and permeabilised with 0.1 % TritonX-100 for a further 10 min. 
The cells was then washed twice with supplemented PBS (w/ 10 % FBS) and 
incubated with Dy488-conjugated rabbit anti-HMGB1 mab (prediluted 1:100 
in supplemented PBS) for 30 min.  Cells were then washed once with PBS, co-




visualized with confocal microscopy (FV1000, Olympus) immediately. 
Images were taken using 60x objective lens and processed using Olympus 
FLUOVIEW Viewer.   
 
Flow cytometric analysis of HMGB1 release. 2 x 105 CT-26 cells were 
treated with drug for 24 h and washed twice with PBS. Cells were fixed, 
permeabilised and stained with Dy488-conjugated rabbit anti-HMGB1 mab as 
above and analyzed by flow cytometry. 
 
ATP secretion assay. 4 x 103 CT-26 cells per well were seeded in 96-well 
plates in heat deactivated complete RPMI. The next day, cells were drug-
treated for 24 h and the conditioned media was carefully extracted for 
extracellular ATP measurement by the luciferin-based ENLITEN ATP Assay 
Kit (Promega). 
 
Quantification of apoptosis by flow cytometry. Apoptosis induced by drug 
treatment was assessed by double staining CT-26 cells with Annexin V-EGFP 
and propidium iodide. Briefly, 2 x 105 CT-26 cells were seeded per well in 12 
well plates in heat deactivated complete RPMI and on the next day, the cells 
were treated with drugs. 24 h later, the cells were detached using trypsin-
EDTA and exactly 2 x 105 cells per well were counted, pelleted and 
resuspended in 500 µL of annexin-V binding buffer (10 mM HEPES/NaOH 
(pH 7.4), 140 mM NaCl and 2.5 mM CaCl2) containing 1 µL annexin V-EGFP 




immediately on a flow cytometer (BD LSRFortessa cell analyser). 
Quantitative analysis was performed using Summit software. 
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Figure S6.1. Cells observed under confocal microscopy after drug treatment 
(4 h) and incubation with H2DCFDA (ROS indicator, green) and ER-Tracker 
Red (red). (a) CT-26 (b) MDA-MB-231 (c) Colocalisation analysis after Pt-
NHC treatment (1 M) on MDA-MB-231. White pixels indicate areas of 
colocalisation as determined by Costes method. 
 
 

























What we call the beginning is often the end 
And to make an end is to make a beginning. 














In this thesis, the author rationalised that new platinum complexes which cling 
to the existing paradigms of targeting DNA and evaluated primarily based on 
the criteria of cytotoxicity are unlikely to have actual therapeutic relevance 
because they are unlikely to offer distinct clinical advantages over existing 
platinum-based agents. Instead, the author has proposed and described several 
ideas which reconceptualises and reinvents conventional approaches towards 
platinum-based anticancer drug design. One such approach was through the 
development of targeted platinum(IV) agents which does not act via apoptosis, 
as is customary, but instead selectively overwhelms targeted cells via necrosis. 
This strategy which was termed “targeted necrosis”, is one way of outwitting 
the defective apoptosis pathways in many resistant cancers hampering many 
conventional chemotherapeutics. In addition, the author has initiated 
pioneering work to exploit and leverage upon the untapped immuno-
modulating capacity of platinum-based agents. The author muses that many 
potentially promising immuno-stimulating platinum complexes synthesized in 
the past may have “fallen through the cracks” simply because this criterion 
was never considered previously. In this work, the author has demonstrated 
that it is possible to either via screening techniques or by careful rationale 
design to develop new platinum complexes which are even more a) 
macrophage-activating or b) immunogenic than current platinum agents in 
clinical use.  This research has thus opened up a new subfield within platinum 
drug design which may warrant further exploration. In closing, the author 




anticancer drug design and may one day, be the new beginning for the 
development of the next generation of platinum-based agents in clinical use.  
 
